Declaration

By submitting this thesis electronically, I declare that the entirety of the work contained therein is my own, original work, that I am the sole author thereof (save to the extent explicitly otherwise stated), that reproduction and publication thereof by Stellenbosch University will not infringe any third party rights and that I have not previously in its entirety or in part submitted it for obtaining any qualification.

Copyright © 2016 Stellenbosch University

All rights reserved
Abstract

Background: Targeted stem cell delivery via macrophage modification is a novel and relatively non-invasive therapeutic intervention. Monocytes circulate through the vasculature and infiltrate damaged tissue in response to chemotactic signalling. Here they differentiate into functionally different macrophage phenotypes - the classically activated pro-inflammatory (M1) or alternatively activated anti-inflammatory (M2) phenotypes. The M1 macrophages are able to cross endothelial barriers, while the M2 anti-inflammatory macrophages are unable to transverse endothelium and instead remain tissue associated. The focus of our research was to produce M1 macrophages in vitro that could transverse endothelium while carrying engulfed stem cells, in order to deliver more stem cells in a relatively short time, to any injured tissue to facilitate recovery.

Methods: Primary isolated monocytes were cultured with Granulocyte Monocyte Colony-Stimulating Factor, Lipopolysaccharide and Interferon gamma for 6 days to pre-differentiate them into M1 macrophages. Cells were treated with a Wortmannin-Concanamycin A-Chloroquine cocktail to achieve phagosome maturation arrest and thus preserve ingested cells in a viable state. Preservation of engulfed stem cells (simulated with fluorescent latex beads covalently labelled with IgG antibody) was qualitatively and quantitatively determined by flow cytometry and live cell imaging, respectively. Bead-containing macrophages were co-cultured with HUVEC cells in a Transwell system, and exposed to Monocyte Chemoattractant Protein 1 (added to bottom well) to determine migration capacity.

Results: Monocytes were differentiated into M1 classically activated macrophages. The majority of these cells (68.67±3.51%) were able to engulf opsonised beads after
successful induction of phagosome maturation arrest – a capacity similar to that of untreated cells (61.19±4.68%). Ingested beads were preserved within macrophages for the duration of our protocol (2 hours), determined by retained red antibody signal on beads and perturbed phagosome acidification. 72.86±16.0 phagosome maturation arrested macrophages were able to transverse a HUVEC coated membrane with 8 μm diameter pores (simulated endothelial layer), while only 70.14±12.6 cells per well migrated when carrying a bead cargo.

Conclusion: A delivery system capable of engulfing, preserving and delivering cargo was successfully induced. Further optimisation of this technique could lead to translation into a novel method for delivery of stem cells with regard to regenerative medicine and may even be used as a drug delivery system for the treatment of various malignancies.
Uittreksel

Agtergrond: Geteikende stamsel afliewering via makrofaag manipulering is 'n nuwe en relatief nie-indringende terapeutiese intervensie. Monosiete sirkuleer deur die bloedvate en infiltreer beskadigde weefsel in reaksie op chemiese sein. Hier kan hulle funksioneel verskillende makrofaag fenotipes vorm - die klassiek-geaktiveerde pro-inflammatoriese (M1) of alternatiewelik geaktiveerde anti-inflammatoriese (M2) fenotipes. Slegs die tipe M1 makrofage is in staat om deur endoteelweefsel te beweeg, terwyl die M2 makrofage in weefsel geleë bly. Die fokus van ons navorsing was om M1 makrofage in vitro te produseer, wat endoteel kan deurdring selfs nadat dit 'n stamsel ingeneem het, ten einde meer stamselle af te lewer in 'n relatief korter tydperk en so doende beskadigde weefseilerstel aan te help.

Metodes: Primêre geïsoleerde monosiete is vir 6 dae gedifferensieer deur hul kwekingsmedia aan te vul met granulosiet-monosiet kolonie-stimulerende faktor, lipopolisakkaried en interferon-gamma, om sodoende M1 makrofage te lewer. M1 selle is daarna behandeld met 'n kombinasie van Wortmannin, Concanamycin A en Chloroquine om die proses van fagosoomverryping te verhoed en sodoende ingeneemde selle in 'n lewensvatbare toestand te bewaar. Bewaring van gefagositeerde stamselle (nageboots deur gebruik te maak van fluoreserende polistireen krale, gemerk met kovalent-gebonde IgG teenliggame) is kwalitatief en kwantitatief bepaal deur vloeisitometrie en lewende sel mikroskopie onderskeidelik. Makrofage met ingeneemde krale is daarna bo-op HUVEC selle in 'n dubbelput (Transwell) sisteem gekweek. Die kultuur is daarna aan monosiet chemooaantrekkingsproteïen 1 (bygevoeg in onderste put) blootgestel om migrasie kapasiteit te bepaal.
Resultate: Monosiete is suksesvol gedifferensieer na die klassiek geaktiveerde M1 makrofaag fenotipe. Die meerderheid van hierdie selle (68,67 ± 3,51%) was in staat om geöpsoniseerde krale te verswelg ná suksesvolle verkoming van phagosome verryping - 'n resultaat soortgelyk aan dié van onbehandelde selle (61,19 ± 4,68%). Opgeneemde krale het binne makrofage behoue gebleef vir die tydsduur van ons protokol (2 ure), soos bepaal deur die behoud van die rooi teenliggaamsein op krale. In terme van migrasie, was 72,86 ± 16,0 behandeld makrofage (per reaksie) in staat om deur 'n HUVEC-bedeekte (endoteel) membraan met porieë, 8 µm in deursnee (te beweeg, in vergelyking met 'n soortegelyke 70,14 ± 12,6 selle per reaksie vir die behandelede selle wat krale bevat het.

Gevolgtrekking: Data bewys dat 'n afleveringstelsel, wat in staat is om 'n vraag in te neem en behoue te laat bly vir aflevering, suksesvol ontwikkel is. Die verdere optimalisering van hierdie tegniek kan lei tot die toepassing daarvan as 'n nuwe terapeutiese modaliteit in regeneratiewe medisyne, vir die aflevering van stamselle en/of farmaseutiese preparate, vir die behandeling van verskeie maligniteite.
Research Outputs

1. Conference contributions:
   - International seminar
   - National seminar
     - Visser JG, Smith C. Developing a macrophage shuttle for transendothelial stem cell delivery. Physiology Society of Southern Africa, Observatory, Cape Town, August 2016
   - International poster presentation

2. Research awards:
   - Visser JG. Wyndham award third prize for oral presentation at Physiology Society of Southern Africa, River Club, Observatory, Cape Town, August 2016
   - Visser JG. Award for the most innovative method at Physiology Society of Southern Africa, River Club, Observatory, Cape Town, August 2016

3. Submitted manuscript:
Acknowledgements

I would like to thank the following for their contribution to the success of this project:

- Our God Jesus Christ for perpetual guidance
- My parents and family for financial and emotional support
- Prof Carine Smith for guidance and building up my experience
- National Research Foundation (NRF) of South Africa for financial support
- Stellenbosch University Central Analytical Facility (CAF), Live cell microscopy unit, for technical assistance
# Table of Contents

**List of Figures** ................................................................................................................... xi

**List of Abbreviations** ......................................................................................................... xii

**Units of Measure** ............................................................................................................... xvi

1. **Chapter 1**: Introduction................................................................................................. 1

2. **Chapter 2**: Literature review......................................................................................... 3
   2.1. Introduction.................................................................................................................. 3
   2.2. Molecular basis of phagocytosis.................................................................................... 3
       2.2.1. Recognition........................................................................................................... 4
       2.2.2. Pseudopodia and Encapsulation.......................................................... 6
       2.2.3. Nascent Phagosomal Stage ........................................................................... 12
       2.2.4. Late Phagosomal Stage ................................................................................. 14
       2.2.5. Phagolysosome Biogenesis Stage ................................................... 16
   2.3. Pathogenic Phagosome Maturation Arrest .............................................................. 17
       2.3.1. Inhibition of Phagosome Maturation ....................................................... 18
       2.3.2. Interference with Phagosome Acidification .............................................. 19
       2.3.3. Prevention of Lysosome Fusion ............................................................... 20
   2.4. Harnessing the Phagocytic Process for Medicine ................................................... 21
       2.4.1. Macrophage IL-10 Enrichment ............................................................... 22
       2.4.2. Brefeldin A Treatment .............................................................................. 23
       2.4.3. Microtubule or Dynein Inhibition .............................................................. 24
       2.4.4. Wortmannin ......................................................................................... 26
       2.4.5. Concanamycin A ................................................................................... 26
       2.4.6. Chloroquine ....................................................................................... 27
       2.4.7. Additional Factors to Consider .................................................................. 27
   2.5. Summary .................................................................................................................... 29
   2.6. Hypothesis ............................................................................................................... 30
   2.7. Objectives ............................................................................................................... 30

3. **Chapter 3**: Materials and Methods ............................................................................. 32
   3.1. Cell Type Selection ............................................................................................... 32
3.2. Ethical Considerations ................................................................. 33
3.3. Monocyte Isolation ................................................................. 33
3.4. Culture Conditions ................................................................. 34
3.5. Pre-differentiation and Polarisation ........................................... 35
3.6. Culture Detachment ................................................................. 36
  3.6.1. Nunc UpCell™ Plates ............................................................... 37
  3.6.2. 35mm Culture Dish with Accutase® Method ...................... 38
3.7. Macrophage Phenotype Analysis ................................................ 38
3.8. Modulating Macrophage Phagosome Maturation ....................... 39
3.9. Visualisation of Ingested “Cargo” Using Fluorescent Beads ......... 40
3.10. Phagocytosis ................................................................. 42
  3.10.1. Live Cell Imaging of Phagocytosis ........................................ 43
  3.10.2. Flow Cytometric Quantification of Phagocytosis ............... 44
3.11. Transmigration System ......................................................... 45
  3.11.1. Fibronectin Coating .............................................................. 46
  3.11.2. HUVEC Cell Culture ............................................................ 47
  3.11.3. Transmigration Assay ........................................................... 48
3.12. Statistical Analysis ................................................................. 51

4. Chapter 4: Results ................................................................. 52
  4.1. Monocyte Differentiation and Polarisation .................................. 52
  4.2. Phagocytosis Model Validation .................................................. 54
  4.3. Intervention: Phagosome Maturation Arrest ......................... 56
    4.3.1. Digestive Capacity ............................................................... 58
    4.3.2. Engulfment Capacity ............................................................ 60
    4.3.3. Acidification ................................................................. 61
  4.4. Macrophage Migration ........................................................... 63

5. Chapter 5: Discussion ............................................................. 66
  5.1. Macrophage Polarisation ......................................................... 66
  5.2. Manipulating Phagosome Maturation ...................................... 69
  5.3. Maintenance of Engulfment Capacity and Migration .............. 72
  5.4. Bioactivity and in vivo Translation ......................................... 73

6. Chapter 6: Conclusions and Recommendations for Future Studies .... 75
List of Figures

Figure 4.1: Monocyte differentiation into macrophages ............................... 52

Figure 4.2: Flow cytometry analysis of macrophage differentiation ............ 53

Figure 4.3: Antibody dispersion off of AbsBeads ......................................... 54

Figure 4.4: Acidification of cellular compartments ....................................... 55

Figure 4.5: Time lapse images of live macrophages .................................... 57

Figure 4.6: Representative flow cytometry scatter plot of macrophage digestion with intensity clusters ................................................................. 59

Figure 4.7: Statistical analysis of macrophage digestive capacity ............... 60

Figure 4.8: Statistical analysis of macrophage engulfment capacity .......... 61

Figure 4.9: Representative flow cytometry scatter plots of macrophage acidification with intensity clusters ................................................................. 62

Figure 4.10: Statistical analysis of macrophage acidification ...................... 63

Figure 4.11: Statistical analysis of migratory capacity of phagosome maturation arrested macrophages ................................................................. 64
# List of Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>AbsBeads</td>
<td>Antibody (IgG) Opsonised Polystyrene Beads</td>
</tr>
<tr>
<td>ANOVA</td>
<td>Analysis of Variants</td>
</tr>
<tr>
<td>ARF</td>
<td>ADP Ribosylation Factor</td>
</tr>
<tr>
<td>ATP</td>
<td>Adenosine Triphosphate</td>
</tr>
<tr>
<td>ATPase</td>
<td>ATP Phosphatase</td>
</tr>
<tr>
<td>BBE</td>
<td>Bovine Brain Extract</td>
</tr>
<tr>
<td>BFA</td>
<td>Brefeldin A</td>
</tr>
<tr>
<td>C6</td>
<td>Carbon at position 6 of a molecule</td>
</tr>
<tr>
<td>C20</td>
<td>Carbon at position 20 of a molecule</td>
</tr>
<tr>
<td>CD14</td>
<td>Cluster of Differentiation 14</td>
</tr>
<tr>
<td>CD45</td>
<td>Cluster of Differentiation 45</td>
</tr>
<tr>
<td>CD64</td>
<td>Cluster of Differentiation 64</td>
</tr>
<tr>
<td>CD86</td>
<td>Cluster of Differentiation 86</td>
</tr>
<tr>
<td>CD163</td>
<td>Cluster of Differentiation 163</td>
</tr>
<tr>
<td>CD206</td>
<td>Cluster of Differentiation 206</td>
</tr>
<tr>
<td>CD274</td>
<td>Cluster of Differentiation 274</td>
</tr>
<tr>
<td>CHM</td>
<td>Complete HUVEC Media</td>
</tr>
<tr>
<td>CO₂</td>
<td>Carbon Dioxide</td>
</tr>
<tr>
<td>COP</td>
<td>Coat Protein Complex</td>
</tr>
<tr>
<td>CMM</td>
<td>Complete Monocyte Media</td>
</tr>
<tr>
<td>DAMP</td>
<td>Damage-associated Molecular Pattern</td>
</tr>
<tr>
<td>ddH₂O</td>
<td>Double-Distilled Hydrogen Dioxide (water)</td>
</tr>
<tr>
<td>DMSO</td>
<td>Dimethyl Sulfoxide ((CH₃)₂SO)</td>
</tr>
<tr>
<td>EDAC</td>
<td>1-ethyl-3-(3-dimethylaminopropyl)- carbodiimide</td>
</tr>
<tr>
<td>EDTA</td>
<td>Ethylenediaminetetraacetic acid</td>
</tr>
<tr>
<td>EEA1</td>
<td>Endosomal Early Antigen 1</td>
</tr>
<tr>
<td>ER</td>
<td>Endoplasmic Reticulum</td>
</tr>
<tr>
<td>ER SNARE</td>
<td>ER Soluble N-ethylmaleimide-sensitive Factor-attachment Protein Receptor</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>FACS</td>
<td>Fluorescence-Activated Cell-Sorting</td>
</tr>
<tr>
<td>FBS</td>
<td>Fetal Bovine Serum</td>
</tr>
<tr>
<td>Fc</td>
<td>Fragment crystallisable</td>
</tr>
<tr>
<td>Fcγ</td>
<td>Fragment crystallisable gamma</td>
</tr>
<tr>
<td>FcγR</td>
<td>Fragment crystallisable gamma Receptor</td>
</tr>
<tr>
<td>FcRn</td>
<td>Neonatal Fragment crystallisable Receptor</td>
</tr>
<tr>
<td>FPR</td>
<td>Formyl Peptide Receptor</td>
</tr>
<tr>
<td>GA</td>
<td>Gentamicin and Amphotericin</td>
</tr>
<tr>
<td>GAP</td>
<td>GTPase-activating Protein</td>
</tr>
<tr>
<td>GEF</td>
<td>Guanine Nucleotide-exchange Factor</td>
</tr>
<tr>
<td>GM-CSF</td>
<td>Granulocyte Macrophage Colony-Stimulating Factor</td>
</tr>
<tr>
<td>GTP</td>
<td>Guanosine Triphosphate</td>
</tr>
<tr>
<td>GTPase</td>
<td>GTP Phosphatase</td>
</tr>
<tr>
<td>hEGF</td>
<td>Human Epidermal Growth Factor</td>
</tr>
<tr>
<td>HLA-DR</td>
<td>Human Leukocyte Antigen – Antigen D Related</td>
</tr>
<tr>
<td>HREC</td>
<td>Health Research Ethics Committee</td>
</tr>
<tr>
<td>HUVEC</td>
<td>Human Umbilical Vein Endothelial Cell</td>
</tr>
<tr>
<td>ICAM-1</td>
<td>Intercellular Adhesion Molecule 1</td>
</tr>
<tr>
<td>INF-γ</td>
<td>Interferon gamma</td>
</tr>
<tr>
<td>IgG</td>
<td>Immunoglobulin G</td>
</tr>
<tr>
<td>IL-4</td>
<td>Interleukin 4</td>
</tr>
<tr>
<td>IL-10</td>
<td>Interleukin 10</td>
</tr>
<tr>
<td>iNOS</td>
<td>Inducible Nitric-oxide Synthase</td>
</tr>
<tr>
<td>IVIS</td>
<td>in vivo Imaging System</td>
</tr>
<tr>
<td>JAM-A</td>
<td>Junctional Adhesion Molecule A</td>
</tr>
<tr>
<td>LAMP</td>
<td>Lysosome-associated Membrane Proteins</td>
</tr>
<tr>
<td>LN₂</td>
<td>Liquid Nitrogen</td>
</tr>
<tr>
<td>LPS</td>
<td>Lipopolysaccharide</td>
</tr>
<tr>
<td>M1</td>
<td>Classically Activated M1 Phenotype Macrophage</td>
</tr>
<tr>
<td>M2</td>
<td>Alternatively Activated M2 Phenotype Macrophage</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>MACS</td>
<td>Magnetic-Activated Cell Sorting</td>
</tr>
<tr>
<td>MAP1S</td>
<td>Mitogen-associated Protein 1S</td>
</tr>
<tr>
<td>MCP-1</td>
<td>Monocyte Chemoattractant Protein 1</td>
</tr>
<tr>
<td>M-CSF</td>
<td>Macrophage Colony-Stimulating Factor</td>
</tr>
<tr>
<td>MES</td>
<td>2-(N-morpholino)ethanesulfonic acid</td>
</tr>
<tr>
<td>MHCII</td>
<td>Major Histocompatibility Complex Class II</td>
</tr>
<tr>
<td>MIF</td>
<td>Macrophage Migration Inhibitory Factor</td>
</tr>
<tr>
<td>MPR</td>
<td>Mannose-6-phosphate Receptor</td>
</tr>
<tr>
<td>MyD88</td>
<td>Myeloid differentiation primary response gene 88</td>
</tr>
<tr>
<td>NADPH</td>
<td>Nicotinamide Adenine Dinucleotide Phosphate</td>
</tr>
<tr>
<td>NaOH</td>
<td>Sodium Hydroxide</td>
</tr>
<tr>
<td>Nef</td>
<td>Viral Negative Factor</td>
</tr>
<tr>
<td>NLR</td>
<td>NOD-like Receptor</td>
</tr>
<tr>
<td>NLRP3</td>
<td>NLR Pyrin Domain Containing 3</td>
</tr>
<tr>
<td>NSF</td>
<td>N-ethylmaleimide-sensitive Factor</td>
</tr>
<tr>
<td>ORP1L</td>
<td>Oxysterol-binding Protein Related-protein 1</td>
</tr>
<tr>
<td>P</td>
<td>Passage</td>
</tr>
<tr>
<td>PAMP</td>
<td>Pathogen-associated Molecular Pattern</td>
</tr>
<tr>
<td>PBMCs</td>
<td>Peripheral Blood Mononuclear Cells</td>
</tr>
<tr>
<td>PBS</td>
<td>Phosphate Buffered Saline</td>
</tr>
<tr>
<td>PD-L1</td>
<td>Programmed Death-Ligand 1</td>
</tr>
<tr>
<td>PenStrep</td>
<td>Penicillin-Streptomycin</td>
</tr>
<tr>
<td>PET</td>
<td>Polyethylene Terephthalate</td>
</tr>
<tr>
<td>PI</td>
<td>Phosphatidylinositol</td>
</tr>
<tr>
<td>PI3k</td>
<td>Phosphatidylinositol 3-kinase</td>
</tr>
<tr>
<td>PI3P</td>
<td>Phosphatidylinositol 3-phosphate</td>
</tr>
<tr>
<td>PI(3,4)P2</td>
<td>Phosphatidylinositol 3,4-bisphosphate</td>
</tr>
<tr>
<td>PI(3,4,5)P3</td>
<td>Phosphatidylinositol 3,4,5-triphosphate</td>
</tr>
<tr>
<td>PI(3,5)P2</td>
<td>Phosphatidylinositol 3,5-bisphosphate</td>
</tr>
<tr>
<td>PI4P</td>
<td>Phosphatidylinositol 4-phosphate</td>
</tr>
<tr>
<td>Acronym</td>
<td>Description</td>
</tr>
<tr>
<td>---------</td>
<td>-------------</td>
</tr>
<tr>
<td>PI4P-5kα</td>
<td>Phosphatidylinositol 4-phosphate 5-kinase α</td>
</tr>
<tr>
<td>PI(4,5)P2</td>
<td>Phosphatidylinositol 4,5-bisphosphate</td>
</tr>
<tr>
<td>PIP3</td>
<td>Phosphatidylinositol 3,4,5-triphosphate</td>
</tr>
<tr>
<td>PIPAAm</td>
<td>poly(N)-isopropylacrylamide</td>
</tr>
<tr>
<td>PMA</td>
<td>Phorbol 12-myristate 13-acetate</td>
</tr>
<tr>
<td>PRR</td>
<td>Pattern Recognition Receptor</td>
</tr>
<tr>
<td>PTEN</td>
<td>PI 3'-phosphotase</td>
</tr>
<tr>
<td>RANTES</td>
<td>Regulated on Activation, Normal T Cell Expressed and Secreted</td>
</tr>
<tr>
<td>RILP</td>
<td>Rab7-interacting-lysosomal-protein</td>
</tr>
<tr>
<td>RLR</td>
<td>RIG-like Receptor</td>
</tr>
<tr>
<td>RNS</td>
<td>Reactive Nitrogen Species</td>
</tr>
<tr>
<td>ROS</td>
<td>Reactive Oxygen Species</td>
</tr>
<tr>
<td>RPMI</td>
<td>Roswell Park Memorial Institute medium</td>
</tr>
<tr>
<td>SapM</td>
<td>Secreted Acid Phosphatase</td>
</tr>
<tr>
<td>SEM</td>
<td>Standard Error of the Mean</td>
</tr>
<tr>
<td>SNARE</td>
<td>Soluble N-ethylmaleimide-sensitive Factor-attachment Protein Receptor</td>
</tr>
<tr>
<td>SNX</td>
<td>Sorting Nexins</td>
</tr>
<tr>
<td>TACO</td>
<td>Tryptophan-aspartate Containing Coat</td>
</tr>
<tr>
<td>TGF-β</td>
<td>Transforming Growth Factor beta</td>
</tr>
<tr>
<td>TLR</td>
<td>Toll-like Receptor</td>
</tr>
<tr>
<td>TM+C</td>
<td>Transmigration Media with Chemokine</td>
</tr>
<tr>
<td>TM-C</td>
<td>Transmigration Media devoid of Chemokine</td>
</tr>
<tr>
<td>TNF-α</td>
<td>Tumour Necrosis Factor α</td>
</tr>
<tr>
<td>UPR</td>
<td>Unfolded Protein Response</td>
</tr>
<tr>
<td>VAMP</td>
<td>Vesicle-associated Membrane Protein</td>
</tr>
<tr>
<td>V-ATPase</td>
<td>Vacuolar-type H+-ATPase</td>
</tr>
<tr>
<td>VCAM-1</td>
<td>Vascular Cell Adhesion Molecule 1</td>
</tr>
<tr>
<td>Vpr</td>
<td>Regulatory viral protein</td>
</tr>
<tr>
<td>WPBTS</td>
<td>Western Province Blood Transfusion Service</td>
</tr>
</tbody>
</table>
Units of Measure

%  percentage
˚C  degrees Celsius
µg/cm²  microgram per square centimetre
µg/ml  microgram per millilitre
µl  microliter
µm  micrometre
µM  micromolar
g  gravitational acceleration
g/mol  gram per mole
h  hour
M  molar
mg  milligram
mg/ml  milligram per millilitre
min  minutes
ml  millilitre
mm  millimetre
mM  millimolar
ng/ml  nanogram per millilitre
nm  nanometre
nM  nanomolar
kDa  kilo Dalton
RPM  revolutions per minute
Chapter 1: Introduction

Broadly, stem cells are cells capable of differentiation into any cell type following appropriate stimulation. In the context of skeletal muscle, the population of stem cells facilitating muscle regeneration are satellite cells (Parise et al. 2008). Unfortunately, in some cases, regeneration is inhibited under pathological conditions (such as myodystrophy) or due to individual genetic profiles or abnormalities (Snijders et al. 2016). Perturbed regeneration may result from more than one cause, but most relevant to the current thesis, one of these contributing factors is a relative lack of sufficient satellite cell numbers at the site of regeneration (Dayanidhi et al. 2015). Therefore, therapeutic delivery of additional satellite cells to the required site should increase the rate and extent of regeneration. Stem cell delivery could thus beneficially attenuate regeneration in chronic pathological states, or recovery acutely after physical injuries. This technique would also utilise the donor’s own stem cells and monocytes. Following in vitro proliferation of these cells, this autologous stem cell therapy could treat chronic diseases. Although this thesis focused on application in skeletal muscle, if successful, this technique could be extrapolated and developed for broader application in a multitude of tissue areas or organs.

Turning attention now to how such stem cell delivery could be achieved, we have identified leukocytes, and in particular phagocytes, as potential vehicles for delivery. Phagocytes – such as macrophages and neutrophils – are responsible for the initial recognition and destruction of invading pathogens. So effective are these phagocytes that nearly 95% of the animal kingdom can elicit self-protection without the need of B or T cells, relying only on evolutionarily conserved innate immune defence (Mills et al. 2015). At least two characteristics of these cells make them ideally suited for this task.
Firstly, they are highly mobile cells, with the ability to readily cross membranes, such as endothelium. This affords them the uncommon cellular trait of migration across different body or tissue compartments to reach the site where they are required.

Secondly, these cells have the capacity for phagocytosis. This primary anti-microbial weapon is an intricate process, starting with pseudopodia extension to engulf particle matter and ending in particle neutralization within a destructive phagolysosome. The fact that these two mechanisms in the “defence” response are highly conserved across species (Mills et al. 2015), testifies to its potency and overall importance for host health. However, from both the microbiology and immunology literature, it is also known that the process of phagocytosis is not infallible. Several papers have described the ability of evolved microbes, such as *Mycobacterium tuberculosis* (Seto et al. 2011), *Leishmania donovani* (Gogulamudi et al. 2015) and *Candida glabrata* (Rai et al. 2015), to hide from the immune system by remaining inside phagocytes without being digested in the phagolysosome. We believe that a lesson can be learned from these microbes, and harnessed to the benefit of regenerative medicine practises.

The next chapter will provide an overview of the literature related to molecular events of phagosome maturation, as well as microbe-associated phagosome maturation arrest and experimental manipulation of these strategies. This is followed by a detailed report of method development regarding the manipulation of phagosome maturation arrest, as well as assessment of potential effects of this intervention on macrophage phagocytic and migratory capacities (Chapter 3). Results are presented and discussed in chapters 4 and 5, before the thesis is rounded off with a discussion of the practical applicability of this technique, additional work required and some recommendations for improvements or further development of the technique.
Chapter 2: Literature Review

A truncated version of this literature review (please refer to Appendix A) has been submitted for publication to *Immunology and Cellular Biology* (outcome pending).

2.1. Introduction

In this review, we will present our hypothesis on how macrophages may be altered for regenerative medicine, and specifically for homologous stem cell delivery. However, we first present an overview of what is currently known about the molecular processes involved in the phagocytic process, aiming to elucidate the molecular mechanisms of phagosome maturation in a temporal and concise manner as to better understand this phenomenon. This will be followed by a discussion of phagosome maturation arrest and the mechanisms used by microbial agents to evade phagosomal neutralization, as well as similar mechanisms at play during normal cell death processes.

2.2. Molecular Basis of Phagocytosis

Phagocytosis involves considerable membrane and cytoskeletal rearrangements in order to encircle and capture (engulf) potential pathogens or matter foreign to the immune system – forming phagosomes – and to mature these nascent phagosomes into phagolysosomes (Huynh et al. 2007). Microbial material is captured inside a nascent phagosome that matures through events relating to the endocytic and autophagic pathway, where fission and fusion events allow for its destructive ability. In the next few sections, these intricate processes will be explained in detail, using macrophages as representative phagocytic immune cell.
2.2.1. Recognition

Matter is recognised as foreign – and thus as potential threat – via binding to specific pattern recognition receptors (PRRs) located both in the cytosol and cell surface of immune cells of both the innate and adaptive branch of the immune system, as well as on epithelial cells such as the vascular endothelium (Anderson & Wadee 2012). PRRs differentiate between molecules that are released by dying self-cells and foreign material through respectively binding to damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs) (Abbas et al. 2014). Necrotic self-cells release formylated peptides like N-formylmethionine from damaged mitochondria (Zhang et al. 2010). These self-originating proteins (classified under DAMPs) can bind to formyl peptide receptors (FPRs) on monocytic cells, initiating chemotaxis and eventually ending in phagocytosis (Bardoel & Van Strijp 2011). Interestingly, these formylated peptides are also characteristic of bacterial proteins. In our opinion, this supports the endosymbiotic theory of mitochondrial evolution, which proposes that mitochondria are foreign organelles that were incorporated into eukaryotic cells for energy production. In this manner cells containing damaged mitochondria, i.e. metabolically compromised cells, are removed via recognition of these DAMPs, irrespective of self or non-self. Recognition of PAMPs is oriented toward many PRR subtypes, such as NOD-like receptors (NLRs) (recognise DAMPs as well), RIG-like receptors (RLRs) and Toll-like receptors (TLRs). NLRs are mainly associated with sterile inflammation like gout via NLRP3 associated inflammasome formation (Misawa et al. 2013). The membrane bound TLRs bind bacterial hallmark molecules both intra- and extracellularly and exhibit some target specificity. The TLR5 subtype typically binds to flagella, while TLR2 and TLR4 bind components of the bacterial cell wall like peptidoglycan and lipopolysaccharide (LPS), respectively.
TLR activation induces recruitment of adaptor proteins and activation of transcription factors for production and release of cytokines, adhesion molecules and costimulators (Abbas et al. 2014). Active TLRs indirectly regulate phagocytosis through Myeloid differentiation primary response gene 88 (MyD88) signalling and activation of the p38 residue to accelerate phagocytosis (Shi et al. 2016). The newly identified mitogen-associated protein 1S (MAP1S) autophagy-related protein (Xie et al. 2011) was also very recently reported to be necessary for TLR activation and effective bacterial phagocytosis (Shi et al. 2016), but more research is required to fully elucidate its role in this context. Many other receptors such as lectin, mannose, complement and RIG-like receptors also assist with pathogen recognition, but the IgG receptors are more closely associated with phagocytosis. IgG antibodies directed against specific pathogenic microbes can attach to bacteria to opsonise them. Opsonisation facilitates phagocytosis of material otherwise ‘invisible’ to macrophages. Macrophages recognise the constant γ heavy chain in Fc regions of IgG antibodies with Fcγ receptors (CD64) on their cell surface. Recognition of IgG opsonised material induces FcγR clustering at the site of material contact that leads to actin polymerization and engulfment through pseudopod extension (Swanson & Hoppe 2004). Formation of pseudopodia and actin polymerization is highly dependent on phosphatidylinositol 3-
kinase (PI3k) recruitment for production of various phosphatidylinositides. The ADP ribosylation factor (ARF) proteins play a pivotal role in activating phosphatidylinositol kinase enzymes to regulate membrane modification (Nie et al. 2003). Specifically, ARF6 has many functions – one of which is being recruited to the tip of forming pseudopodia where it activates type I PI3k substrate production via activation of other phosphatidylinositol kinases (Honda et al. 1999). ARF6 is also essential for actin polymerization during pseudopod extension (Zhang et al. 1998). This collectively ensures particle capture and membrane fusion behind the opsonised particle to form a phagosome. FcγR mediated phagocytosis is the main form of phagocytosis simulated in experimental phagocytosis models, because engulfment does not require stimulation by other cells types like T cells or NK cells, explained further by Liu et al. (2013).

2.2.2. Pseudopodia and Encapsulation

Following recognition, phagocytosis is initiated with the extension of pseudopodia. Particle internalisation and phagosome formation is achieved within 5 min after introduction of the foreign agent under culture conditions (Visser & Smith, unpublished data). Macrophages specifically are extremely ambitious in their phagocytic ability and are able to engulf particles into phagosomes which are closely comparable with their own size (Huynh et al. 2007). Interestingly, a form of cell suicide termed “frustrated phagocytosis” has been reported, where macrophages even tried to engulf the opsonised culture plate surfaces they were grown on (Cox et al. 1999). This phenomenon presented a useful model with which to investigate the mechanics of pseudopod formation. These “frustrated” macrophages were able to increase their surface area by over 20% (Cox et al. 1999). The way in which this phenomenal change in cell shape can be achieved, has been debated to some extent. One theory
postulated that the macrophage membrane is corrugated, possibly allowing a flattening out of the membrane during extra-large particle engulfment (Hallett & Dewitt 2007). However, quantitative spectroscopy has shown that during healthy phagocytosis, membrane surface area indeed enlarges to such a degree that surface flattening alone cannot fully account for it (Hackam et al. 1998). In addition, portions of the plasma membrane are also lost from the cell surface when it forms the membrane of newly formed phagosomes, so that even more membrane replenishment is required.

These findings raise the questions of where the extra membrane comes from and what controls it, since these are vital considerations in understanding the processes determining the efficacy and speed of phagocytosis. Specific membrane reservoirs have not been identified within cells, but general cellular sources are known. For example, in the case of osteoclasts, exocytosis of late endosomes has been shown to function distinctively to deliver membrane components and increase cell surface area during bone reabsorption (Rousselle & Heymann 2002). In the context of macrophages and pseudopod formation specifically, a few candidates have been investigated. Initially, Gagnon et al. (2002) proposed that the Endoplasmic Reticulum (ER) may fuse with the plasma membrane at the base of extending pseudopodia, forming a continuity through which the particle can slide into the ER lumen. This idea was supported by Becker et al. (2005) who neutralized the ER soluble N-ethylmaleimide-sensitive factor-attachment protein (SNARE) receptor (ER SNARE), ERS24, with intracellular antibodies and showed that phagocytosis efficiency of large particles (>3μm) was reduced. Subsequently, Hatsuzawa et al. (2006) also blocked ERS24 (together with syntaxin 18 and D12) and postulated a pivotal role of syntaxin 18 during ER fusion with phagosomes after finding syntaxin 18 expression on isolated
phagosomes, although they acknowledged that this does not prove actual ER-membrane fusion. Furthermore, although, many ER proteins are recruited to phagosomes during events such as pseudopod extension (vesicle-associated membrane protein 3, VAMP3) (Coppolino et al. 2001) and phagosome maturation (syntaxin 7 and 13) (Collins et al. 2002), this does not substantiate a direct fusion of the ER with phagosomes. As evidenced by several reviews on this topic, the theory of Gagnon and colleagues seemed to have been accepted by some groups (Garin et al. 2001; Desjardins 2003), but not all. Several other authors have argued that the role of the ER during phagocytosis still needs some elucidation (Touret et al. 2005; Groothuis & Neefjes 2005). More recently, using a variety of techniques including immunological, biochemical, electron microscopy and fluorescence microscopy, Huynh et al. (2007) indeed could not find any evidence of the ER fusing to the plasma membrane during phagocytosis. Also, since phagosomes acidify during maturation via a proton gradient created by the vacuolar-type H+-ATPase (V-ATPase) proton pump, and the ER membrane is permeable to protons and devoid of V-ATPase (Paroutis et al. 2004), the theory of simple ER fusion is probably unlikely to fully explain the phenomenon. Considering all points of view and data available to us, we speculate that the ER likely fuses with phagosomal membranes – however, it could be in a ‘kiss and run’ or ‘kiss of death’ fashion, as seen during autophagosome fusion with lysosomes (Jahreiss et al. 2008) and cytotoxic CD8+ T cell mediated cell death (Trambas & Griffiths 2003).

This could result in an exchange or delivery of ER localised proteins to phagosomes, without complete membrane exchange through fusion. Furthermore, ER engagement was observed during large particle uptake (>3μm) and mostly during FcγR mediated phagocytosis (Becker et al. 2005), meaning that ER engagement is likely size and receptor specific.
A more likely candidate is the enzyme group of PI3ks that phosphorylate the 3’ inositol phospholipid of inositol rings. These kinases are classified into three families based on their substrate used for lipid phosphorylation: types I, II and III.

The type I PI3ks consists of four isoforms: PI3kα,β,γ and δ. All these isoforms use phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) as a substrate to generate phosphatidylinositol 3,4,5-triphosphate (PI(3,4,5)P3, or PIP3) (Hawkins & Stephens 2015). This PI3k substrate concentration is kept at optimal level by phosphatidylinositol 4-phosphate 5-kinase α (PI4P-5kα) through its phosphorylation of phosphatidylinositol 4-phosphate (PI4P) to PI(4,5)P2 (Beemiller et al. 2006). The PI3kδ isoform is unique to immune cells as it is normally only expressed on lymphoid and myeloid cell lineages (Okkenhaug 2013).

Botelho et al. (2000) found transiently high PI(4,5)P2 expression on extending pseudopodia with its disappearance shortly after phagocytic cup closure and nascent phagosome formation. Furthermore, type I PI3ks recruitment and subsequent PIP3 expression has been shown to occur on extending pseudopodia during engulfment of antibody-opsonised particles (Marshall et al. 2001). Throughout the literature, PIP3 is seen as the main propagating agent during pseudopod extension. However, apart from the apparent steric association of PI(4,5)P2 to PI3ks – necessary for its phosphorylation to PIP3 – PI(4,5)P2 itself seems to have an equally important role in pseudopod formation. Active ARF6 induces PI(4,5)P2 production through activation of PI4P-5kα during phagocytosis (Honda et al. 1999). The produced PI(4,5)P2 can then recruit WASP/N-WASP proteins to facilitate actin polymerization during phagocytosis (Miki et al. 1996). More recently, Scott et al. (2002) presented supporting findings that inhibition of PI(4,5)P2 hydrolysis or overexpression thereof, prevented actin disassembly (required for successful material engulfment). The 3’ phosphorylated
inositols, PIP$_3$ and phosphatidylinositol 3,4-bisphosphate (PI(3,4)P$_2$), are known to regulate actin polymerization in a G-protein coupled manner, resulting in changes in cell shape, cell movement and phagocytosis itself (Mazaki et al. 2012). However, previously mentioned findings support a role of PI(4,5)P$_2$ together with its alternatively 3-position phosphorylated homologues during actin regulation, even if only in disassembling actin by its disappearance. This highlights the independent role of PI(4,5)P$_2$ (by extension also ARF6 and PI4P-5kα) as an engulfment regulator and not only a type I PI3k substrate for PIP$_3$ production. The role of type I PI3ks was further elucidated by Vieira et al. (2001) who postulated, via antibody mediated type I PI3ks inhibition, that this type of PI3ks together with its substrate (PI(4,5)P$_2$) and product (PIP$_3$) were essential for pseudopod formation around relatively large particles (>3μm in diameter) and their subsequent ingestion, but not for the further maturation of phagosomes.

The Type II PI3ks are not well described but current evidence points to the notion that this enzyme family produces either PI(3,4)P$_2$ or phosphatidylinositol 3-phosphate (PI3P) on endosomal or plasma membranes (Falasca & Maffucci 2012; Posor et al. 2013) by either of their three isoforms: PI3kC2α, C2β, C2γ. Thus, type II PI3ks, could contribute to production of PI(3,4)P$_2$ on extending pseudopodia for actin regulation and additional membrane, or it could facilitate phagosome maturation through production of PI3P on phagosomes.

The last PI3k family is the type III PI3ks that consist of only one catalytic subunit, VPS34, in humans: hVPS34. Type III PI3ks phosphorylate phosphatidylinositol (PI) to PI3P on endosomes and autophagosomal structures (Backer 2008). Formation of PI3P is accompanied by the closure of the phagocytic cup and subsequent disappearance of PI(4,5)P$_2$ (Botelho et al. 2000) that lead to and are essential for
maturation of newly formed phagosomes (Vieira et al. 2001). Thus the function of PI3P is centred more around phagosomal/endosomal maturation than as a source of extra membrane during engulfment. Additionally, PI3P expression could be negatively regulated during maturation by the (FYVE domain containing protein) PI 5’-kinase, PIKfyve, via phosphorylation at the 5-position to produce phosphatidylinositol 3,5-bisphosphate (PI(3,5)P2) (Hazeki et al. 2012).

From the literature consulted, it seems that the origin of these relatively large amounts of “extra” membrane is most likely the phosphoinositides produced by PI3k enzymes. In support of this, non-specific inhibition of the PI3ks enzyme superfamily (which induced drastically decreased PIP₃, PI(3,4)P₂ and PI3P synthesis during phagocytosis), prevented treated cells from producing the 20% surface area increase usually observed during suicidal “frustrated phagocytosis” (Cox et al. 1999). This suggests that PI3ks activity is one of the chief sources of membrane during pseudopodia extension and phagocytosis. Additionally, a significant amount of membrane could also be supplied by recycling endosomes and sorting nexins (SNX), which collect membrane and other phagocytic components from endosomes and newly formed phagosomes called nascent phagosomes. Interestingly, this recycling machinery is also dependent on PI3P expression for docking onto intracellular structures (Fairn & Grinstein 2012), further supporting our notion of PI3ks as important role player in this context. Not all engulfed material is destined for degradation and subsequently need to be recycled by the recycling endosomes and SNX mentioned above. Recycling endosomes, partly identified by the Rab11 superfamily, is responsible for pinching off reusable cargo during the nascent phagosomal stage (Lemmon & Traub 2000). One of three Rab11 isoforms, Rab11a, is expressed on the nascent phagosome itself and facilitates phagosome fusion with early endosomes and
Golgi-derived vesicles (Fairn & Grinstein 2012). Rab11a also has a crucial role in proinflammatory signalling as it delivers TLR4, responsible for detection of lipopolysaccharide such as *E. coli* LPS, to maturing phagosomes (Husebye et al. 2010). The Rab11 superfamily seems necessary for engulfment itself as well, since Cox et al. (2000) reported that prevention of Rab11 GDP/GTP cycling by mutant alleles, inhibited particle internalization. Furthermore, the GTPase, ARF6, also controls trafficking of recycling endosomes to the membrane (van Ijzendoorn 2006) and inhibition thereof resulted in a block in pseudopod extension (Niedergang, F. et al. 2003), suggesting that recycling endosomes serve as an additional reservoir for plasma membrane during pseudopod extension. The greater part of cargo retrieval and sorting is done in the early phagosomal stage because most of the machinery is dependent on PI3P for docking (Fairn & Grinstein 2012), supporting the findings of Cox et al. (1999) previously mentioned. However, some of the SNX can form higher order structures with Vps26, Vps29 and Vps35 – these are called retromers (Cullen & Korswagen 2011). These retromers function in the presence of PI3P, but also active Rab7, giving them a limited time gap to recycle cargo between early stage and late stage phagosome maturation (between Rab5 to Rab7 transitioning), discussed below. This is in no doubt a finely tuned, complex process that merits further research in order to be fully elucidated.

**2.2.3. Nascent Phagosomal Stage**

This stage can be structurally distinguished from the pseudopod extension/engulfment stage by phagocytic cup closure behind the engulfed material of interest. Pseudopod closure is highly dependent on type I PI3k together with expression of PI3P and PI(4,5)P2. Inhibition of PI3k with the nonspecific protein inhibitor, LY294002,
prevented successful antibody opsonized particle engulfment due to unsuccessful pseudopod closure (Beemiller et al. 2006).

In contrast to pseudopod formation, the process of phagosome formation and maturation is relatively well described, although some controversies remain. Successfully engulfed material is encapsulated into nascent phagosomes characterized by Rab5 GTPase expression (Fairn & Grinstein 2012). Rabex-5, a guanine nucleotide-exchange factor (GEF), is initially recruited to newly formed endosomes by the already present Rab22a (Zhu et al. 2009) and functions to activate Rab5 (Horiuchi et al. 1997). Active Rab5 then recruits endosomal early antigen 1 (EEA1) (Scott et al. 2002) and the type III PI3K, hVPS34, (Kinchen et al. 2008) to the nascent phagosome. hVPS34 generates PI3P on the cytosolic face of nascent phagosomes that serve as docking station for a variety of maturation effectors. The FYVE domain of EEA1 can then dock onto PI3P to ensure later EEA1-mediated tethering and fusion of phagosomes with late endosomes for further maturation (Vieira et al. 2002). EEA1 thus seems to play a central role in phagosome maturation, as postulated by Fratti et al. (2001), after they illustrated that intracellular antibodies against EEA1 arrested phagosome maturation. However, around the same time as this study, Vieira et al. (2001) reported a dominant negative mutant of EEA1 which did not induce maturation arrest. They suggested that other FYVE domain containing proteins could be involved in PI3P binding that lead to subsequent maturation. Zinc finger FYVE domains, present in proteins like EEA1 and PIKfyve, recognize the hydrophilic head of PI3P on the cytosolic leaflet and allow binding of these proteins with substantial specificity to PI3P, resulting in this docking (Pathki et al. 1998). These contradicting findings on the necessity of EEA1 could be explained by its tendency for complex formation with other proteins. EEA1 has been reported to form a
macromolecular complex with Rabaptin-5, Rabex-5 and N-ethylmaleimide-sensitive factor (NSF) that interacts with syntaxin 13 (another SNARE) to facilitate membrane fusion (McBride et al. 1999). NSF disassembles these SNARE complexes via ATP hydrolysis after membrane fusion, blocking further action (Jahn & Scheller 2006). This could mean the maturation inhibition reported by Fratti et al. (2001) was achieved through the inability of antibody-bound EEA1 to form a macromolecular complex (likely due to steric hindrance), but the dominant negative form of EEA1 could, thus resulting in unperturbed phagosome maturation.

2.2.4. Late Phagosomal Stage

Transition to the late phagosomal stage is marked by GTPase-activating protein (GAP)-mediated Rab5 inactivation/dissociation (Fairn & Grinstein 2012) and Rab7 recruitment, together with late endosome fusion and expression of other markers such as mannose-6-phosphate receptor (MPR), lysobisphosphatidic acid (Fratti et al. 2001) and lysosome-associated membrane proteins (LAMP) (Desjardins 1995). It is also during this stage that PI3P is incorporated and degraded inside the phagosomal lumen via inward budding of the limiting membrane (Gillooly et al. 2000). Briefly, the PI 3’-phosphotase (PTEN) and PIKfyve eliminate PI3P via hydrolysis to PI and phosphorylation to PI(3,5)P2, respectively (Hazeki et al. 2012). Elimination of PI3P is likely necessary for the removal of nascent phagosomal effector proteins dependent on PI3P expression, such as EEA1 and other FYVE domain containing proteins. The late phagosomal stage initiates about 10-30 min after nascent phagosome formation, at least under in vitro conditions (Fratti et al. 2001). This is in accordance with the disappearance of PI3P about 10 min after its formation (Vieira et al. 2001).
Rab7 is expressed on both late endosomes/late phagosomes and lysosomes (Meresse et al. 1995). This expression profile allows Rab7 to regulate membrane trafficking between early endosome/nascent phagosomes and late endosomes as well between late endosome/late phagosomes and lysosomes (Press et al. 1998). The fusion between nascent phagosomes and late endosomes may allow the close proximity of Rab7 and PI3P that facilitates SNX retromer functioning reported by Cullen & Korswagen (2011), as mentioned in section 2.2.2. In this manner, the SNX retromers possibly recycle cargo between nascent phagosomes and late phagosomes, rather than nascent phagosomes and recycling endosomes, as hinted at earlier. This Rab7 GTPase accelerates maturation to the phagolysosome biogenesis stage with the help of Rab7-interacting-lysosomal-protein (RILP) (Harrison et al. 2003). The Rab7 associated proteins RILP and oxysterol-binding protein related-protein 1 (ORP1L) together link phagosomes to dynein (Johansson et al. 2007), which centripetally moves these late phagosomes along microtubules toward lysosomes for fusion (Harrison et al. 2003). Johansson et al. (2005) reported that ORP1L preferentially binds to active, GTP-Rab7 and that this association seems to sustain the GTP-bound state of Rab7. This prolonged activation could be required for successful dynein linkage. Dynein mediated fusion with lysosomes seems to be dependent on the HOPS complex as well as Rab7 (Akbar et al. 2011). HOPS is a tethering protein responsible for keeping phagosomes in close proximity to lysosomes, a function parallel to that of EEA1 (Hickey & Wickner 2010). Furthermore, disassembly of the microtubular network with nocodazole ablated centripetal movement of phagosomes, suggesting a dependency of macrophages to dynein for maturation (more detail provided in section 2.4.3.).
2.2.5. Phagolysosome Biogenesis Stage

Phagosome fusion with lysosomes is the last stage of maturation and is referred to as phagolysosome biogenesis (Seto et al. 2011). This stage was reported to occur about 1h after nascent phagosome formation under in vitro conditions (Jahraus et al. 1998). Our unpublished data indicate this stage is initiated closer to 30 min after nascent phagosome formation; however, it is important to keep in mind the nature of the internalised particle as this will influence progression to further stages and subsequent digestion. Fusion is mediated by the SNARE proteins (syntaxin 7, syntaxin 8, VAMP7 and VAMP8) (Becken et al. 2010) and provides the phagolysosome with the needed proteases (e.g. cathepsin D), reactive nitrogen species (RNS) and reactive oxygen species (ROS) with which to neutralize the ingested particle. Lysosome fusion also increases LAMP expression and effectuates an acidic phagosomal environment (Jahraus et al. 1994).

It may seem that Rab5 and Rab7 are the chief GTPases regulating endosomal and phagosomal maturation, as discussed in the previous section, but research has discerned significant roles for some other Rab proteins as well. For example, Rab10 has been shown to regulate sufficient recycling of proteins back to the plasma membrane and is present on nascent phagosomes even before Rab5 (Cardoso et al. 2010). Also, phagolysosomal protein degradation is hugely dependant on proteases like cathepsin D, delivered from the Golgi. Delivery is controlled by the trans-Golgi network-localised Rabs (22b, 32, 34,38 and 43) (Ng et al. 2007) that were shown to have various association and dissociation kinetics with the maturing phagosome (Seto et al. 2011). Blockage of cathepsin D delivery via dominant-negative Golgi-localized Rab alleles resulted in arrested phagosome maturation. Rab34 has also been implicated in phagolysosome biogenesis through its association with RILP (Wang &
Hong 2002). Another ER-localized Rab, Rab20, was shown to co-localize with V-ATPase on the phagosome, suggesting an involvement in phagosome acidification and maintenance thereof (Curtis & Gluck 2005). Seto et al. (2011) more recently reinforced this finding by reporting that dominant negative alleles of Rab20 and Rab39 prevent phagosomal acidification.

Phagocytosis has seemingly evolved from an endocytic nutrient gathering process in almost all eukaryotic cells to a specialized mechanism of self-defence conserved uniquely to professional phagocytes. In this manner a certain degree of redundancy exists in phagocytosis, most likely in order to be “fool proof”. However, as seen in the literature, at least some pathogens are able to adapt in order to escape degradation and neutralisation by phagocytosis to ensure their own survival. The most effective mechanisms employed by these microbes entail phagosome maturation arrest. Interestingly, these pathogens do not evade being transported into the phagocytic cell – rather they use the host cell as nutrient supply, so that they not only survive, but thrive.

### 2.3. Pathogenic Phagosome Maturation Arrest

Pathogenic phagosome maturation arrest is a hallmark of bacterial and viral host immune evasion. Many intracellular pathogens like *Mycobacterium tuberculosis*, *Candida glabrata*, HIV-1 and *Leishmania donovani* have evolved divergent mechanisms to modulate phagocytic digestion (Thi et al. 2012). Well characterized mechanisms of phagosome maturation arrest include (a) interference with PI3k function and PI3P biogenesis (*M. tuberculosis* & *C. glabrata*; Rai et al. 2015), (b) perpetuation of Rab5 expression (*L. pneumophila*, Clemens et al. 2000), (c) prevention of centripetal movement of nascent phagosomes (*M. tuberculosis* & HIV-1; Dumas et
al. 2015), (d) blocking of fission and fusion with lysosomes and endosomal organelles (
*M. tuberculosis* & *L. donovani*; Gogulamudi et al. 2015), (e) raising pH levels by
causing phagosomal acid leakage (*C. neoformans*; Tucker & Casadevall 2002), (f)
lysis of the phagosomal membrane to escape digestion (*Salmonella spp.*; Fain &
Grinstein 2012) and even (g) active macrophage killing (filamentous *C. albicans*; Gaur
et al. 2013). Although the mechanisms by which these pathogens evade phagocytosis
have been identified, they are not well understood and only a few have been
sufficiently studied in the context of phagocytosis. For the sake of brevity, we limited
ourselves here to a very brief overview of the mechanisms most relevant to this review.

2.3.1. Inhibition of Phagosome Maturation

*M. tuberculosis* survive intracellularly mainly by working against PI3ks, secreting the
acid PI 3’-phosphatase (SapM) to dephosphorylate PI3P, thus preventing EEA1 from
docking onto the phagosome (Vergne et al. 2005). Mycobacterial phagosomes also
retain the tryptophan-aspartate containing coat (TACO) protein, expressed on the
cytosolic leaflet of the plasma membrane involved in intracellular membrane
trafficking, cytokinesis and cytoskeletal remodelling (Gogulamudi et al. 2015). TACO
retention causes prolonged Rab5 expression - although some maturation effectors
can still bind the phagosome, this occurs in relative absence of PI3P, so that the FYVE
domain mediated binding of EEA1 is greatly perturbed (Simonsen et al. 1998), which
largely prevents lysosome fusion (Ferrari et al. 1999) to ensure a more alkaline and
hydrolase deficient phagosome (Clemens et al. 2000).

In contrast, the survival mechanisms of *C. glabrata* are largely dependent on active
PI3ks. *C. glabrata* encodes the enzyme PI3k and (similar to the type III PI3ks, hVPS34)
produces fungal PI3P through phosphorylation of PI (Strahl & Thorner 2007). In this
manner, the PI3P content of phagosomes could increase during the early stages of maturation where PI3P has not yet come into play. This could then lead to a PI3P rich phagosome being identified as already partly matured due to its PI3P phenotype, thus halting further maturation processes. Deletion of the two functional subunits of fungal PI3k (CgVps15 and CgVps34), led to alleviated phagosomal maturation arrest with greatly reduced fungal survival (99% of fungus died) and virulence in phorbol 12-myristate 13-acetate (PMA) differentiated THP-1 macrophages (Rai et al. 2015), providing evidence for its importance.

In addition, HIV-1 invasion is associated with inhibited phagosome formation as well as phagosome maturation arrest through microtubule perturbations. Several viral role players have been implicated here, such as the viral negative factor (Nef) (Mazzolini et al. 2010) and the regulatory viral protein (Vpr) (Dumas et al. 2015). Although we could not find a study to specifically implicate PI3k in these mechanisms, it is highly likely that these mechanisms are also PI3k related, since both Nef and Vpr (as well as Tat) have been shown to achieve several other effects, such as Regulated on Activation, Normal T Cell Expressed and Secreted (RANTES) production and down-regulation of the ARF6 endocytic pathway, via PI3k-dependent routes (Blagoveshchenskaya et al. 2002; Zhu et al. 2009; Gangwani et al. 2013; Nookala et al. 2013).

### 2.3.2. Interference with Phagosome Acidification

Hydrolase deficiency and retarded acidification are mainly brought about in two ways by *M. tuberculosis*. Firstly, hydrolysis is exacerbated by limited expression of Rab7. This GTPase has been shown to transiently localise to mycobacterial phagosomes, preventing needed RILP recruitment, but also limiting cathepsin D protease delivery
Secondly, mycobacteria also stimulate dissociation of the V-ATPase associated Rab20, preventing phagosomal acidification (Seto et al. 2011).

2.3.3. Prevention of Lysosome Fusion

Leishmania promastigotes are phagocytosed into phagosomes that retain TACO, blocking fusion with lysosomes and ensuring a neutral pH environment in which this parasite can multiply and differentiate into its amastigote stage (Mukkada et al. 1985; Ferrari et al. 1999). However, after differentiation, this parasite allows phagosome fusion with lysosomes to achieve an acidic environment in which the amastigotes can thrive. Interestingly, these phagosomes then also exhibit low expression of late phagosomal/endosomal markers such as LAMP, V-ATPase and Rab7 (Vinet et al. 2009).

In addition to preventing lysosome fusion, Leishmania further protects itself by inhibited recruitment of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase to the phagosome, resulting in perturbed ROS production (Moradin & Descoteaux 2012). Similarly, M. tuberculosis was reported to stimulate release of Tumour Necrosis Factor α (TNF-α) and interleukin 10 (IL-10) by infected macrophages (Sendide et al. 2005), resulting in a deactivation of ROS and NOS release from these macrophages (Redpath et al. 2001) to inhibit their microbicidal effect. IL-10 specifically also down-regulates secretion of pro-inflammatory cytokines like interferon gamma (INF-γ) and TNF-α (Redpath et al. 2001) and results in a shift toward a Th2-type cell expansion in the alveoli (de Almeida et al. 2012) with a shift towards an alternatively activated, anti-inflammatory, M2 macrophage phenotype (Smith et al. 2008).

These studies illustrate quite clearly that pathogens are able to manipulate the phagocytic process in various different ways. In doing so, they ensure not only their...
survival, but also their propagation and distribution through the host. However, in our opinion, it is also this manipulability of the phagocytic process that makes it ideal for use in regenerative medicine.

2.4. Harnessing the Phagocytic Process for Medicine

The current detailed understanding of the exact molecular mechanisms governing phagocytosis as well as perturbations achieved by pathogenic mechanisms, allows exploitation of this process for therapeutic purposes. After thorough study of the relevant literature, we have formulated a hypothesis on the use of this knowledge for potential therapeutic application in regenerative medicine and possibly other clinical fields as well.

Macrophages can engulf particles seemingly endless in size if one takes into account the suicidal “frustrated phagocytosis” reported by Cox et al. (1999). This suggests that they are able to engulf the majority of pathogenic microbes and almost all host somatic cells. Other factors influence phagocytosis, such as bacterial receptor ligands and macrophage co-stimulation by T-cells or other innate immune cells (e.g. NK cells) (Liu et al. 2013). Fortunately, the innate immune system has evolved to ensure macrophage target affinity and specificity together with the capacity to reach isolated tissue areas to neutralise hidden pathogens (Mills et al. 2015). Unfortunately, pathogen evolution alongside macrophages has equipped them with mechanisms to elude host defence, many of which are centred on perturbing phagocytosis to sustaining the pathogen inside macrophages. Though unwanted and detrimental to the host in the presence of pathogens, we believe that these modulations that pathogens can elicit on the process of phagocytosis, may be exploited for gain. We hypothesise that by inducing phagosome maturation arrest in a manner similar to that
of pathogens, but without pathogen involvement, the highly motile macrophages may be modified to render them useful as shuttles to carry "cargo" to specific areas within the host. The nature of this cargo could range from drugs to be delivered, to live stem cells, depending on the therapeutic aim. Of all potential options, the idea of a macrophage carrying a live stem cell – for example to increase muscle regenerative capacity in patients suffering from myodystrophy – is most enticing.

Let us consider for a moment what this would practically entail. Fundamentally, these macrophages would have to be isolated from patient blood and modified in vitro in order for it to maintain an ingested stem cell in a viable state within its phagosomes after autologous reinfusion. To achieve this, we propose induction of “artificial" phagosome maturation arrest. This will have to be achieved in a manner that will not compromise macrophage capacity for particle ingestion. A variety of methods by which this may be achieved have been unknowingly uncovered by researchers elucidating the details of phagosome maturation. Below, we evaluate the feasibility of these methods in terms of safety for in vivo application.

2.4.1. Macrophage IL-10 Enrichment

IL-10 is used by *M. tuberculosis* as a powerful inhibitor of phagosome maturation, discussed earlier. This is also supported by O'Leary et al. (2011) who found that macrophages containing killed *M. tuberculosis* produced less IL-10 than cells infected with live *M. tuberculosis*, showing that *M. tuberculosis* upregulates IL-10 production to protect itself against destruction. As this anti-inflammatory and anti-microbial cytokine is produced in vivo one can argue that it is a promising agent to use for therapeutic phagosome maturation arrest, although some problems do exist.
As shown previously, the IL-10-mediated maturation inhibiting effect of *M. tuberculosis* is also dependent on MAPKp38 activation in human macrophages (Song et al. 2003). This is supported by data reported by O’Leary et al. (2011), who significantly restored phagosome maturation by inhibiting MAPKp38 in *M. tuberculosis*-containing macrophages. Subsequent addition of rIL-10 to these cells resulted in the reoccurrence of maturation arrest, testifying to the plasticity of this technique. However, O’Leary et al. (2011) reported that the IL-10-induced maturation arrest occurs both in the presence of viable and non-viable *M. tuberculosis*, but not in its absence, suggesting that *M. tuberculosis* infection is necessary for IL-10 to induce maturation arrest. This problem can probably be overcome by identification of the essential bacterial component, which – if not antigenic or pathogenic itself – can be administered as co-treatment. A more problematic fundamental flaw to this approach is the phenotypic change that IL-10 effects in macrophages. IL-10 is known to polarize macrophages towards the alternatively activated (M2) phenotype (Chazaud et al. 2009; Mia et al. 2014). Although the anti-inflammatory phenotype is desired in terms of resolution of inflammation and wound healing, M2 macrophages do not readily cross endothelial barriers (Arnold et al. 2007). This would significantly inhibit the actual delivery of the ingested stem cell to the intended target tissue. This complication however highlights the need for another step in the process – macrophages will have to be polarised towards the M1 phenotype, to ensure sufficient mobility.

### 2.4.2. Brefeldin A Treatment

The fungal antibiotic, Brefeldin A (BFA), inhibits a subtype of Golgi associated GEFs (ARF-GEFs) that facilitate the GDP/GTP cycling of ARF family proteins (Donaldson et al. 1992). These ARF-GEFs express a Sec7 domain that Brefeldin A recognises and inhibits by direct binding to it (Shin & Nakayama 2004). ARFs play a central role in
regulating plasma membrane traffic (Zhang et al. 1998), actin polymerization and activating phosphatidylinositol kinases for phosphatidylinositol production. Active ARF mediated membrane trafficking is controlled via coat proteins expressed on cellular transport vesicles (Kreis et al. 1995). ER and Golgi bilaterally traveling transport vesicles are coated with proteins such as calnexin and coat protein complex type I (COPI) and type II (COPII) (Letourneur et al. 1994). COPI is recruited to phagosomes and contributes to recycling of phagosomal components (Berón et al. 2001). Active ARF1 is necessary for this COPI recruitment and inhibited COPI expression has been shown by Berón et al. (2001) to partly perturb phagosomal recycling events. Thus, because BFA sensitive ARF-GEFs control ARF1 activity that in turn allows COPI recruitment, BFA treatment could potentially induce phagosome maturation arrest by preventing sufficient recycling of phagosomal components. However, Beemiller et al. (2006) found BFA-mediated inhibition of ARF-GEFs did not lead to subsequent inactive ARF1 expression on phagosomes. This suggests that the cells adapted to ARF-GEF inhibition by recruiting GEFs that are insensitive to BFA treatment. In addition, dual specificity of ARF was reported for BFA: ARF1 and ARF5, but not ARF6 – the main ARF implicated in encapsulation – was reported to be sensitive to BFA (Zeeh et al. 2006). The effect of BFA on phagosome maturation thus remains largely unknown.

2.4.3. Microtubule or Dynein Inhibition

As mentioned earlier, dynein is vital for centripetal and centrifugal delivery of phagosomes to lysosomes for fusion. The dynactin complex has been shown to facilitate cargo binding to dynein for centripetal movement (Blocker et al. 1997), while the Rab5 GTPase regulates motility of endosomes (Nielsen et al. 1999), likely through a phosphoinositide and EEA1 dependent manner. It is widely accepted that
microtubule disruption negatively influences phagosome centripetal movement and coinciding maturation. In regard to this, Blocker et al. (1996) has shown inhibition of phagosome movement via microtubule disassembly after nocodazole treatment. Nocodazole could thus induce phagosome maturation arrest, but the associated microtubule disassembly could perturb pseudopod extension via inhibited PI3k delivery, thereby inhibiting uptake of stem cells into macrophages. Furthermore, it is possible that nocodazole induced microtubule disassociation could block cellular motility and chemotactic reactivity, ablating the very characteristic of macrophages we intend to exploit.

Thus, placing focus on dynein motor inhibition could pose a more viable solution. Ciliobrevin D is a dynein motor blocker that inhibits the GTPase activity of dynein (Chou et al. 2011). Ciliobrevin D is also a dynein specific inhibitor and does not affect kinesin-1 and 5 ATPase activity (Firestone et al. 2012), making this compound a promising unidirectional inhibitor of centripetal movement only. Furthermore, Ciliobrevin D does not disrupt microfilament structure (Misawa et al. 2013). Moreover, Sainath & Gallo (2014) found that Ciliobrevin D inhibited bidirectional mitochondria, lysosome and Golgi-derived vesicle transport. Ciliobrevin D has recently been suggested as modulator of lysosome mechanics (Lin et al. 2015) and has been used in autophagy studies (Li et al. 2016). It has further been utilised to elucidate the formation of NLR pyrin domain containing 3 (NLRP3) mediated inflammasome formation in bone marrow derived macrophages (Misawa et al. 2013), but its effects on phagosome maturation have not been reported. This compound seems to be promising for the purpose of inducing phagosome maturation arrest and should be further investigated in this context.
2.4.4. Wortmannin

This fungal steroid metabolite is a known potent, selective and irreversible inhibitor of all three PI3k subtypes (Vieira et al. 2001) via covalent binding (Yuan et al. 2007). A subsequent study by Vieira et al. (2003) reported virtually complete elimination of phagosome fusion with late endosomes and lysosomes after Wortmannin treatment. These inhibitory roles for Wortmannin suggest it to be an ideal candidate for our purposes. However, not all effects of Wortmannin are equally desired. For example, PI3K-inhibition by Wortmannin was reported to enhance TLR-mediated inducible nitric-oxide synthase (iNOS) expression, to activate NF-κB and to up-regulate cytokine mRNA production (Hazeki et al. 2006), suggesting a pro-inflammatory role. In addition, Wortmannin treatment was also shown to prevent large particle (>3μm) engulfment through inhibiting PI3P formation (Cox et al. 1999). Together these data suggest that the use of Wortmannin for macrophage modification will require a finely optimised protocol, to ensure maximal phagosome maturation arrest, without compromising the encapsulation process or eliciting an inflammatory response.

2.4.5. Concanamycin A

Concanamycin A is a plecomacrolide that specifically inhibits the V-ATPase proton pump. This enzyme is responsible for energizing the membranes of eukaryotic cells, both intracellular and plasma membranes (Huss et al. 2002). V-ATPase is also expressed on the late phagosome and ensures an acidic pH during phagosome maturation. The V-ATPase consists of two complexes, the catalytic $V_1$ located on the cytosolic side of membranes and the translocating $V_0$ unit bound to the membrane (Huss & Wieczorek 2012). Concanamycin A covalently binds to the subunit c of the translocating $V_0$ complex (Huss et al. 2002), thereby preventing proton influx into
phagosomes, resulting in an alkaline pH of about 7.5 (Yates et al. 2005). Concanamycin A is commonly used in experimental models for its inhibition of autophagy (e.g. Yano et al. 2016).

2.4.6. Chloroquine

Chloroquine is a 4-aminoquinoline that indirectly prevents acidification of intracellular vacuoles (Akpovwa 2016). This weak base accumulates within vacuoles or phagosomes via ion trapping and reduces the pH to about 6.5 if used at 10μM (Weber et al. 2000). This compound is readily used as an anti-malarial drug and was very recently suggested as a possible Ebola drug, since its alkalinizing action would prevent intracellular viral replication, provided that its concentration can be maintained at effective dose (Akpovwa 2016). The fact that chloroquine is a known medication is a benefit, since its safety for human consumption has been established. Similar to Concanamycin A, chloroquine has proven efficacy in the context of (auto)phagosome maturation arrest.

From this information, we conclude that a number of potential treatments may be considered as candidate treatments with which to achieve macrophage modification for the purpose of hosting one or more live stem cells, increasing the feasibility of our hypothesis.

2.4.7. Additional Factors to Consider

Of course, although the maintenance of the stem cell inside the macrophage is a major consideration and an important problem to solve, it is not the only one. In order for the stem cells to be ingested by the modified macrophage, they will have to be opsonised, especially since autologous cells will ideally be used for this technique, to
minimise side-effects. Furthermore, the opsonisation process should not interfere with stem cell function after delivery at the site earmarked for regeneration. However, we believe that this can be overcome using advanced technology and a multidisciplinary approach. Recently, great advances have been made in the field of abiotic membrane-active polymers that can coat cell membranes whilst maintaining cell viability (Marie et al. 2014). These polymers can be “decorated” with an opsonin to enhance encapsulation, after which the polymer can be deconstructed by e.g. slight temperature change or vibration.

Another question is whether the number of stem cells ingested should be limited. From the frustrated phagocytosis model, it is known that macrophages have an exceptional capacity for membrane “extension”, so that several stem cells can theoretically be ingested by an individual macrophage. Indeed, this was the case in preliminary studies in our lab (Visser & Smith, unpublished data). However, we believe that the number of stem cells ingested per macrophage can be limited by optimising the time allowed for engulfment. Alternatively, flow cytometry sorting could be employed to sort for cells with optimal number of ingested stem cells.

Once reinfused, macrophages should naturally migrate to sites requiring regeneration. Of course, in order to achieve maximal benefit, the chemotactic signal could also be manipulated, and the known vast array of exciting tracking methods may be employed to track the final destination of the modified macrophages. These processes are, however, not within the scope of this review, which is focused on modification of the macrophage itself.

The final consideration to include in this review is the release of the stem cell at the appropriate destination site. A plethora of mechanisms exist to induce cell death or
exocytosis. One example is Brefeldin A. Although it has doubtful application for phagosome maturation arrest, BFA may prove useful in later stages of cell cargo delivery, by inducing apoptosis in the macrophage. BFA can induce ER stress (Tseng et al. 2014) through inhibited anterograde protein trafficking between the ER and Golgi (Alvarez & Sztul 1999). Prolonged BFA treatment can cause chronic ER stress and subsequent mobilization of the compensatory unfolded protein response (UPR). If the UPR is unable to resolve ER stress, this compensatory mechanism shifts from pro-survival to pro-death and mobilizes cell death responses like apoptosis (Hetz 2012). Apoptosis is achieved under chronic treatment conditions (15h – 40h) (Alvarez & Sztul 1999), which allows sufficient time for the processes of engulfment, reinfusion and in vivo transportation to be completed. A favourable consideration in this context is that BFA does not affect engulfment capacity of large (3μm) or small (0.8μm) particles, despite its ER traffic inhibitory effects (Becker et al. 2005), possibly due to the insensitivity of ARF6 to BFA mentioned earlier. Of course, as with all other phases, other candidate methods – such as targeted exocytosis – should also be considered and optimised. Leishmania donovani promastigotes multiply and differentiate into amastigotes inside arrested phagosomes (Moradin & Descoteaux 2012). These amastigotes then escape the macrophage to continue their life cycle. This poorly understood phenomenon could be exploited to induce exocytosis in stem cell carrying macrophages.

2.5. Summary

In summation, modern science has substantially increased our understanding of molecular role players not only in the phagocytic process, but also in regenerative medicine. We firmly believe that by pooling resources across multiple disciplines, the
remaining obstacles can be overcome to achieve the therapeutic technique we outlined here. If phagosome maturation could be arrested, these macrophages could be used as an *in vivo* delivery system for phagocytosed “cargo”.

Delivery of laboratory-enhanced or conditioned stem cells, using an autologous physiologically relevant vehicle, will be a significant step forward in terms of individualised medicine, and especially in disease states where no current mainstream therapy has proven effective.

### 2.6. Hypothesis

The scope of this thesis was to address the first steps in creating such a delivery system. We hypothesised that macrophage phagosome maturation arrest could be experimentally induced by *in vitro* treatment with a Wortmannin, Concanamycin A and Chloroquine cocktail, without limiting phagocytic engulfment capacity or transendothelial migratory capability of macrophages.

### 2.7. Objectives

In order to test our hypothesis, we formulated the following objectives:

1. Isolation of a pure population of primary monocytes
2. Culturing and polarisation of peripheral human monocytes to induce a classically activated (M1) macrophage phenotype
3. Inducing M1 phagosome maturation arrest by acute administration of a combination of Wortmannin, Concanamycin A and Chloroquine.
4. Developing a model to qualitatively and quantitatively assess phagocytic and digestive capacity.
Chapter 3: Materials and Methods

This chapter deviates from the typical format of a thesis methods chapter. Since method development was a big part of my research topic, it is (in my opinion) important to also present the process followed. Therefore, apart from the optimised method, various technical considerations and the process through which the final protocol was derived, will also be presented. Methods are presented chronologically, to illustrate the sequence of multiple steps which all had to be synchronised to achieve a result.

3.1. Cell Type Selection

Primary isolated human monocytes were chosen above immortalised cells lines for a number of reasons. Firstly, it was decided that, given the multi-stepped complexity of the process and the numerous role players involved when manipulating a physiological, and specifically an immunological, process, the in vitro work should resemble the in vivo situation as closely as possible. In this way, the transfer from in vitro to eventual in vivo application should progress more smoothly - practical translation of results for human therapeutics was an important consideration in the design of this study. Secondly, and related to the applicability of data to in vivo situations, repeated exposures to low temperatures or DMSO (as is common practice in cell culture maintenance) may result in anomalies in these cells that may affect assessments made. Just one example of such a change is the perturbation in cytochrome P-450 activity after exposure to 0.1% DMSO (Busby et al. 1999). Thirdly, established immune cell lines such as THP-1 cells were originally isolated from unhealthy donors, in this case acute monocytic leukaemia (Tsuchiya et al. 1980), but not all abnormalities of these cells have been recorded, so that it is not possible to ascertain normality of the cell mechanics that we proposed to investigate here. Lastly,
in our experience, although primary macrophages are notoriously adherent, commercial macrophage lines are considerably less adherent in culture. This suggests an alteration in adhesion molecule expression in these cells and given the importance of cell adhesion in cell migration, this is perhaps the most clear-cut reason for our choice to opt for using primary cells.

3.2. Ethical Considerations

Ethical clearance exemption for isolation of human monocytes from purposely donated blood was obtained from the Subcommittee C Human Research Ethics Committee (HREC) of Stellenbosch University (Reference # X15/05/013).

3.3. Monocyte Isolation

Buffy coats were collected specifically for our study by the Western Province Blood Transfusion Service (WPBTS), using donors between the age of 18 – 25 years. Donors were informed of the study and consent were obtained from all donors, by the WPBTS. Monocytic population isolation was performed within 8 hours of each donation. A double gradient centrifugation protocol was employed, as this protocol is more widely used in blood cell separation and avoids possible confounding and/or undesired effects, such as possible inactivation of CD14 surface complexes (associated with antibody binding), which is commonly associated with positive Magnetic-Activated Cell Sorting (MACS) and Fluorescence-Activated Cell-Sorting (FACS) (Tomlinson et al. 2013).

Briefly, buffy coats – containing all circulating leukocytes together with residual erythrocytes and platelets – were layered onto Histopaque 1.077 g/ml (Sigma-Aldrich, #10771) at a 2:1 ratio and centrifuged at 400 x g for 30 min at 23°C. Peripheral Blood
Mononuclear Cells (PBMCs) were collected with a plastic Pasteur pipette and washed twice in PBS-EDTA (1x Phosphate Buffered Saline containing 0.5 M Ethylenediaminetetraacetic acid) (Sigma-Aldrich, #P4417 + #E9884) at 300 x g for 10 min at 23°C. Purified PBMCs were resuspended in RPMI 1640 without phenol red (Sigma-Aldrich, #R0883), containing 10% FBS (Fetal Bovine Serum) (Sigma-Aldrich, #12003C) and layered onto a 42.56% iso-osmotic 1.131 g/ml percoll (Sigma-Aldrich, #E0414) solution at a 1.25:1 ratio. The iso-osmotic percoll solution consisted of 48.6% advanced RPMI 1640 with phenol red (Life Technologies, #12633-020), 42.56% percoll, 5.4% FBS and 3.44% 10x PBS. Separation of monocytes from PBMCs was achieved at 550 x g for 30 min at 23°C. Monocytes were collected with a plastic Pasteur pipette and washed once in PBS-EDTA at 400 x g for 10 min at 23°C. Monocytes were then resuspended in Complete Monocyte Media (CMM).

3.4. Culture Conditions

Complete Monocyte Media consisted of advanced Roswell Park Memorial Institute medium (RPMI) 1640 with phenol red containing 10% Human Serum from AB patient (Sigma-Aldrich, #H4522), 100 U/mL Penicillin-Streptomycin (PenStrep) (Life Technologies, #15140148) and 2 mM Glutamax (Life Technologies, #35050-061).

Monocytes were seeded at 4x10^6 cells/well (2x10^6 cells/ml) onto Nunc UpCell™ plates (AEC-Amersham, #174901) or 35 mm culture dishes (Bio-Smart Scientific, #20035) and cultured with CMM. Images of cell monolayers were taken at time points 24 hours, 96 hours and 144 hours to assess differentiation. In order to promote differentiation into M1 type macrophages, 50 ng/ml GM-CSF (Granulocyte Macrophage Colony-Stimulating Factor) (Sigma-Aldrich, #SRP3050) was added to each well directly after seeding (Mia et al. 2014). Similar, 50 ng/mL M-CSF (Macrophage Colony-Stimulating Factor).
Factor) (Sigma-Aldrich, #SRP3110) was added to each well to promote M2 type macrophage differentiation, when appropriate. Growth factors were added after every media change. Cells were allowed to adhere for 24 hours after which media was aspirated, cell monolayers washed with warm PBS and fresh media introduced. Thereafter media was changed every 72 hours. Cells were cultured for a total of 6 days. Incubator conditions were kept at 37°C with an 80% humidified environment and 5% CO₂.

### 3.5. Pre-differentiation and Polarisation

Following pre-differentiation with GM-CSF and M-CSF as described earlier, macrophages were polarised to M1 phenotype via pre-treatment with 50 ng/ml LPS (Lipopolysaccharide) (Sigma-Aldrich, #L2762) and 20 ng/ml IFN-γ (Interferon-gamma) (Sigma-Aldrich, #I3265) for a period of 24 hours (Liu & Yang 2013). Similarly, M2 macrophage polarisation was done with 20 ng/ml each of IL-4 (Interleukin 4) (Sigma-Aldrich, #SRP4137), IL-10 (Interleukin 10) (Sigma-Aldrich, #SRP3071) and TGF-β (Transforming Growth Factor beta) (Sigma-Aldrich, #SRP3171) for a period of 24 hours. A M1 and M2 population was cultured to better determine induction of M1 phenotype when expressed against the opposite, M2 phenotype. This is a better representation than an unpolarised population, defined as M0, but likely consisting of a mixed population of M1 and M2 macrophages, expressed in scatter plots as a double signal peak for M1 markers (as shown in Section 4.1, Figure 4.2). The pro-inflammatory M1 phenotype was specifically used in this study for its transendothelial migratory capability (Arnold et al. 2007) that fit the delivery requirements of this project. Furthermore, despite controversial reports of GM-CSF treatment promoting M1 phenotypic differentiation (Mia et al. 2014), other reports led to the choosing of this
cytokine for our study purposes. For example, a recent paper claimed increased migration and chemotaxis after treatment with this cytokine (Dabritz et al. 2015), which would further promote cell migratory capacity. Additionally, the phagocytic capacity or engulfment capacity of macrophages has been shown to increase after treatment with this cytokine (Eischen et al. 1991). This is important for our study because the engulfment aspect of phagocytosis needs to be maintained after phagosome maturation arrest. The arrest inducing agent, Wortmannin, has been shown to prevent engulfment of large (>3 µm) particles (Vieira et al. 2001). In this regard, GM-CSF treatment was used to maintain engulfment capacity.

Macrophage differentiation was also recorded over time using a phase contrast DSZ5000X inverted biological microscope (Lasec, South Africa) with ScopeTek software and DCM-510, 5 mega pixel camera. A representative population was imaged 24 hours, 96 hours and 144 hours after isolation at 20x magnification. This was done to evaluate morphological changes during differentiation.

### 3.6. Culture Detachment

Monocytic cells are notoriously adherent, which poses some technical difficulties when cultures have to be maintained for a number of days. Cells used in the transmigration assay were seeded and harvested from Nunc UpCell™ plates. To save costs, cells designated for analysis using live cell imaging and flow cytometry were seeded, maintained and harvested from 35mm culture dishes using Accutase® (Sigma-Aldrich, #A6964) cell detachment solution. Macrophages were challenged against antibody opsonised polystyrene bead (AbsBeads) after being harvested with either method. The ability of both UpCell™ and Accutase® methods to allow AbsBeads phagocytosis directly after reseeding, was similar, indicating well preserved functionality with both
methods for the purposes of this study. The next paragraphs will provide some more specific detail on these two culture methods.

3.6.1. Nunc UpCell™ Plates

UpCell™ plates are coated with a temperature responsive polymer called poly(N-isopropylacrylamide) (PIPAAm). This dynamic polymer is capable of cycling between hydrophobic and hydrophilic states, depending on ambient temperature. PIPAAm is hydrophilic at 20˚C, causing hydration and extension of the polymer. The hydrophilicity of the surface interferes with protein adsorption and subsequently results in cell detachment (Collier et al. 2001). The turning point of PIPAAm between hydrophilicity and hydrophobicity is 32˚C; this point is defined as the lower critical solution temperature. At 37˚C the hydrophobic polymer is dehydrated, causing contraction of PIPAAm. The hydrophobic surface is capable of stronger binding to the interior of cell surface proteins, compared to hydrophilic surfaces, leading to cell adhesion (Lampin et al. 1997). Accordingly, UpCell™ plates were placed onto warmed (37˚C) gel packs when removed from the incubator to change media or introduce growth factors, in order to maintain the hydrophobic state. Cell detachment was achieved by removing UpCell™ plates from the incubator, aspirating media and replacing with advanced RPMI 1640 at a temperature of only 10˚C. Plates were then incubated at 10˚C. Similar to Collier et al. (2001), we found that primary macrophages optimally detached when incubated for 60 min. Cell viability was maintained after this incubation period. In order to limit exposure time to low temperature, plates were only incubated for 30 min at 10˚C after which the cell monolayer was carefully scraped off with a cell scraper. This adaption increased total cell yield, but had no noticeable effect on viability. Thus 60 min incubation was used to limit mechanical stress associated with handling cells.
3.6.2. 35mm Culture Dish with Accutase® Method

A pilot study using 8-chamber slides with glass culture surfaces (which was required to facilitate live cell imaging and reduce reagent turnover) revealed a reluctance of primary monocytes to adhere to glass. Conversely, monocytes potently adhered to polystyrene surfaces of 35mm culture dishes. These dishes were also compatible with confocal live cell imaging. Harvesting primary monocytes with trypsin broke down surface pseudopodia resulting in cell death. Accordingly, macrophages were harvested with Accutase® cell detachment solution. Media was aspirated, cell monolayer washed with 23°C PBS and 1 ml Accutase® injected onto dishes. Cells were incubated at 23°C for 10 min after which dishes were swirled and another 1 ml Accutase® added for further incubation of 10 min at 23°C. Cells were collected and centrifuged at 400 x g for 5 min at 37°C. Accutase® cell detachment solution auto-inhibits at 37°C eliminating the need to neutralise with media.

3.7. Macrophage Phenotype Analysis

After pre-differentiation and macrophage M1/M2 polarisation, macrophage phenotype was quantitatively confirmed by flow cytometry (BD FACSARia Cell Sorter, Becton Dickinson, USA), using BD FACSDiVa v6.1.3 software. Single stain and multiple stain solutions were prepared by mixing appropriate amounts of fluorescent antibody markers with 1 ml PBS. Media was aspirated from culture dishes and replaced with appropriate 1 ml single stain or multiple stain PBS solution. Antibody binding was facilitated at 37°C for 10 min before PBS was removed and cells harvested with Accutase®. Harvested populations were centrifuged at 400 x g for 5 min at 37°C and resuspended in warm PBS. Populations were filtered, relocated to flow cytometry tubes and immediately analysed. Unstained samples were prepared to determine
background fluorescence. Single stain samples (containing only one marker) were used for fluorescent signal optimisation and compensation for potential spill-over between fluorophores. Multiple stain samples were used for data collection and labelled with the following fluorescent antibody markers: Alexa Fluor 647 Rabbit Anti-Human CD274 (PD-L1) (640/665nm) (Cell Signalling, #15005S), BB515 Mouse Anti-Human CD86 (490/515nm) (BD Bioscience, #564544) and V450 Mouse Anti-Human MHCII (HLA-DR) (405/448nm) (BD Bioscience, #561359). The appropriate lasers were used to excite fluorophores and emission was captured using appropriate band pass filters. Data collection was done by recording 3x10⁵ events for every donor in triplicate and thresholds were set up by recording 8x10⁵ events. After appropriate training in the technical flow cytometry procedures by a staff member of the Central Analytical Facility (CAF) at Stellenbosch University, I was able to perform these analyses independently.

3.8. Modulating Macrophage Phagosome Maturation

Phagosome maturation arrest was induced in order to preserve the “cargo” to be delivered by macrophages within M1 macrophages. Briefly, cells were pre-treated with 10 μM Chloroquine (Sigma-Aldrich, #C6628) from 1h before initiation of phagocytosis, followed by 100 nM Wortmannin (Sigma-Aldrich, #W1628) at 30 min prior to phagocytosis and 100 nM Concanamycin A (Sigma-Aldrich, #C9705) immediately before initiation of phagocytosis. Macrophages were incubated in an 80% humidified environment at 37˚C with 5% CO₂ throughout this period. Chloroquine is a weak base capable of permeating cell membranes. Exposure to this compound specifically leads to its accumulation in lysosomes, causing alkalisation thereof and preventing fusion with phagosomes (Yang et al. 2013). This agent also non-specifically increases the
pH of phagosomal as well as other vacuolar cell structures, such as autophagosomes. Similarly, Concanamycin A contributes to a less acidic phagosomal lumen by specific inhibition of V-APase proton pump. Covalent binding to this enzyme prevents proton influx into phagosomes (Huss et al. 2002). The higher alkalinity induced by these agents functionally contribute to phagosome maturation arrest by preventing protein degradation. Conversely, Wortmannin directly contributes to the induction of phagosome maturation arrest by covalently binding to PI3ks (Vieira et al. 2001). Binding inhibits production of PI3P and other phosphatidylinositols chiefly needed for phagosome maturation.

3.9. Visualisation of Ingested “Cargo” Using Fluorescent Beads (AbsBeads)

Blue fluorescent carboxylate modified polystyrene beads (either 4.5 μm or 6 μm in diameter) (Polysciences, #18340-5 + #19102-2) were used as a stem cell model. The 4.5 μm diameter beads were chosen for their similar size to skeletal muscle satellite cells and served as representation during transmigration assays. Furthermore, the 6 μm beads were used to determine the phagocytic capacity of phagosome maturation arrested macrophages compared to digestive macrophages, since Wortmannin treatment was previously reported to limit the size capacity of phagocytosis (Vieira et al. 2001). Since normal digestive phagosomes are unable to break apart polystyrene beads, beads were coated with a digestible IgG protein in order to facilitate visualisation of intraphagosomal digestion. (The carboxylate modification on these microspheres can be activated to allow covalent binding to proteins.) Fluorescent Alexa Fluor 647 Goat Anti-Human IgG (Life Technologies, #A21445) was chosen as protein coating. The antibody coating allowed visualisation and identification of beads
in maturation arrested phagosomes in comparison to those in digestive phagosomes. A loss in red fluorescent signal would be suggestive of digestion – irrespective of the reason for the signal loss, which could be antibody protein degradation, conjugated fluorophore inactivation or breakage of covalent bonds between antibody and bead. Antibodies were coated onto beads using a protocol obtained from Life Technologies (Invitrogen 2001). After adaptation of this protocol, antibody coating was achieved by dissolving 2 mg/ml IgG solution in 50 mM MES (2-(N-morpholino)ethanesulfonic acid) buffer (Sigma-Aldrich, #M5287) and adding 5 ml of 4.5 μm or 6 μm bead suspension to the solution. The solution was incubated at 23°C for 30 min to allow for antibody coating. EDAC (1-ethyl-3-(3-dimethylaminopropyl)- carbodiimide) (Sigma-Aldrich, #E2247) was added to a final concentration of 0.4 mg/ml and thoroughly vortexed. The pH was adjusted to 6.5 ± 0.2 using dilute NaOH and placed on an orbital shaker to incubate overnight at 23°C. The addition of EDAC and increase in pH serves to prevent bead agglomeration during overnight incubation. Glycine (Sigma-Aldrich, #G7126) was added to a final concentration of 100 mM and solution was incubated at 23°C for 1h. Beads were pelleted by centrifuging at 4000 x g for 20 min at 23°C and washed three times with 50 mM PBS at the same centrifugal velocity. Beads were resuspended for storage in 50 mM PBS containing 2 mM sodium azide at 2.89x10^7/ml stock. According to the supplier, these antibody coated beads, hereafter referred to as AbsBeads, retained the IgG coating for up to 17 months when stored at 4°C.

Noteworthy, false positives can be yielded from passive adsorption (not absorption) of positively charged particles to the external surface of the cell membrane (Thiele et al. 2001). However, this is not applicable to our study as the negatively charged carboxylate modified beads used, do not tend to do this. Flow cytometric analysis also
served to distinguish between free bead populations and beads ingested into macrophages (Appendix C), averting this problem.

3.10. Phagocytosis

Macrophage recognition and engulfment of foreign material is achieved *in vivo* through secondary stimulation by other cell types such as CD4+ T-cells and NK cells (Liu et al. 2013). In the absence of these supportive cells *in vitro*, engulfment is possible through Fcy receptor engagement with IgG opsonised material, as shown in numerous studies (Vieira et al. 2001; Hazeki et al. 2012; Segawa et al. 2014). However, this is only achieved if IgG opsonin is of same-species origin or if the FcyR possesses cross-species reactivity to foreign IgG. Specifically, a lack of human neonatal Fc receptor (FcRn) cross-reactivity to sheep, rat, mouse and bovine IgG has been reported (Ober et al. 2001). This antibody scavenging FcRn did however possess rabbit and guinea pig cross reactivity. These findings can be extrapolated to other FcR subtypes such as FcyR. Therefore, the cross reactivity of macrophage FcyR to goat IgG was addressed in the present study. The Alexa Fluor 647 Goat Anti-Human IgG used to coat and opsonise AbsBeads was not recognised by primary M1 macrophages, expanding on previous FcRn-cross-reactivity data. Thus, the AbsBeads required additional IgG opsonisation to induce engulfment by human macrophages, and therefore, AbsBeads were incubated in serum obtained from a healthy (O+) donor. Experimentally-induced perpetually activate unbound carboxylate modifications on AbsBeads allowed nonspecific binding of serum proteins, resulting in macrophage recognition and engulfment.

AbsBeads solution was incubated with serum at a 1:1 ratio for 24h. AbsBeads were then introduced into M1 macrophage population at 1.156x10^6 AbsBeads/well, marking
the initiation of phagocytosis. Phagocytosis and particularly phagosome maturation arrest was assessed over a 2h period.

3.10.1. Live Cell Imaging of Phagocytosis

Visual representation of phagocytosis was recorded with a Carl Zeiss LSM780 confocal microscope with ELYRA S.1 Superresolution platform (Carl Zeiss, Germany) using ZEN 2011 imaging software. This allowed qualitative analysis of digestive capacity as well as cell viability, motility and pseudopod extension during recognition and engulfment. Monocytes were appropriately cultured into a M1 macrophage population after which phagosome maturation arrest was induced in treatment groups and AbsBeads introduced into arrest-treatment as well as control groups. Time lapse images were taken for 2 hours from initiation of phagocytosis. Cells were imaged in a humidified environment at 37°C in the presence of 5% CO₂. CellMask™ Orange Plasma Membrane Stain (554/567nm) (Life Technologies, #C10045) was used to label macrophages. CellMask™ non-specifically binds phospholipid bilayers with its hydrophobic anchoring tail and fluorescently labelled hydrophilic head. Fluorescent labelling of conventional membrane markers such as CD14 or CD45 was avoided as antibody binding to these membrane proteins could influence phagocytosis resulting in a statistical false negative. The pH sensitive pHrodo® Green E. coli BioParticles® (509/533nm) (Life Technologies, #P35366) were introduced onto cells to distinguish acidic phagosomes. This marker is fluorescent in acidic pH (<6.0) while non-fluorescent in physiological pH. Acidic phagosomes are present in unaffected control samples where phagocytosis is unaltered, while phagosome maturation arrested macrophages exhibit more alkaline pH (>6.0) values. pHrodo® was introduced at a final concentration of 1 mg/ml immediately before the initiation of phagocytosis. AbsBeads were introduced into control as well as treated groups at 1.156x10⁶
cells/well. Indigestible blue fluorescent beads distinguished cells devoid of cargo due to digestion thereof from cells devoid of cargo due to not participating in phagocytosis. Similarly, digestible red IgG distinguished cells capable of cargo degradation from phagosome maturation arrested macrophages. Appropriate tracks were set up with optimal individual laser intensities. A random field of view was chosen as representative for the population and imaged at 20x magnification with minimal cycle time between images.

3.10.2. Flow Cytometric Quantification of Phagocytosis

Macrophage engulfment and digestive capacity was quantified with BD FACSARia Cell Sorter flow cytometer using BD FACSDiVa v6.1.3 software. Monocytes were appropriately cultured into M1 population after which phagosome maturation arrest was induced in treated groups. Similar to live cell imaging, AbsBeads and pHrodo® were introduced into media and phagocytosis allowed to commence for 2 hours. No CellMask™ was used to label cells. Media was then aspirated and cells harvested with Accutase®. Harvested populations were centrifuged at 400 x g for 5 min at 37°C and resuspended in warm PBS. Populations were filtered, relocated to flow cytometry tubes and immediately analysed. Unstained samples consisting only of macrophages were prepared to determine background fluorescence. One single stain sample consisted of only AbsBeads with no cells while the second was only pHrodo® treated macrophages. These samples were used in fluorescent signal optimisation and compensation for possible spill-over between fluorophores. Multiple stain samples were used for data collection and consisted of AbsBeads at 1.156x10⁶ cells/well and pHrodo® at 1 mg/ml final concentration. The appropriate lasers were used to excite fluorophores and emission was captured using appropriate band pass filters. Data collection was done by recording 3x10⁵ events (in this case both cells and beads will
be counted as events) for every donor in triplicate and thresholds were set up by recording $8 \times 10^6$ events.

### 3.11. Transmigration System

The transendothelial migratory capacity of cargo-carrying macrophages was assessed in a co-culture model using BD Falcon Cell Culture Inserts and Companion Plates. The transmigration complex consisted of inserts with membranes at the bottom which were placed into accompanying wells of 24-well plates. Migration through these inserts toward a chemotactic agent was indicative of *in vivo* diapedetic capacity. Inserts had a transparent polyethylene terephthalate (PET) membrane with pore sizes of either 3 µm or 8 µm (BD Bioscience, #353096 + #353067). Inserts were coated with Human Umbilical Vein Endothelial Cells (HUVEC) to better simulate the *in vivo* environment for migration. Reasons for this are; under *in vivo* conditions chemokines bind proteoglycans exposed on endothelial cells, which directs the movement of migrating leukocytes, and effective migration entails movement of macrophages through an endothelial cell layer (Imhof & Aurrand-Lions 2004). Proteoglycan binding maintains access to the leukocyte chemokine receptor binding site on the chemokine (Proudfoot et al. 2000). This allows presentation of the proteoglycan bound chemokine to leukocytes on the luminal side of endothelium. Leukocyte recognition via its G-protein-coupled receptor induces a prompt integrin-activation signal that culminates in migration from circulation into tissue (Imhof & Aurrand-Lions 2004).

Additionally, we simulated different cellular environments under which to test migration efficiency. Firstly, endothelial exposure to LPS and IFN-γ are characteristic of inflamed tissue. This being the tissue type M1 macrophages infiltrate, it is of importance to ascertain the effect thereof on cargo carrying phagosome maturation arrested...
macrophages. Secondly, GM-CSF was also added along with the chemokine to appropriate groups. GM-CSF is argued to promote macrophage differentiation more strongly toward a M1 phenotype than M2 (Jaguin et al. 2013). In part, the reason therefore is its production in inflamed tissue areas where monocytes predominantly differentiate to M1, compared to the presence of M-CSF in circulation before migration has occurred (Mia et al. 2014). Additionally, GM-CSF was reported to promote migration and chemotaxis in macrophages (Dabritz et al. 2015) as well as recruitment of undifferentiated monocytes to tissue areas, due to local production of GM-CSF by resident macrophages (Shi et al. 2006). Taken together, these reports could have a profound effect on migration of macrophages into tissue areas expressing this cytokine.

3.11.1. Fibronectin Coating

Human Umbilical Vein Endothelial Cells (HUVECs, gifted from University of Cape Town) are unable to adhere to culture plate surfaces without the appropriate coating. For this reason, HUVECs were cultured on fibronectin-coated surfaces. Briefly, prior to introducing HUVECs, tissue culture flasks as well as transmigration insert-well complexes were coated with $1 \mu g/cm^2$ fibronectin (Sigma-Aldrich, #F0895). The appropriate amount, according to growth area, of $1 mg/ml$ fibronectin stock was mixed with enough $1x$ PBS to cover the entire growth area. Flasks or plates were incubated at $37^\circ C$ for 1 hour to allow coating before the fibronectin-PBS solution was removed and containers left to dry in a laminar flow hood under UV light overnight. Culture containers were placed in resealable sterile bags to preserve sterility. These coated surfaces maintained fibronectin expression and adherence capacity when stored for up to 2 months at room temperature.
3.11.2. HUVEC Cell Culture

HUVEC cells of passage 3 (P3) were thawed from liquid nitrogen-stored cryo vials and injected directly onto fibronectin coated T25 flasks, without centrifugation. DMSO used in freezing was diluted by the addition of 4 ml Complete HUVEC Media (CHM). CHM was made up with Endothelial Cell Growth Medium (EBM) containing 2% FBS, 0.4% Bovine Brain Extract (BBE), 0.1% human Epidermal Growth Factor (hEGF), 0.1% Ascorbic Acid, 0.1% GA (30 µg/ml Gentamicin and 15 µg/ml Amphotericin) and 0.1% Hydrocortisone. EBM was obtained from Lonza (#CC-3121) and the additional compounds were bought as supplementary unit from Lonza (#CC-4133). Media was replaced 24 hours after seeding and thereafter every 48 hours until 90% confluency. Media was aspirated and HUVEC cells harvested by washing with warm PBS and introducing 0.25% Trypsin (Celtic Diagnostics, #L0931-500). Cell monolayers were incubated at 37°C for 5 min in shaking incubator to allow for cell detachment. Trypsin was neutralised with EBM and cell suspension centrifuged at 1500 RPM for 3 min at 23°C. Supernatant was removed and cell pellet resuspended in appropriate media for seeding in appropriate flask or inserts.

For the transmigration assay, HUVECs were seeded onto fibronectin-coated transmigration inserts at 1x10^5 cells/insert (2x10^4 cells/ml) with 200 µl CHM in the insert as well as 700 µl CHM in the well, to prevent fluid loss through the insert membrane. These HUVECs were cultured for 3 days prior to the start of the transmigration assay to allow formation of a continuous cell monolayer. For migration protocols simulating potential pro-inflammatory physiological conditions, HUVEC cells were also pre-treated with either 50 ng/ml LPS or 20 ng/ml IFN-γ for 24 hours before the start of transmigration assay.
3.11.3. Transmigration Assay

Macrophages were prepared and after a total of 2 hours (UpCell™ harvesting is another 1 hour) AbsBeads-exposed macrophages were collected, centrifuged at 400 x g for 5 min at 23°C and resuspended in Transmigration Media devoid of Chemokine (TM-C) – the latter was prepared with EBM containing 2% FBS, 0.4% BBE and 0.1% Ascorbic acid. Macrophages were introduced onto inserts at 3x10⁵ cells/insert (6x10⁴ cells/ml) and TM-C media filled up to 200 µl in total for each insert. For this part of the experiment, macrophages were resuspended in EBM media (and not RPMI) in order to prevent adverse effects on the HUVEC monolayer. Hydrocortisone was removed from this step because it is immunosuppressive due to its glucocorticoid nature and could therefore cause a false negative during migration analysis. The hEGF facilitates HUVEC cell proliferation, and because endothelial cells are not proliferative during migration in vivo it could influence signalling pathways and hinder chemokine presentation to macrophages, thus it was also omitted from experimentation. Furthermore, since the transmigration step was only 2:30 hours in duration, there was no need for addition of antibiotics such as GA.

Transmigration Media with Chemokine (TM+C) was injected into the bottom well of the insert-well complex at 700 µl final volume for every well. TM+C consisted of 100 ng/ml Monocyte Chemoattractant Protein 1 (MCP-1) (Sigma-Aldrich, #SRP3109) together with the same compounds and concentrations as TM-C. Where appropriate, TM+C also contained 50 ng/ml GM-CSF. LPS and IFN-γ was not added to TM+C. These compounds were used to treat HUVECs and was added to CHM in the upper insert, 24h prior to experimentation, at 50 ng/ml and 20 ng/ml, respectively. MCP-1 was chosen as chemokine for its specificity for monocytes/macrophages, as well as because previous research done in our group has shown it to be effective in a co-
culture setup (Africa & Smith 2015). The MCP-1 protein is relatively large, with a molar mass of 8600 g/mol (8.6kDa), making it susceptible to protein denaturation when made up in solution in the absence of a stabilising agent. Bovine serum albumin (BSA) can be used to stabilize MCP-1 in solution. However, this was not deemed suitable for our purposes, as stabilisation could affect its tertiary structure and interfere with endothelial cell or macrophage recognition and binding to the chemokine (Imhof & Aurrand-Lions 2004).

The transmigration complex was placed in a 80% humidified environment at 37˚C with 5% CO₂ and cells were left to migrate for 2:30 hours. At the end of this period, cells were fixed by addition of pre-warmed 4% paraformaldehyde directly into each well and insert, at a volume equal to that of the media in each well. (Fixative was added directly to culturing media to maintain the initial number of cells that could otherwise be washed away if media was removed before fixing). After 10 minutes, the fixative was removed and replaced with 1x PBS. Data acquisition was done using a phase contrast DSZ5000X inverted biological microscope (Lasec, South Africa) using ScopeTek software and DCM-510, 5 mega pixel camera. The entire macrophage population on the bottom of all outer wells were counted at 10x magnification using a cell counter and in the presence of trypan blue (Sigma-Aldrich, #T8154) at a final concentration of 0.014%. Trypan blue was not added to illuminate viable cells (as intact cell membranes are also permeable to trypan blue after fixing), but to increase phase contrast and facilitate counting.

To further simulate in vivo conditions, HUVECs were pretreated with IFN-γ and LPS for 24 hours. Treatment of macrophages with IFN-γ has been shown to reduce migratory capacity in response to MCP-1 stimulation via inhibited actin remodelling (Hu et al. 2008). However, this study was done under static in vitro conditions and the...
cytokine-effect on macrophages was determined, not endothelial cells. IFN-γ induced displacement of the tight junction protein, junctional adhesion molecule (JAM)-A, to the luminal surface of endothelial cells has a negative effect on macrophage migration under static conditions, but no significant effect under simulative blood flow conditions (Imhof & Aurrand-Lions 2004). Furthermore, IFN-γ was reported to induce secretion of macrophage migration inhibitory factor (MIF) in tubular epithelial cells (Rice et al. 2003). The MIF cytokine upregulates macrophage migration, despite its convoluted name, by promoting expression of adhesion molecules such as intercellular adhesion molecule (ICAM)-1 and vascular cell adhesion molecule (VCAM)-1 on vascular endothelium (Cheng et al. 2010). MIF also acts in a paracrine and autocrine fashion to initiate MCP-1 secretion from these endothelial cells, resulting in greater migration into tissue (Kasama et al. 2010). Thus, the effect of IFN-γ on static transmigration following pretreatment of HUVECs with this endogenous pro-inflammatory cytokine was examined. On the other hand, LPS release from gram negative bacteria is associated with inflammation and induced adhesion molecule expression on endothelial cells (Abbas et al. 2014). Although the study at hand focused on macrophage infiltration into damaged tissue areas to facilitate regeneration, phagosome maturation arrested macrophages could infiltrate both these IFN-γ and LPS associated inflammatory sites in response to adhesion molecule expression.

A pilot transmigration study, identical to the one described above, was done using adherent monocytes (i.e. not macrophages) polarized with 50 ng/ml LPS and 20 ng/ml IFN-γ directly after isolation for 24 hours prior to assessment. This was carried out to investigate the possibility of shortening the preparation time of primary macrophages by using monocytes - aiming toward a possible translational application for the treatment for more acute conditions where preparation time is limited. Monocytes were
capable of sufficient AbsBeads uptake after 1h challenge. However, no cell migration was found at experimental end point in any group, including control groups devoid of AbsBeads (data not shown). Thus, in the results section, we will report only the results obtained in macrophages.

3.12. Statistical Analysis

All statistical analysis was done using Graph Pad Prism 5. All data are presented as means ± SEM. Student’s t-test and one-way analysis of variants (ANOVA) were conducted where appropriate. A p-value of <0.05 was considered statistically significant.
Chapter 4: Results

All experiments were conducted at least in duplicate and repeated a minimum of three times. For all experiments with an intervention component, suitable controls were included with every run.

4.1. Monocyte Differentiation and Polarization

![Monocyte Differentiation and Polarization](image_url)

**Figure 4.1: Monocyte differentiation into macrophages.** Monocytes were cultured under standard conditions in 35mm culture dishes and imaged with a phase contrast microscope at 20x magnification for all images. (A) imaged 24h, (B) 96h and (C) 144h after isolation.

Images were taken of the isolated monocytic cells in culture at different time points from initiation of the GM-CSF-driven pre-differentiation to evaluate general morphological changes during differentiation of monocytes into macrophages. Representative images (Figure 4.1) of cells cultured on polystyrene surfaces show a
striking increase in cell size over time. A gradual increase in cell size, across a 72-hour period, can be seen by comparing frame B (96 hours after isolation) to frame A (24 hours), followed by a seemingly more drastic change, as seen in frame C (144 hours). Across this last 48-hour period, cells exhibited greater increases in size and notably developed morphological changes characterized by surface pseudopodia and cell flattening, when compared to the initial 72-hour period.

![Figure 4.2: Flow cytometry analysis of macrophage differentiation.](image)

Cells were assessed after 144-hour (6-day) culture period with fluorescent antibodies against CD86, MHCIi and CD274. Panel (A) indicates a M0 population while (B) indicates M1 and (C) M2. Vertical lines indicate fluorescence thresholds, with cell populations to the left staining negative, and those to the right positive for the particular fluorescent label.
To quantitatively support findings shown in figure 4.1, flow cytometry was done to determine the efficacy of the M1 polarisation, by phenotyping of differentiated cells using M1 membrane markers.

The M1 polarisation protocol (GM-CSF, LPS and IFN-γ treatment) clearly resulted in an M1 phenotype, with high expression of M1 markers CD86, MHCII and CD274 (Figure 4.2 panel B), when compared to the much lower M1 membrane protein expression in cells polarised using the M2 (M-CSF, IL-10, IL-4 and TGF-β treatment) protocol (panel C). Panel C in fact illustrates no expression of M1 markers, since only background fluorescence (below threshold) was detected. The undifferentiated M0 population expressed a lower and combined fluorescent signal, indicated by double signal peaks on threshold values (panel A).

4.2. Phagocytosis Model Validation

![Figure 4.3: Antibody dispersion off of ingested AbsBeads.](image)

Figure 4.3: Antibody dispersion off of ingested AbsBeads. Enlarged confocal microscope images of a control cell showing red antibody dispersion off of AbsBeads into the cell. Frames taken at 10 min (A) and 60 min (B) after introduction of AbsBeads. Arrow indicates dispersion of antibody. Time lapse images taken at 20x magnification.
Representative images show a cell not treated for phagosome maturation arrest at high magnification (Figure 4.3). Frame A shows the cell in the process of engulfment at 10 min. The same cell is shown in frame B at 60 min with red antibody signal expression inside the cell. This illustrates that at this time point, the antibody coating was removed from AbsBeads and was dispersed throughout the phagosome (indicated by arrow), before its complete degradation and accompanying loss of red signal (not shown here). This visually validates our model and confirms that an antibody coating around these beads can be used as a model for phagosomal digestion studies. Note that pHrodo® was not used in figure 4.3 for the sake of clarity, as doing so would have obscured the intracellular signal which indicates the antibody digestion from the bead.

Figure 4.4: Acidification of cellular compartments. Time lapse images of a live control cell showing AbsBeads ingestion coinciding with acidification. Frames captured at 10 min (A) and 60 min (B) after AbsBeads challenge. Arrows indicate individual acidic compartments within the cell. Images taken at 20x magnification.

Having validated the use of AbsBeads to indicate phagosomal digestion, the next validation step was to illustrate that digestion coincides with phagosome acidification. Similar to figure 4.3, ingestion of AbsBeads by a representative control cell occurred...
10 min after challenge (Figure 4.4 frame A). At this time some lysosome or phagosome acidification can already be seen (indicated by white arrows). Frame B shows the same cell at 60 min after challenge with green signal expression around two AbsBeads as well as dispersed throughout the cell. This represents unaffected phagosome maturation and acidification during phagocytosis. Additionally, individual green acidic compartments can be distinguished at magnifications as low as 20x, supporting the visual power of pHrodo® as a marker of acidification.

This phagocytic model is completely novel with regard to the quantitative as well as qualitative assessment thereof, and established materials have never before been used in conjunction or for the study of phagocytosis in the context of similar projects.

4.3. Intervention: Phagosome Maturation Arrest

Having sufficiently validated and characterised the model in terms of time course of events and efficacy of markers, the phagosome maturation arrest protocol was implemented. Phagosome maturation arrest is required to preserve the cargo taken up by macrophages, in this case AbsBeads.
Figure 4.5: Time lapse images of live macrophages. Control cells (panel: A, B, C) and phagosome maturation arrested cells (panel: D, E, F). Frames taken at 10 min, 60 min and 120 min after AbiBeads challenge. Representative cells are indicative of phagocytic capacity (white circles). Loss in red antibody signal is indicated by blue arrows. Green digestive cells with acidic phagosomes showing a loss in red antibody signal are indicated by yellow arrows. Pseudopod extension, cell motility and red antibody preservation are indicated with white arrows. Lighter background shade (D, E, F) is due to phase contrast signal, used to visualise pseudopodia. Images taken at 20x magnification.
Time lapse images of a representative macrophage populations are shown in figure 4.5. The right hand side panel (phagosome maturation arrested cells: D, E, F) shows maintained red antibody signal throughout the 2-hour imaging period, with the absence of green acidic signal (indicated by white arrows). Compared to control cells on the left hand side panel (A, B, C) showing green acidification (indicated by yellow arrows) as well as loss in red antibody signal (blue arrows) over the same time period. This illustrates successful induction of phagosome maturation arrest and maintenance thereof for up to 2 hours. White arrows (Frames D, E, F) indicate cells that initiated phagocytosis as early as 10 min after AbsBeads challenge (Frame D) and actively moved toward a bead to achieve ingestion at 60 min (Frame E). Noteworthy, preserved cell motility and pseudopod extension is seen throughout the treated panel, also indicated by white arrows. (Pseudopodia extension likely serves to sample the surrounding environment and it is possible that the cell indicated with a white arrow at the bottom of frame E and F, attempted to ingest the nearby bead.)

4.3.1. Digestive Capacity

Representative quantitative flow cytometry scatter plots are presented in Figure 4.6. Scatter plots illustrate macrophage degradative capacity expressed as red antibody fluorescent signal over number of AbsBeads per cell. Control samples show a loss in red signal after the 2-hour phagocytosis endpoint, indicated with a red circle. This “degradation tail” represents cells capable of removing the red antibody coating around beads and subsequently digesting the IgG itself or inactivating the IgG fluorescent label. These outcomes were jointly classified as representatives of digestion. In these representative plots for example, an untreated control population was analysed and yielded 5.88% macrophages, capable of sufficient protein degradation to achieve signal loss below the threshold. Conversely, 55.93% of this
population maintained antibody coating in the absence of arresting agents. This discrepancy is likely due to a relatively short experimental period. The nature of ingested material directly affects digestive tempo, thus, utilization of an extended phagocytic period would yield greater degradation. Nevertheless, this 55.93% yield is overshadowed by 79.22% of a phagosome maturation arrested population expressing sufficient signal after the same period. More importantly, only 0.66% of treated cells contained inviable cargo, compared to a 5.88% control yield. This phenomenon was evident in all samples tested, as supported by statistical analysis showing significant cargo degradation in 1.23 ± 0.26% of cells after treatment, compared to 7.52 ± 0.98% of untreated cells (p<0.0001) (Figure 4.7).

Scatter plots (Figure 4.6) also present a linear relationship between the number of beads per cell and the antibody expressed on each bead. This is represented by the red intensity regions indicated with arrows and is shown more clearly in the “treated” scatterplot. These are clusters of cells expressing similar fluorescent signal for both
beads and antibodies. Additionally, the most prominent region of degradation, indicated by a degradation tail, is found in clusters expressing a lower density of beads. Thus, it can be derived that the degree of digestion is correlated to number of beads in the cell i.e. the nature of the material is dependent on time needed to degrade it.

![Figure 4.7: Statistical analysis of macrophage digestive capacity](image)

4.3.2. Engulfment Capacity

Macrophage engulfment capacity, defined as the number of cells containing any number of beads after 2 hours, was determined. A representative bead positive population, shown in figure 4.6 scatter plots, yielded 61.81% (55.93% + 5.88%) under control conditions, whereas 79.88% (79.22% + 0.66%) of phagosome maturation arrested cells contained beads. This is supported when inversely determining engulfment i.e. assessing the number of cells unable to ingest material, represented by populations negative to both beads and antibody, from control and treatment conditions (Figure 4.6). Representative phagocytically uninvolved macrophages constituted 36.91% and 19.04% with and without phagosome maturation arrest, respectively (Figure 4.6). Statistical analysis of all populations (Figure 4.8) indicated maintained engulfment capacity. The non-significant difference is represented as

![Graph showing % Cells containing AbsBeads with no red signal](image)
68.67 ± 3.51% of treated cells containing beads while 61.19±4.68% of cells were capable of engulfment in control groups (p=0.207). Considering these findings, it seems phagosome maturation arrest had no effect on engulfment capacity. This is also seen in figure 4.5 where the number of AbsBeads ingested is not notably affected under control or treatment conditions, respectively (indicated by white circles).

Figure 4.8: Statistical analysis of macrophage engulfment capacity. Measured as the percentage of cells containing any number of ingested AbsBeads. Cells were analysed with flow cytometry. Values expressed as percentages from scatter plots and presented as mean ± SEM (n=3). p=0.207 vs control.

4.3.3. Acidification

Macrophage degradative capacity and phagosome maturation is dependent on phagosome acidification (Fairn & Grinstein 2012). For this reason, fluorescent antibody signal was plotted over pHrodo® fluorescence intensity (Figure 4.9). Representative cells under control conditions achieved phagocytosis to near completion as indicated by a collective acidity signal of 94.39% (54.47% + 39.92%) above threshold. Taking into account that this figure represents the same cell population assessed in figure 4.6, one can extrapolate that almost all cells were phagocytically mature and in the process of digestion, however, were not allowed sufficient time to completely degrade antibody. Conversely, the phagocytic process
was interrupted in phagosome maturation arrested cells. These cells maintained a more alkaline (pH >6) intracellular environment, presented by 95.42% (76.50% + 18.92%) of cells with insufficient signal intensity. Only a small cell population of 4.59% (3.84% + 0.75%) achieved phagosomal acidification after treatment, compared to 94.39% under control conditions. Phagosome inability to acidify was also statistically significant with 29.17 ± 8.40% acidic cells after treatment, compared to 92.09±1.09% under control conditions (p<0.0001) (Figure 4.10). This acidification is also visually presented in figure 4.4 indicated by white arrows, as well as in figure 4.5 indicated by yellow arrows.

The control population of 39.92% (Figure 4.9) represent acidic cells expressing no antibody signal. This population can be defined in two ways. Firstly, this population could have ingested AbsBeads or only residual antibody and degradation thereof was completed before cells were assessed, however, insufficient time was available to regain homeostatic pH at >6.0 before the 2-hour time point. Secondly, the ingestion of

![Figure 4.9: Representative flow cytometry scatter plots of macrophage acidification with intensity clusters. Antibody signal intensity (y-axis) expressed over acidic pHrodo® signal intensity (x-axis). 3x10⁵ events collected.](image)
pHrodo® BioParticles® into these cells could have induced acidification in an attempt to degrade this marker, leading to cells devoid of antibody but still acidic. Additionally, autophagy could also play a role in representing a false degradative phagosome or acidic autophagosome. Due to the above reasons these plots were used for statistical assessment of acidification only and not degradation directly.

Figure 4.10: Statistical analysis of macrophage acidification. Measured by green fluorescence signal intensity. Cells were analysed with flow cytometry. Values expressed as percentages from scatter plots and presented as mean ± SEM (n=3). ### = p<0.0001 vs control.

4.4. Macrophage Migration

Arrested macrophages exposed to a MCP-1 chemokine gradient significantly migrated through HUVEC coated membranes with 8 µm pores (72.86 ± 16.0 cells per well) compared to arrested control samples (22.43 ± 3.60 cells per well), not exposed to MCP-1 (p < 0.01) (Figure 4.11). This verifies a significant induction of migration in response to chemokine stimulation as opposed to a passive migration, driven by gravity. Additionally, phagosome maturation arrested macrophages maintained ability to transverse endothelial barriers in response to MCP-1. Macrophages containing 4.5 µm AbsBeads maintained migration capacity, as indicated by 70.14 ± 12.6 migrated cells per well when compared to cells without AbsBeads (72.86 ± 16.0 cells per well) However, migration of these AbsBeads containing macrophages was still significantly
more when compared to control (22.43 ± 3.60 cells per well, p < 0.005). Of note, migrated cells were frequently inviable and presented as perforated cell membranes containing AbsBeads. The likely cause of this reduced viability, is uncontrolled AbsBeads engulfment causing membrane shattering during attempted migration through pores with insufficient size.

The influence of potentially confounding in vivo factors was also determined (Figure 4.11). The GM-CSF cytokine was added to MCP-1 containing media. Although not significant, there seemed to be a trend for reduction in migration, with 63.57 ± 11.3 migrated cells in this group. However, migration was still significantly increased when compared to control (p < 0.005). Noteworthy, the addition of cytokine did not diminish MCP-1 stimulated migration (p = 0.704) compared to AbsBeads group. However, the
slight reduction in migration is contradictory to previous reports that presented an exposure to GM-CSF upregulated migration and chemotaxis (Dabritz et al. 2015).

No significant outcome after treatment with either LPS (72.14 ± 15.3) or IFN-γ (63.43 ± 12.8) was found, compared to AbsBeads group. However, the somewhat lower trend in migrated cell population following IFN-γ pretreatment could be argued as a result of prior macrophage polarisation together with IFN-γ induced displacement of JAM-A, as our assay was also done under static conditions (previously discussed in section 3.11.3.).
Chapter 5: Discussion

The aims of this study were met with the development of a modified, non-destructive macrophage population capable of engulfment and transmembrane movement. This was achieved by re-evaluation of previous findings in the literature regarding phagosome maturation arrest and application of this knowledge in a novel context. By combining subdisciplines in physiology, these customarily detrimental effects in the context of immune cell function, were used in a manner and setting which may bring about therapeutic outcome. More specifically, the known positive effects of macrophage infiltration on tissue healing – or more specifically muscle healing and regeneration (Arnold et al. 2007) – was manipulated to achieve a vehicle for the delivery of therapeutic modalities such as stem cells or even pharmaceuticals.

Since the development of an in vivo delivery system is by nature a complex, multi-stepped process, the entire process was outside of the scope of a single MSc thesis. Therefore, this thesis focused on the manipulation of macrophages to render them incapable of digestion of engulfed “cargo”, while maintaining their capacity for engulfment and transendothelial migration. We report on the successes achieved in this more limited context.

5.1. Macrophage Polarisation

Monocytes were cultured and exposed to GM-CSF for 144 hours as well as LPS and IFN-γ for 24 hours, in order to polarise them into a M1 macrophage phenotype (Mia et al. 2014). This phenotype was necessary for the purpose of our study, as this is the only phenotype previously shown to migrate endothelial barriers after differentiation (Arnold et al. 2007; Chazaud et al. 2009). The M1 phenotype is also capable of particle engulfment and digestion as this is the main phenotype to which inflammatory
monocytes are differentiated (Imhof & Aurrand-Lions 2004; Freeman & Grinstein 2014). This being said, the main function of circulating undifferentiated monocytes are tissue infiltration during inflammation. In an attempt to circumvent extended culture periods, we assessed the migratory capacity of phagosome maturation arrested monocytes containing AbsBeads. Unfortunately, no migration was seen (section 4.4). Our data thus confirms that only differentiated macrophages, and not peripheral monocytes, would be suitable carrier cells.

In terms of the pre-differentiation step, there are two major results to interpret: the size increase of cells, and changes in their expression of macrophage markers. Successful differentiation into macrophages was evident from the images shown in Figure 4.1, which illustrates a striking increase in cell size over the 6-day culture period. A time dependent increase in proximity between cells, allowing cytokine or paracrine production to effectively influence differentiation (Silverthorn 2010; Freeman & Grinstein 2014), was considered as an inducive effect to cell enlargement. However, cell proximity was not noticeably increased and the number of cells did, in fact decrease, in relation to enlargement. Therefore, cell enlargement can be attributed to experimentally introduced GM-CSF that acts both as a cytokine and growth factor to increase cell adherence (represented in figure 4.1 as cell flattening) and also cell enlargement (Dabritz et al. 2015). This can be applied to cell enlargement seen in frame A to B (24 hours and 96 hours after isolation, respectively), however, does not sufficiently explain the considerable cell enlargement, over a relatively shorter time period (48 hours of elapsed time), seen when comparing frames C and B. The experimental concentration of GM-CSF remained constant throughout. However, differentiated macrophages could have sufficiently matured to locally produce
additional GM-CSF by this time point (Shi et al. 2006), which could explain this abrupt cell enlargement (Abbas et al. 2014).

Interestingly, the reduction in cell number observed (Figure 4.1) could be as a result of repeated media changes and PBS washes, but seeing as monocyte/macrophages are particularly adherent in vitro (Collier et al. 2001), this is unlikely. A more feasible explanation could simply be the relatively short lifespan of monocytes in circulation (10-20 hours) (Guyton & Hall 2011). Monocyte in vivo extravasation is needed to induce differentiation into resident tissue macrophages. This process ensures a prolonged lifespan by providing a protective and nutrient- and chemokine-rich extracirculatory environment which augments cell survival. In contrast, under in vitro conditions, monocytes were unable to infiltrate tissue and was forced to differentiate under relatively unprotected and chemokine-poor conditions. The absence of tissue infiltration, exposed cells to possible apoptotic and/or autophagic inducers that would normally be attenuated in tissue niches. Thus, macrophages were kept in a circulatory environment as opposed to tissue and likely underwent some degree of apoptotic cell death throughout this time. However, this should be seen as an artefact of the in vitro nature of cell culture models, rather than a confounding factor in this study.

In terms of evidence for macrophage polarisation, the flow cytometry signal intensity graphs show monocyte differentiation as well as successful polarisation to achieve macrophage M1 phenotype in the majority of cells (Figure 4.2). This marker profile is in accordance with published studies on this topic (Mia et al. 2014; Ka et al. 2014) and confirms that our protocol successfully polarised primary peripheral monocytes into M1 macrophages, which should have high capacity for transendothelial migration (Arnold et al. 2007; Chazaud et al. 2009). Interestingly, changes in MHCII expression are used for identification of both M1 and M2 populations in the literature. Since M1
polarisation is associated with elevated MHCII expression (Mia et al. 2014) and exposure to IL-10 (used during our M2 polarisation protocol) is known to down-regulate MHCII expression (Abbas et al. 2014), MHCII is (in our opinion) a particularly useful marker with which to assess macrophage phenotype polarisation in our context.

5.2. Manipulating Phagosome Maturation

Previous research has been centred around microbial and parasitic immune evasion with ensuing reports linking phagosome maturation arrest as part of pathogenesis, throughout. A plethora of interventions is employed to achieve immuno-protection, including interference with PI3ks, Rab5, Rab7, EEA1, V-ATPase, endosomal and lysosomal fusion events and recruitment of digestive proteases (Rai et al. 2015; Clemens et al. 2000; Seto et al. 2011; Vergne et al. 2003; Puri et al. 2013; Ghigo et al. 2002). Manipulation of these detrimental aspects has never before been attempted in the context of regeneration or drug delivery. As no previous research has focussed on intentional induction of phagosome maturation arrest, notwithstanding previous studies into autophagy modulation, no literature exists with which to compare current data. Similarly, the viability of mammalian proteins after phagosome maturation or arrest thereof has never before been determined and previous work in this context has focused on viability and immunogenicity of microorganisms, which is not relevant to the current study design, although it may provide some hints for interpretation of current data in terms of the efficacy with which digestion was inhibited.

In the current study, Concanamycin A and Chloroquine treatment was employed to block phagosome acidification. The rationale therefore is underpinned by observations gathered from two microorganisms capable of blocking phagosome acidification and
inducing phagosome maturation arrest in that manner: *Mycobacterium tuberculosis* and the *Leishmania* superfamily.

Concanamycin A is a selective V-ATPase inhibitor that directly affects phagosomal acidification by preventing formation of a proton gradient (Huss et al. 2002). It simulates a situation similar to *Leishmania* that prevents recruitment of the V-ATPase. Chloroquine, on the other hand, is a weak base able to alkalinise phagosomes that leads to a block in lysosome fusion due to this raised phagosomal pH (Akpovwa 2016). This in turn then simulates the block in endosome/lysosome fusion seen under conditions of TACO retention. In our study, blocked phagosome acidification was represented by a reduction or absence of green pHrodo® signal in treated cell populations (Figures 4.5, 4.9, 4.10).

We also utilized the PI3k inhibitory effect of Wortmannin to prevent formation of PI3P on maturing phagosomes (Vieira et al. 2001; Hawkins & Stephens 2015). Wortmannin is a steroidal fungal metabolite that non-specifically inhibits subtype I, II and III PI3ks by covalent binding to lysine residue in the catalytic unit of this enzyme (Wymann et al. 1996; Liu et al. 2005). Supported by previous studies (Nakanishi et al. 1995; Yano et al. 1993; Jackson et al. 2004), Wortmannin has shown prolonged effective inhibition of PI3ks, resulting in phagosome maturation arrest.

An interesting point for discussion, given the ultimate goal for *in vivo* application, is the fact that the 20 position carbon (C20) of Wortmannin is highly reactive with nucleophiles in solution, resulting in an extremely short half-life of 0.99 min (59.4 seconds) in culture media (Yuan et al. 2006). Therefore, a Wortmannin paradox was proposed and investigated by Yuan and colleagues (Yuan et al. 2007) to determine the relative effectiveness of this metabolite *in vivo* and *in vitro* against its highly reactive
nature. Briefly, investigation found that Wortmannin resides within cell culture solution under various C20 amino acid derivatives that undergo dynamic transitioning between different nucleophile donors to form other derivatives, while also reverting to unmodified Wortmannin. These derivatives vary in their capability to inhibit PI3ks. Noteworthy, of the nucleophiles tested, the C20-lysine derivative was the weakest PI3k inhibitor and also the most stable, forming a physiologically irreversible binding that yields negligible Wortmannin reformation. We extrapolated from this that Wortmannin cycles between C20 derivatives until exposure to lysine, found free within cell culture or contained in the PI3k catalytic unit. The resultant irreversible covalent binding induces prolonged inhibition, however, due to steric hindrances in the catalytic unit, Wortmannin is vulnerable to intramolecular attack by its C6 position hydroxyl group (responsible for the reversibility of C20 derivatives to reform Wortmannin and other compounds after binding to different nucleophiles (Yuan et al. 2007)). Subsequently, the bond can be broken and PI3k regains fractional activity until repeated binding with C20 derivatives. Together, this poses an explanation for why macrophages in this study readily engulfed 6 µm as well as 4.5 µm AbsBeads, contradictory to previous reports of Wortmannin-induced haltering of phagocytosis (at the same concentration), in a size dependant manner and an inability to engulf particles larger than 3 µm (Cox et al. 1999; Vieira et al. 2001). A possible additional reason for the discrepancy in reports could also be altered adhesion molecules of the immortalised cells (RAW264.7) used by Vieira and colleagues. This alteration could have negatively influenced phagocytosis and prevented large particle engulfment, which was not observed during our study with use of primary cells.
5.3. Maintenance of Engulfment Capacity and Migration

The capacity for engulfment of AbsBeads was maintained in macrophages after treatment to induce phagosome maturation arrest. This engulfment capacity of primary differentiated macrophages has never before been assessed after experimental induction of phagosome maturation arrest. Previous studies touching on this aspect, focus on absolute engulfment as maintained or blocked, rather than determination and quantification of the extent to which engulfment was mediated. For this reason, no data exists to which our findings can be compared – in the artificial bead ingestion context as well as microbiology context. The most applicable research done in this context, was that of Vieira et al. (2001) who treated RAW264.7 with Wortmannin and reported an inability to engulf larger particles (this topic was already discussed above). Similarly, Cox et al. (1999) reported an abortive form of “frustrated phagocytosis” where macrophages attempted to engulf the culture plate they were grown on (section 2.2.2.). Furthermore, the almost limitless capacity for engulfment is supported by findings of membrane enlargement via stretching and “ruffling” out of grooves (Hallett & Dewitt 2007) as well as de novo membrane production (Huynh et al. 2007), which enables engulfment of particles similar in size to the macrophages themselves. Thus, the number of ingested particles is unlikely to be a limiting factor in migration capacity. In order to support this interpretation, further studies can more directly determine whether the number of ingested particles affects migration. Aside from these few reports, no other studies have quantified the capacity for phagocytosis and none exist on migration of cells containing extensive phagosomal content. Nevertheless, current data indicates that phagosome maturation arrest does not affect engulfment capacity or migration capacity in primary cells. Importantly, our results obtained in primary cells, stresses the importance of study design to minimise confounding factors (in this case
e.g. changes in adhesion molecule expression in primary vs. immortalised cells), to allow for most accurate data yield and data interpretation.

5.4. Bioactivity and in vivo Translation

Turning attention to considerations related to in vivo application, it is important to consider feasible time frames within which our model could function, as this would dictate conditions that could benefit from this particular model. Despite the known, very short physiological half-life for Wortmannin (59.4 seconds) (Yuan et al. 2006), it is known to elicit prolonged perturbation (Jackson et al. 2004), as discussed earlier. Notwithstanding research into this “Wortmannin paradox”, no time dependant studies have determined bioactivity of this compound. Similarly, Concanamycin A has been used in numerous studies to determine the role of V-ATPase and its associated processes in vitro, however, research has not elucidated the period of V-ATPase inhibition by Concanamycin A – irrespective of concentration. Nonetheless, Chloroquine was recently proposed as a possible therapeutic treatment for Ebola due to its pH elevating effect (Akpovwa 2016). As proposed by Akpovwa, one problem regarding the feasibility of Chloroquine as an Ebola treatment is un-perpetuated bioactivity. Thus, the bioactivity of these compounds have not been determined.

Currently our knowledge on the modulation for maturation arrest as employed in the current study, only extends to 2 hours, and drug-interaction was not comprehensively assessed. The combination of drugs could potentially augment activity of one or more of the other drugs used, or even create some redundancy. Future studies should investigate drug-interactions and assess more doses of the three compounds in isolation or in combination. Also, the effective time frame limits of our maturation arresting cocktail should be investigated to further optimise the intervention protocol.
with the aim of *in vivo* therapeutic application. For example, should a longer period be required for effective treatment than achieved with the current protocol, a possibility is to coat the AbsBeads/cargo with the arrest inducing cocktail to initiate phagosome maturation arrest only after engulfment, so as to prolong effectiveness without increasing dosage of the treatment and by releasing compounds in a delayed-release fashion.

Time constraints of the current working model of this delivery system are a key consideration for therapeutic application. Currently, preparation time from isolation of stem cells and monocytes, culturing and reintroduction into host is ±7 days. To shorten this period, a pilot transmigration study was done using phagosome maturation arrested monocytes activated and cultured for a total of 24h (Section 4.4). As mentioned earlier, although sufficient uptake of AbsBeads was recorded – providing proof for engulfment capacity – these cells failed to transverse endothelium. Explanations for this outcome could be insufficient cell maturation to allow a M1 phenotype (also not assessed during pilot) that has been shown to transmigrate *in vitro* (Arnold et al. 2007; Chazaud et al. 2009). Additionally, these unmatured monocytes could be less robust, compared to M1 macrophages, and their exposure to the arrest inducing cocktail could have had adverse effects. Thus, taken all of these data and literature into consideration, this model is probably not suitable for acute application. Rather, it should be applied to chronic pathological conditions where more effective regeneration would improve prognosis, such as in myodystrophy.
Chapter 6: Conclusions and Recommendations for Future Studies

In conclusion, this thesis describes a novel technique with which successful phagosome maturation arrest was achieved in pre-differentiated and polarised M1 macrophages. The intervention cocktail was shown to result in satisfactory preservation of intra-phagosomal cargo after engulfment, without negatively affecting engulfment capacity or macrophage migratory capacity.

As mentioned in the introduction section of the thesis in Chapter 1, this study is the first step in a much bigger endeavour. Thus, many more studies are required before arriving at a feasible therapeutic option for clinical application. Minor optimisation steps have already been touched on in the discussion section. However, in addition, several follow-up studies are envisaged. For example, probably the first step would be to replace AbsBeads with stem cells in order to assess viability of ingested cells via assessment of physiological indicators of viability. Since traditional XTT or propidium iodide staining is not feasible for a cell-in-cell situation, we propose assessment of markers of cell survival, apoptosis and/or autophagy using immunocytochemical staining of permeabilised cells. Pilot studies are already under way to investigate the feasibility of coating these stem cells with a protective co-block polymer, which could contribute to cell survival.

A second study could use a more physiologically relevant in vitro model, such as the SynVivo microfluidics system, to simulate capillary networks with which to evaluate macrophage migration capacity under physiologically accurate sheer flow rates.

At this point, the first in vivo study can be considered. Importantly, the specificity of migration to only the intended areas for regeneration has to be assessed, in order to prevent cargo delivery and thus undesired tissue growth in unwanted tissue areas.
Current literature in the context of stem cell therapy by infusion into circulation, suggest that this is probably not a problem, since progression of stem cells to more differentiated forms is largely determined by the cellular environment. However, this has to be confirmed as a safety precaution. We propose labelling macrophages or stem cells with a suitable marker and to assess the migratory path and speed of macrophages in live, sedated rodents, using a whole body visualisation system, such as the IVIS (in vivo Imaging System) already accessible to us.

In order to optimise macrophage mobility in vivo, it is also important to consider physical limits of cells in an in vivo environment, i.e. whether there should be a limit to the number of consecutive engulfments and thus number of stem cells contained in any single macrophage. Macrophages containing too many stem cells may physically not be able to migrate through the smaller blood vessels, or have difficulty migrating across endothelium. To address this, fluorescence activated cell sorting (FACS) can be used to optimise the migrating macrophage population in terms of phagosomal contents/number, to ascertain optimal migration capacity. By using similar interventions as used in this study to quantify digestion and engulfment, one can separate single or double bead/cell containing macrophages via setting up a threshold and polarizing cells in real time for sorting according to attraction to voltage gates.

Finally, induced release of macrophage cargo has to be achieved after tissue infiltration. The aim is to design the co-block polymer coating of stem cells so that it could assist with the release of the satellite cell. For example, these polymers can be designed to break-down in response to specific externally applied stimuli, such as infrared light or vibration at specific frequency (given the superficial nature of skeletal muscle, this is a feasible option). In this scenario, the inner layer of the polymer could be decorated with an agent inducing macrophage cell lysis or even apoptosis, to
facilitate release of the stem cell. However, this step is still some time off and the processes by which this may be achieved is less clearly defined at this point.

Although many more steps are required in the development of this delivery system, an autologous delivery system such as this has immense translational applicability, not only in the context of regenerative medicine for stem cell delivery but also delivery of therapeutic compounds. For example, the anthracycline Doxorubicin, is currently being researched and used to treat an array of cancerous tissue growths. Regrettably, current administrative methods are focussed on a ‘saturation’ approach, as with the greater embodiment of medicine. This approach results in the exposure of non-target or non-cancerous tissue to drugs. In the case of Doxorubicin specifically, cardiotoxicity is a major problem brought about in this manner. Thus, if successful, a delivery system such as the one proposed here, could be adapted also for application here.
References


Curtis, L.M. & Gluck, S., 2005. Distribution of Rab GTPases in mouse kidney and comparison with...
vacuolar H+-ATPase. *Nephron Physiology*, 100, pp.31–42.


Ghigo, E. et al., 2002. Survival of Tropheryma whippelii, the Agent of Whipple’s Disease, Requires


Harrison, R.E. et al., 2003. Phagosomes fuse with late endosomes and/or lysosomes by extension of membrane protrusions along microtubules: role of Rab7 and RILP. *Molecular and Cellular Biology*, 23, pp.6494–6506.


Husebye, H. et al., 2010. The Rab11a GTPase controls Toll-like receptor 4-induced activation of interferon regulatory factor-3 on phagosomes. *Immunity*, 33, pp.583–596.


Appendix A: Literature Review

Harnessing phagocytosis for regenerative medicine: lessons from microbes

Johan Georg Visser, Carine Smith

Department of Physiological Sciences, Stellenbosch University, South Africa

Corresponding author:

Prof Carine Smith
Department of Physiological Sciences
Stellenbosch University
Private Bag X1
Matieland
7602
South Africa

Conflict of interest.
The authors declare no conflict of interest.
Abstract

Macrophages and neutrophils are evolutionarily equipped for host defence, mainly as a result of their high capacity for phagocytosis and diapedesis. The fact that these processes are highly conserved across species - nearly 95% of the animal kingdom is devoid of both B and T cells - testifies to its effectiveness in neutralising invaders. Despite this, these processes are also manipulated and exploited by bacteria and viruses for their own pathogenic propagation. Perturbation of phagocytosis for intracellular pathogen survival is generally achieved through phagosome maturation arrest. This prevents phagosome acidification, recruitment of enzymes or even modulation of phagocyte killing capacity. In order to understand the complexities of phagocytic evasion, one first needs to appreciate the equally complex and redundant process that is phagocytosis. In this review, the molecular aspects of phagocytosis, from initial recognition and pseudopod extension to successful neutralization and degradation of foreign material is concisely discussed in a temporal manner. This is followed by recent information from the literature related to pathogenic evasion, with focus on specific bacteria and viruses such as *Mycobacterium tuberculosis* and HIV, to illustrate how these pathogens manipulate the phagocytic process. After conveying our understanding of these processes, a hypothesis for an unorthodox approach to regenerative medicine is formulated: that of experimental modification of phagocytes to achieve maturation arrest, to render these cells capable of internalising and transporting cargo such as live stem cells or therapeutic drugs, to specific tissues, without damage to this cargo while in transit.
Introduction

Phagocytes, such as macrophages and neutrophils, are responsible for non-specific recognition and destruction of invading pathogens. At least two characteristics of these cells make them ideally suited for this task. Firstly, they are highly mobile cells, with the ability to readily cross membranes, such as endothelium. This affords them the uncommon cellular trait of migration across different body or tissue compartments to reach sites where they are required. Secondly, these cells have the capacity for phagocytosis – an intricate process, starting with pseudopodia extension to engulf particle matter and ending in particle neutralization within a destructive phagolysosome. The fact that these two mechanisms are highly conserved across species\(^1\) testifies to its potency and overall importance for host health. However, it is also known that the process of phagocytosis is not infallible. Several papers have described the ability of evolved microbes, such as *Mycobacterium tuberculosis*\(^2\), *Leishmania donovani*\(^3\) and *Candida glabrata*\(^4\), to hide from the immune system by remaining inside phagocytes without being digested in the phagolysosome.

We believe that a lesson can be learned from these microbes, and harnessed to the benefit of regenerative medicine practises. In this review, we will present our hypothesis on how this may be achieved. However, we first present an overview of what is currently known about the molecular processes involved in the phagocytic process, aiming to elucidate the molecular mechanisms of phagosome maturation in a temporal and concise manner as to better understand this phenomenon. This will be followed by a discussion of phagosome maturation arrest and the mechanisms used by microbial agents to evade phagosomal neutralization, before we will elaborate on the potential for application of this knowledge in an unorthodox, novel approach to regeneration.

Molecular basis of phagocytosis

Phagocytosis involves considerable membrane and cytoskeletal rearrangements in order to encircle and capture (engulf) potential pathogens or matter foreign to the immune system – forming
phagosomes — and to mature these nascent phagosomes into phagolysosomes. Microbial material is captured inside a nascent phagosome that matures through events relating to the endocytic and autophagic pathway, where fission and fusion events allow for its destructive ability. In the next few sections, these intricate processes will be explained in detail, using macrophages as representative phagocytic immune cell.

Recognition

Matter is recognised as foreign — and thus as potential threat — via binding to specific pattern recognition receptors (PRRs) located both in the cytosol and cell surface of immune cells of both the innate and adaptive branch of the immune system, as well as on epithelial cells such as the vascular endothelium. PRRs differentiate between molecules that are released by dying self-cells and foreign material through respectively binding to damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs) (ref. 7). Necrotic self-cells release formylated peptides like N-formylmethionine from damaged mitochondria. These self-originating proteins (classified under DAMPs) can bind to formyl peptide receptors (FPRs) on monocytic cells, initiating chemotaxis and phagocytosis. Interestingly, these formylated peptides are also characteristic of bacterial proteins. In our opinion, this supports the endosymbiotic theory of mitochondrial evolution, which proposes that mitochondria are foreign organelles that were incorporated into eukaryotic cells for energy production. In this manner, cells containing damaged mitochondria, i.e. metabolically compromised cells, are removed via recognition of these DAMPs, irrespective of self or non-self. Recognition of PAMPs is oriented toward many PRR subtypes, such as NOD-like receptors (NLRs) (recognise DAMPs as well), RIG-like receptors (RLR) and Toll-like receptors (TLRs). NLRs are mainly associated with sterile inflammation via NLRP3-inflammasome activation. The membrane bound TLRs bind bacterial hallmark molecules both intra- and extracellularly and exhibit some target specificity. The TLR5 subtype typically binds to flagellae, while TLR2 and TLR4 bind components of the bacterial cell wall like peptidoglycan and lipopolysaccharide (LPS), respectively. TLR2 forms a
heterodimer with TLR1 or TLR6 to bind the N-terminal cysteine modification on lipoproteins of bacteria, as illustrated in mycobacterium. This lipoprotein modification is uniquely conserved in over 2000 different bacterial proteins, which can all be recognised by binding of this heterodimer. Other TLRs like TLR3, TLR7, TLR8 and TLR9 are intracellular receptors and recognize bacterial dsRNA and DNA.

TLR activation induces recruitment of adaptor proteins and activation of transcription factors for production and release of cytokines, adhesion molecules and costimulators. Active TLRs indirectly regulate phagocytosis through MyD88 signalling and activation of the p38 residue to accelerate phagocytosis. The newly identified mitogen-associated protein 1S (MAP1S) autophagy-related protein was also very recently reported to be necessary for TLR activation and effective bacterial phagocytosis, but more research is required to fully elucidate its role in this context. Many other receptors including lectin, mannose, complement and RLRs also assist with pathogen recognition, but the IgG receptors are more closely associated with phagocytosis, where IgG-binding opsonises bacteria to facilitate phagocytosis of material otherwise ‘invisible’ to phagocytes. Macrophage Fcγ surface receptors (CD64) recognise the constant γ heavy chain in Fc regions of the IgG, which induces FcγR clustering at the site of material contact that leads to actin polymerization and engulfment through pseudopod extension. Formation of pseudopodia and actin polymerization is highly dependent on phosphatidylinositol 3-kinase (PI3k) recruitment for production of various phosphatidylinositides. The ADP ribosylation factor (ARF) proteins play a pivotal role in activating phosphatidylinositol kinase enzymes to regulate membrane modification. Specifically, ARF6 has many functions, such as being recruited to the tip of forming pseudopodia where it activates type I phosphatidylinositol 3 kinase (PI3k) substrate production via activation of other phosphatidylinositol kinases, and activation of actin polymerization during pseudopod extension. This collectively ensures particle capture and membrane fusion to form a phagosome. FcγR mediated phagocytosis is the main form of phagocytosis simulated in experimental phagocytosis models, because engulfment does not require stimulation by lymphoid cells, as explained further by Liu.
Pseudopodia and encapsulation

Following recognition, phagocytosis is initiated with the extension of pseudopodia. Particle internalisation and phagosome formation is achieved within 5 min after introduction of the foreign agent under culture conditions (Visser and Smith, unpublished data). Macrophages specifically are extremely ambitious in their phagocytic ability and are able to engulf particles which are closely comparable with their own size. Interestingly, a form of cell suicide termed “frustrated phagocytosis” has been reported, where cultured macrophages attempted to engulf opsonised tissue culture plate surfaces, increasing cell surface area by over 20% (ref. 18). This phenomenon presented a useful model with which to investigate the mechanics of pseudopod formation, and the mechanism(s) by which this phenomenal change in cell shape are achieved has been debated to some extent. One theory postulated that the macrophage membrane is corrugated, possibly allowing a flattening out of the membrane during extra-large particle engulfment. However, quantitative spectroscopy has shown that during healthy phagocytosis, membrane surface area indeed enlarge to such an extent that surface flattening alone cannot fully account for it.

This raises the questions of where the extra membrane comes from. Specific membrane reservoirs have not been identified within cells, but general cellular sources exist. For example, in osteoclasts, exocytosis of late endosomes has been shown to deliver membrane components and increase cell surface area during bone reabsorption. Also in the context of macrophage pseudopod formation, a few candidates have been investigated. Initially, Gagnon proposed that the ER may fuse with the plasma membrane at the base of extending pseudopodia, forming a continuity through which the particle can slide into the ER lumen. This idea was supported by Becker, who reported that phagocytosis efficiency of large particles (>3μm) was reduced after neutralization of the ER soluble N-ethylmaleimide-sensitive factor-attachment protein (SNARE) receptor, ERS24. The theory of Gagnon and colleagues was however not accepted by all, as others have argued that the role of the ER during phagocytosis still needs some elucidation. More recently, using a variety of techniques including
immunological, biochemical, electron microscopy and fluorescence microscopy, Huynh indeed could not find any evidence of the ER fusing to the plasma membrane during phagocytosis. Also, since phagosomes acidify during maturation via a proton gradient created by the vacuolar-type H\(^+\)-ATPase (V-ATPase) proton pump, and the ER membrane is permeable to protons and devoid of V-ATPase (ref. 24), the theory of simple ER fusion is probably unlikely to fully explain the phenomenon. We speculate that the ER likely fuses with phagosomal membranes – however, it could be in a ‘kiss and run’ or ‘kiss of death’ fashion, as seen during autophagosome fusion with lysosomes\(^{25}\) and cytotoxic T cell-mediated cell death\(^{26}\). This may result in an exchange or delivery of ER localised proteins to phagosomes, without complete membrane exchange through fusion. Furthermore, since ER engagement was observed during large particle uptake (>3μm) and mostly during FcγR mediated phagocytosis\(^{22}\), ER engagement is likely size- and receptor-specific.

A more likely candidate is the enzyme group of phosphatidylinositol 3 kinases (PI3k) that phosphorylate the 3’ inositol phospholipid of inositol rings. These kinases are classified into three families based on their substrate used for lipid phosphorylation: types I, II and III. The type I PI3ks consists of four isoforms, PI3kα,β,γ and δ, which all use phosphatidylinositol 4,5-bisphosphate (P(4,5)P2) as substrate to generate phosphatidylinositol 3,4,5-triphosphate (P(3,4,5)P3, or PIP\(_3\)) from phosphatidylinositol 4,5-bisphosphate (P(4,5)P2) (ref. 27). This PI3k substrate concentration is kept at optimal level by phosphatidylinositol 4-phosphate 5-kinase α (PI4P-5kα) through its phosphorylation of phosphatidylinositol 4-phosphate (PI4P) to P(4,5)P2 (ref. 28). The PI3kδ isoform is unique to immune cells as it is normally only expressed on lymphoid and myeloid cell lineages\(^{29}\).

Botelho\(^{30}\) found transiently high P(4,5)P2 expression on extending pseudopodia with its disappearance shortly after phagocytic cup closure and nascent phagosome formation. Furthermore, type I PI3ks recruitment and subsequent PIP\(_3\) expression has been shown to occur on extending pseudopodia during engulfment of antibody-opsonised particles\(^{31}\). Throughout the literature, PIP\(_3\) is seen as the main propagating agent during pseudopod extension. However, apart from the apparent
stERIC association of PI(4,5)P2 to PI3ks – necessary for its phosphorylation to PIP₃ – PI(4,5)P2 itself seems to have an equally important role in pseudopod formation. Active ARF6 induces PI(4,5)P2 production through activation of PI4P-5kα during phagocytosis. PI(4,5)P2 then recruit WASP/N-WASP proteins to facilitate actin polymerization in a G-protein coupled manner during phagocytosis.

The role of type I PI3ks was further elucidated by antibody mediated type I PI3ks inhibition, which illustrated that type I PI3ks – together with its substrate (PI(4,5)P2) and product (PIP₃) – were essential for ingestion of large particles (>3μm in diameter), but not for phagosome maturation.

The Type II PI3ks are not well described but current evidence points to the notion that this enzyme family produces either PI(3,4)P2 or phosphatidylinositol 3-phosphate (PI3P) on endosomal or plasma membranes by either of their three isoforms: PI3kC2α, C2β, C2γ. Thus, type II PI3ks, could contribute to production of PI(3,4)P2 on extending pseudopodia for actin regulation and additional membrane, or it could facilitate phagosome maturation through production of PI3P on phagosomes.

The last PI3k family is the type III PI3ks that consist of only one catalytic subunit, VPS34, in humans: hVPS34. Type III PI3ks phosphorylate phosphatidylinositol (PI) to PI3P on endosomes and autophagosomal structures. Formation of PI3P is accompanied by the closure of the phagocytic cup and subsequent disappearance of PI(4,5)P2 (ref. 30), which lead to and are essential for maturation of newly formed phagosomes. Thus the function of PI3P is centred more around phagosomal/endosomal maturation than as a source of extra membrane during engulfment. Additionally, PI3P expression could be negatively regulated during maturation by the (FYVE domain containing protein) PI 5’-kinase, PIKfyve, via phosphorylation at the 5-position to produce PI(3,5)P2 (ref. 36).

From the literature consulted, it seems that the origin of these relatively large amounts of “extra” membrane is most likely the phosphoinositides produced by PI3k enzymes. In support of this, non-specific inhibition of the PI3ks enzyme superfamily (which induced drastically decreased PIP₃, PI(3,4)P2 and PI3P synthesis during phagocytosis), prevented production of the 20% increased surface area.
usually observed in the “frustrated phagocytosis” model mentioned earlier. This suggests that PI3ks activity is one of the chief sources of membrane during pseudopodia extension and phagocytosis. Additionally, a significant amount of membrane could also be supplied by recycling endosomes and sorting nexins (SNX), which collect membrane and other phagocytic components from endosomes and newly formed phagosomes called nascent phagosomes. Interestingly, this recycling machinery is also dependent on PI3P expression for docking onto intracellular structures\textsuperscript{37}, further supporting our notion of PI3ks as important role player in this context. Not all engulfed material is destined for degradation and subsequently need to be recycled by the recycling endosomes and SNX mentioned above. Recycling endosomes, partly identified by the Rab11 superfamily, is responsible for pinching off reusable cargo during the nascent phagosomal stage\textsuperscript{38}. One of three Rab11 isoforms, Rab11a, is expressed on the nascent phagosome itself and facilitates phagosome fusion with early endosomes and Golgi-derived vesicles\textsuperscript{37}. Rab11a also has a crucial role in pro-inflammatory signalling as it delivers TLR4, responsible for detection of lipopolysaccharide such as E.coli LPS, to maturing phagosomes\textsuperscript{39}. The Rab11 superfamily seems necessary for engulfment itself as well, since Cox\textsuperscript{40} reported that prevention of Rab11 GDP/GTP cycling by mutant alleles, inhibited particle internalization. Furthermore, the GTPase, ARF6, also controls trafficking of recycling endosomes to the membrane and inhibition thereof resulted in a block in pseudopod extension\textsuperscript{41}, suggesting that recycling endosomes serve as an additional reservoir for plasma membrane during pseudopod extension. The greater part of cargo retrieval and sorting is done in the early phagosomal stage because most of the machinery is dependent on PI3P for docking\textsuperscript{37}, supporting the findings of Cox and colleagues\textsuperscript{18,40} mentioned previously. However, some of the SNX can form higher order structures with Vps26, Vps29 and Vps35 – these are called retromers\textsuperscript{42}. These retromers function in the presence of PI3P, but also active Rab7, giving them a limited time gap to recycle cargo between early stage and late stage phagosome maturation (between Rab5 to Rab7 transitioning), discussed below. This is in no doubt a finely tuned, complex process that merits further research in order to be fully elucidated.

\textit{Nascent phagosomal stage}
This stage can be structurally distinguished from the pseudopod extension/engulfment stage by phagocytic cup closure behind the engulfed material – a process highly dependent on type I PI3k (ref. 28).

In contrast to pseudopod formation, the process of phagosome formation and maturation is relatively well described, although some controversies remain. Successfully engulfed material is encapsulated into nascent phagosomes characterized by Rab5 GTPase expression (ref. 37). Rabex-5, a guanine nucleotide-exchange factor (GEF), is initially recruited to newly formed endosomes by the already present Rab22a (ref. 43) and functions to activate Rab5 (ref. 44). Active Rab5 then recruits endosomal early antigen 1 (EEA1) (ref. 45) and hVPS34 (ref. 46) to the nascent phagosome. hVPS34 generates PI3P on the cytosolic face of nascent phagosomes that serve as docking station for a variety of maturation effectors. The FYVE domain of EEA1 can then dock onto PI3P to ensure later EEA1-mediated tethering and fusion of phagosomes with late endosomes for further maturation (ref. 47). Inhibition of EEA1 reportedly arrest phagosome maturation (ref. 48), but a dominant negative mutant of EEA1 which did not induce maturation arrest has also been reported (ref. 33), suggesting that other FYVE domain containing proteins could be involved in PI3P binding that lead to subsequent maturation. Zinc finger FYVE domains, present in proteins like EEA1 and PIKfyve, recognize the hydrophilic head of PI3P on the cytosolic leaflet and may allow binding of these proteins with substantial specificity to PI3P, resulting in this docking (ref. 49). These contradicting findings on the necessity of EEA1 could be explained by its tendency for complex formation with other proteins. EEA1 has been reported to form a macromolecular complex with Rabaptin-5, Rabex-5 and N-ethylmaleimide-sensitive factor (NSF) that interacts with syntaxin 13 (another SNARE) to facilitate membrane fusion (ref. 50). NSF disassembles these SNARE complexes via ATP hydrolysis after membrane fusion, blocking further action (ref. 51). This could mean that the maturation inhibition reported by Fratti (ref. 48) was achieved through the inability of antibody-bound EEA1 to form a macromolecular complex (likely due to steric hindrance), while the dominant negative form of EEA1 can, thus resulting in unperturbed phagosome maturation.
Late phagosomal stage

Transition to the late phagosomal stage is marked by GTPase-activating protein (GAP)-mediated Rab5 inactivation/dissociation and Rab7 recruitment, together with late endosome fusion and expression of other markers such as mannose-6-phosphate receptor (MPR), lysobisphosphatidic acid and lysosome-associated membrane proteins (LAMP) (ref. 52). During this stage, PI3P is incorporated and degraded inside the phagosomal lumen via inward budding of the limiting membrane. Briefly, the PI 3-phosphatase (PTEN) and PIKfyve eliminate PI3P via hydrolysis to PI and phosphorylation to PI(3,5)P2, respectively. Elimination of PI3P is likely necessary for the removal of nascent phagosomal effector proteins dependent on PI3P expression, such as EEA1 and other FYVE domain containing proteins. The late phagosomal stage initiates about 10-30 min after nascent phagosome formation, at least under in vitro conditions. This is in accordance with the disappearance of PI3P about 10 min after its formation.

Rab7 is expressed on both late endosomes/late phagosomes and lysosomes. This expression profile allows Rab7 to regulate membrane trafficking between early endosome/nascent phagosomes and late endosomes as well between late endosome/late phagosomes and lysosomes. The fusion between nascent phagosomes and late endosomes may allow the close proximity of Rab7 and PI3P that facilitates SNX retromer functioning reported by Cullen & Korswagen. In this manner, the SNX retromers possibly recycle cargo between nascent phagosomes and late phagosomes, rather than nascent phagosomes and recycling endosomes, as hinted at earlier. This Rab7 GTPase accelerates maturation to the phagolysosome biogenesis stage with the help of Rab7-interacting-lysosomal-protein (RILP) (ref. S6). The Rab7 associated proteins RILP and oxysterol-binding protein related-protein 1 (ORP1L) together link phagosomes to dynein, which centripetally moves these late phagosomes along microtubules toward lysosomes for fusion. Johansson reported that ORP1L preferentially binds to active, GTP-Rab7 and that this association seems to sustain the GTP-bound state of Rab7. This prolonged activation could be required for successful dynein linkage. Dynein
mediated fusion with lysosomes seems to be dependent on the HOPS complex as well as Rab7 (ref. 59). HOPS is a tethering protein responsible for keeping phagosomes in close proximity to lysosomes, a function parallel to that of EEA1 (ref. 60). Furthermore, disassembly of the microtubular network with nocodazole ablated centripetal movement of phagosomes, suggesting a dependency of macrophages to dynein for maturation (more detail later).

**Phagolysosome biogenesis stage**

Phagosome fusion with lysosomes, or phagolysosome biogenesis, is the last stage of maturation and was reported to occur \( \approx 1 \text{h} \) after nascent phagosome formation under *in vitro* conditions\(^6\). Fusion is mediated by the SNARE proteins (syntaxin 7, syntaxin 8, Vesicle-associated membrane protein (VAMP) 7 and VAMP8) (ref. 62) and provides the phagolysosome with the needed proteases (e.g. cathepsin D), reactive nitrogen species (RNS) and reactive oxygen species (ROS) which neutralized the ingested particle. Lysosome fusion also increases LAMP expression and effectuates an acidic phagosomal environment\(^6\). Although Rab5 and Rab7 are the chief GTPases regulating endosomal and phagosomal maturation, research has discerned significant roles for other Rab proteins too. For example, Rab10 regulates recycling of proteins back to the plasma membrane and is present on nascent phagosomes even before Rab5 (ref. 64). Also, phagolysosomal protein degradation is hugely dependant on proteases like cathepsin D, which is delivered from the Golgi under control of the trans-Golgi network-localised Rabs (22b, 32, 34,38 and 43) (ref. 65) that were shown to have various association and dissociation kinetics with the maturing phagosome\(^7\). Rab34 has also been implicated in phagolysosome biogenesis through its association with RILP (ref. 66), while the ER-localized Rab20 was shown to co-localize with V-ATPase on the phagosome, suggesting an involvement in phagosome acidification\(^7\). Seto\(^2\) more recently reinforced this finding by reporting that dominant negative alleles of Rab20 and Rab39 prevented phagosomal acidification.

Phagocytosis seem to have evolved from an endocytic nutrient gathering process in almost all eukaryotic cells, to a specialized mechanism of self-defence conserved uniquely to professional
phagocytes. A certain degree of redundancy exists in phagocytosis, most likely in order to be “fool proof”. However, as seen in the literature, at least some pathogens are able to arrest phagosome maturation to ensure their own survival. Interestingly, these pathogens do not evade being transported into the phagocytic cell – rather they use the host cell as nutrient supply, so that they not only survive, but thrive.

Pathogenic modulation

Pathogenic phagosome maturation arrest is a hallmark of bacterial and viral host immune evasion. Many intracellular pathogens like *Mycobacterium tuberculosis*, *Candida glabrata*, HIV-1 and *Leishmania donovani* have evolved divergent mechanisms to modulate phagocytic digestion. Well characterized mechanisms of phagosome maturation arrest include (a) interference with PI3k function and PI3P biogenesis, (b) perpetuation of Rab5 expression, (c) prevention of centripetal movement of nascent phagosomes, (d) blocking of fission and fusion with lysosomes and endosomal organelles, (e) raising pH levels by causing phagosomal acid leakage, (f) lysis of the phagosomal membrane to escape digestion and even (g) active macrophage killing. Of these, only a few have been sufficiently studied in the context of phagocytosis. For the sake of brevity, we limited ourselves here to a very brief overview of the most relevant mechanisms.

Inhibition of phagosome maturation

*M. tuberculosis* survive intracellularly mainly by dephosphorylating PI3ks and thus preventing EEA1 docking onto the phagosome. Mycobacterial phagosomes (and also those containing *Leishmania*) also retain the tryptophan-aspartate containing coat (TACO) protein, which causes prolonged Rab5 expression. Although some maturation effectors can still bind the phagosome, absence of PI3P and EEA1 largely prevents lysosome fusion, resulting in a more alkaline, hydrolase deficient phagosome. In addition to the PI3P-dependent pathway, M. tuberculosis also effects hydrolase deficiency and
retarded acidification via limiting expression of Rab7 and Rab20, as well as limiting delivery of cathepsin D protease\textsuperscript{2,70}.

In contrast, the survival mechanisms of \textit{C. glabrata} are largely dependent on active PI3ks. \textit{C. glabrata} encodes the enzyme PI3k and produces fungal PI3P through phosphorylation of PI (ref. 71), increasing PI3P content of phagosomes during the early stages of maturation where PI3P has no role yet. However, this early increase elicits endogenous negative feedback which halts maturation, as recently illustrated by deletion of two functional subunits of fungal PI3k in infected THP-1 macrophages\textsuperscript{4}.

HIV-1 invasion is associated with inhibited phagosome formation as well as phagosome maturation arrest through microtubule perturbations, for which several viral role players have been implicated, e.g. viral negative factor (Nef) (ref. 72) and regulatory viral protein (Vpr) (ref. 73). Although we could not find a study to specifically implicate PI3k here, these mechanisms are likely also PI3k related, since both Nef and Vpr (as well as Tat) achieve several other effects, such as RANTES production and down-regulation of the ARF6 endocytic pathway, via PI3k-dependent routes\textsuperscript{74,75}.

Modulation of killing capacity

Another similarity between \textit{Mycobacteria} and \textit{Leishmania} is that both result in perturbed ROS production, although via different pathways\textsuperscript{76,77} which inhibits macrophage microbicidal effect.

These studies illustrates quite clearly that pathogens are able to manipulate the phagocytic process to ensure their survival, propagation and distribution through the host. In our opinion, it is also this manipulability of the phagocytic process that makes it ideal for use in regenerative medicine.

Harnessing phagocytosis for medicine

The relatively detailed understanding of molecular mechanisms governing phagocytosis, as well as perturbations achieved by pathogenic mechanisms, allows for therapeutic exploitation of this process.
We have formulated a hypothesis on the use of this knowledge in regenerative medicine and possibly other clinical fields as well.

Firstly, macrophages seem able to engulf particles seemingly endless in size (considering the “frustrated phagocytosis” model), suggesting that they have the capacity to engulf the majority of pathogenic microbes and almost all host somatic cells. Secondly, pathogens evolving alongside macrophages have acquired mechanisms to elude host defence - many of which involve perturbation of phagocytosis. Based on these facts, we hypothesise that by inducing phagosome maturation arrest (without pathogen involvement), the highly motile macrophages may be modified to useful shuttles for carrying “cargo” to specific areas within the host. The nature of this cargo could range from drugs to live stem cells, depending on the therapeutic aim. Of all potential options, the idea of a macrophage carrying a live stem cell – for example to increase muscle regenerative capacity in patients suffering from myodystrophy – is most enticing.

Let us consider what this would practically entail. Fundamentally, these macrophages would have to be isolated from patient blood and modified \textit{in vitro} in order for it to maintain an ingested stem cell in a viable state within its phagosomes after autologous reinfusion. We propose induction of phagosome maturation arrest, but in a manner that will not compromise particle ingestion capacity.

A variety of methods by which this may be achieved have been unknowingly uncovered by research on phagosome maturation. Below, we evaluate the feasibility of these methods in terms of safety for \textit{in vivo} application.

\textit{Macrophage IL-10 enrichment}

IL-10 is used by \textit{M. tuberculosis} as a powerful inhibitor of phagosome maturation, as discussed earlier. Since IL-10 is synthesised endogenously, it seems a promising agent to use. However, IL-10-mediated maturation arrest was demonstrated to be dependent on presence of a bacterial component\textsuperscript{78}. Ethical complexities aside, this problem may be overcome by identification of the essential bacterial component.
component, which – if not antigenic or pathogenic – could be administered as co-treatment. A greater issue here is the phenotypic change that IL-10 effects in macrophages, polarizing macrophages toward the alternatively activated (M2) phenotype. Although this anti-inflammatory phenotype is desired in terms of resolution of inflammation and wound healing, M2 macrophages do not readily cross endothelial barriers. This would significantly inhibit the actual delivery of the ingested stem cell to the intended target tissue. This complication however highlights another requirement – only M1 macrophages should be used, to ensure sufficient mobility.

**Brefeldin A treatment**

The fungal antibiotic Brefeldin A (BFA), inhibits a subtype of Golgi associated GEFs (ARF-GEFs) that facilitate the GDP/GTP cycling of ARF family proteins. These ARF-GEFs express a Sec7 domain that BFA recognises and inhibits by direct binding to it. ARFs play a central role in regulating actin polymerization and activating phosphatidylinositol kinases for phosphatidylinositol production, as well as plasma membrane traffic via coat proteins expressed on cellular transport vesicles. ER and Golgi bilaterally traveling transport vesicles are coated with proteins such as calnexin and coat protein complex type I (COPI) and type II (COPII) (ref. 85). COPI is recruited to phagosomes and contributes to recycling of phagosomal components. Active ARF1 is necessary for this COPI recruitment and inhibited COPI expression has been shown by Berón to partly perturb phagosomal recycling events. Thus, because BFA-sensitive ARF-GEFs control ARF1 activity that in turn allows COPI recruitment, BFA treatment could potentially induce phagosome maturation arrest by preventing sufficient recycling of phagosomal components. However, Beemiller found BFA-mediated inhibition of ARF-GEFs did not lead to subsequent inactive ARF1 expression on phagosomes. This suggests that the cells adapted to ARF-GEF inhibition by recruiting GEFs that are insensitive to BFA treatment. In addition, dual specificity of ARF was reported for BFA: ARF1 and ARF5, but not ARF6 – the main ARF implicated in encapsulation – was reported to be sensitive to BFA (ref. 87). The effect of BFA on phagosome maturation thus remains largely unknown.
As mentioned, dynein is vital for centripetal and centrifugal delivery of phagosomes to lysosomes for fusion. The dynactin complex has been shown to facilitate cargo binding to dynein for centripetal movement, while the Rab5 GTPase regulates motility of endosomes, likely through a phosphoinositide and EEA1 dependent manner. It is widely accepted that microtubule disruption (e.g. by nocodazole) negatively influences phagosome centripetal movement and coinciding maturation. However, the microtubule disassembly associated with nocodazole administration could perturb pseudopod extension via inhibited PI3k delivery, thereby inhibiting uptake of stem cells into macrophages, and may block cellular motility and chemotactic reactivity, abating the very characteristic of macrophages we intend to exploit.

In the same context, Ciliobrevin D is a dynein motor blocker that inhibits the GTPase activity of dynein specifically without affecting kinesin-1 and 5 ATPase activity or microtubule structure, making this compound a more promising inhibitor of centripetal movement only. Recently, Ciliobrevin D was suggested as modulator of lysosome mechanics and was utilised to elucidate the formation of NLR pyrin domain containing 3 (NLRP3) mediated inflammasome in bone marrow-derived macrophages. Its effects on phagosome maturation remain to be further elucidated.

Wortmannin

This fungal steroid metabolite is a known potent, selective and irreversible inhibitor of all three PI3k subtypes via covalent binding, virtually eliminating phagosome fusion with late endosomes and lysosomes. However, not all effects of Wortmannin are equally desired. For example, PI3K-inhibition by Wortmannin was reported to enhance TLR-mediated inducible nitric-oxide synthase (iNOS) expression, to activate NF-κB and to up-regulate cytokine mRNA production, suggesting a pro-inflammatory role. In addition, Wortmannin treatment was also shown to prevent large particle (>3μm) engulfment through inhibiting PI3P formation. Together these data suggest that the use of
Wortmannin for macrophage modification will require a finely optimised protocol, to ensure maximal phagosome maturation arrest, without compromising the encapsulation process or eliciting an inflammatory response.

*Concanamycin A*

Concanamycin A is a plecomacrolide that specifically inhibits the V-ATPase proton pump. This enzyme is responsible for energizing the membranes of eukaryotic cells, both intracellular and plasma membranes\(^{95}\). V-ATPase is expressed on late phagosomes and ensures an acidic phagosomal pH. Concanamycin A covalently binds to the subunit c of the translocating \(V_0\) complex of V-ATPase (ref. 95), thereby preventing proton influx into phagosomes and maintaining an alkaline environment around pH 7.5 (ref. 96) which inhibits progression of autophagy, making Concanamycin A a candidate worthy of exploration in this context.

*Chloroquine*

Chloroquine is a 4-aminoquinoline that indirectly prevents acidification of intracellular vacuoles\(^{97}\). This compound is readily used as an anti-malarial drug and was very recently suggested as a possible Ebola drug, since its alkalinizing action would prevent intracellular viral replication, provided that its concentration can be maintained at effective dose\(^{97}\). The fact that chloroquine is a known medication is a benefit, since its safety for human consumption has been established. Similar to concanamycin A, chloroquine has proven efficacy in the context of (auto)phagosome maturation arrest.

From this information, we conclude that positive basic data exist for a number of potential treatments that may be used for macrophage modification, but that more research is required for optimisation of single-compound or cocktail doses.

*Additional factors to consider*
Although maintenance of stem cell viability inside phagosomes is a major consideration and an important problem to solve, it is not the only one. In order for the stem cells to be ingested by the modified macrophage, they will also have to be opsonised, especially since autologous cells will ideally be used for this technique. Importantly, opsonisation should not interfere with stem cell function after its delivery. We believe that this can be over the best solution here is using advanced technology and a multidisciplinary approach. Recently, great advances have been made in the field of abiotic membrane-active polymers that can coat cell membranes whilst maintaining cell viability\(^9\). These polymers can be “decorated” with an opsonin to enhance encapsulation; the polymer can be deconstructed by e.g. slight temperature change or vibration, releasing a largely unaffected stem cell.

Another question is whether the number of stem cells ingested should be limited, to ensure that physical size of macrophages does not hamper migration. It is known that macrophages have an exceptional capacity for membrane “extension”, so that several stem cells can theoretically be ingested by an individual macrophage. Indeed, this was the case in preliminary studies in our lab (Visser and Smith, unpublished data). However, we believe that the number of stem cells ingested per macrophage can simply be optimised via altering the time allowed for engulfment. Alternatively, flow cytometry sorting could be employed to sort for cells with an optimal number of ingested stem cells.

Once reinfused, macrophages should naturally migrate to sites requiring regeneration. Of course, in order to achieve maximal benefit, the chemotactic signal could also be manipulated, and the known vast array of exiting tracking methods may be employed to track the final destination of the modified macrophages. These processes are however not within the scope of this review, which is focused on modification of the macrophage itself.

The final consideration to include in this review is the release of the stem cell at the appropriate destination site. A plethora of mechanisms exist to induce cell death or exocytosis. One example is Brefeldin A. Although it has doubtful application for phagosome maturation arrest, BFA may prove useful in later stages of cell cargo delivery, by inducing apoptosis in the macrophage\(^9\). Apoptosis was

---

Stellenbosch University  [https://scholar.sun.ac.za](https://scholar.sun.ac.za)
reported under chronic treatment conditions (15h – 40h) (ref. 100), which allows sufficient time for the processes of engulfment, reinfusion and in vivo transportation to be completed. A favourable consideration in this context is that BFA does not affect engulfment capacity of large (3μm) or small (0.8μm) particles, despite its ER traffic inhibitory effects22, possibly due to the insensitivity of ARF6 to BFA mentioned earlier. Of course, as with all other phases, other candidate methods – such as targeted exocytosis – should also be considered and optimised. Again we may take lessons from microbes: *Leishmania donovani* promastigotes multiply and differentiate inside maturation arrested phagosomes, before escaping the macrophage to continue their life cycle76. This poorly understood phenomenon could potentially be exploited to induce exocytosis of stem cells from macrophages.

**Conclusion**

In conclusion, modern science has substantially increased our understanding of molecular role players not only in the phagocytic process, but also in regenerative medicine. We firmly believe that by pooling resources across multiple disciplines, the remaining obstacles can be overcome to achieve the therapeutic technique we outlined here. Delivery of laboratory-enhanced or conditioned stem cells, using an autologous physiological vehicle, will be a significant step forward in terms of individualised medicine, and especially in disease states where no current mainstream therapy has proven effective.
Acknowledgements

The authors would like to acknowledge the South African NRF for funding (student bursary to Johan Georg Visser).

Conflict of interest

The authors declare no conflict of interest.
References


49 Patki V, Lawe DC, Corvera S, Virbasius J V., Chawla A. A functional PtdIns(3)P-binding motif.


69 Clemens DL, Lee BY, Horwitz MA. Deviant expression of Rab5 on phagosomes containing the intracellular pathogens Mycobacterium tuberculosis and Legionella pneumophilia is associated with altered phagosomal fate. *Infect Immun* 2000; **68**: 2671–2684.


76 Moradin N, Descoteaux A. Leishmania promastigotes: building a safe niche within macrophages. *Front Cell Infect Microbiol* 2012; **2**: 121.


97 Akpovwa H. Chloroquine could be used for the treatment of filoviral infections and other viral infections that emerge or emerged from viruses requiring an acidic pH for infectivity. *Cell Biochem Funct* 2016; : 191–196.


Appendix B: S.O.P.s

Ethical Exception

Ethical exemption for isolation of human monocytes from donated blood (buffy coats) was received from the Health Research Ethics Committee (HREC) of Stellenbosch University on 8 July 2015 (Ethics Reference #: X15/05/013).

Obtaining O+ Buffy coats

1. Contact Hayley at the Western Province Blood Transfusion Service: haylay@wpbts.org.za
2. Request information to obtain ethical clearance, if needed.
3. Contact Kashief at kashief@wpbts.org.za to arrange a pick up time for buffy coats.
4. Note: Fresh blood takes about a day to be processed so the buffy coats will only be available for pick up from 4pm.
5. Arrange with Kashief to look up the ages of the patients (this is a favour).
6. Take a blood transport container with two cold ice packs to keep buffy coats cold and prevent cell clumping.
7. Buffy coats need to be processed as soon as possible to ensure a viable population of cells are gathered.
8. Note: Cells clump and die if not isolated as soon as possible.

Monocyte Isolation

To facilitate balancing of the centrifuge, it is recommended to process two buffy coats in parallel. However, take care to use separate materials for each donor and not to mix the cells.

1. Carefully disinfect the plastic bags containing the buffy coats and transfer the contents of each donor buffy coat to a 50mL tubes.
2. For each buffy coat fill two 50mL tubes with 16mL Ficoll/Histopaque solution (1.077 g/mL). The Ficoll/Histopaque should be at room temperature for the preparation.
3. Mix 22mL buffy coat blood with 10mL cold RPMI to facilitate layering.
4. Layer this 32mL buffy/RPMI mixture on top of the Ficoll/Histopaque solution for the first density gradient. Be careful to do this slowly and carefully in order to prevent mixing both layers.
5. Centrifuge at 400 x g without brake for 30 min at 23°C.
6. For each gradient collect the white ring of peripheral blood mononuclear cells (PBMCs) which is located between the two phases with a plastic Pasteur pipette and transfer to a 50mL tube.

7. Fill each tube with 1mM PBS-EDTA up to the 45mL mark.

8. Centrifuge at 300 x g for 10 min without brake at 23˚C.

9. Aspirate supernatant and wash pellet again with 45mL PBS-EDTA.

10. For each donor pool the pellets in 20mL RPMI-1640 without phenol red containing 10% FBS.

11. Prepare the iso-osmotic Percoll solution for the second density gradient: For two donors mix 23.13mL Percoll solution (density: 1.131 g/mL) in a 50mL tube with 1.87mL 10x PBS. Then transfer 23mL of this solution to a new 50mL tube and add 27mL RPMI-1640 with phenol red containing 10% FBS to obtain a 42.56% iso-osmotic Percoll solution. The Percoll should be at room temperature for the preparation.

12. For each donor transfer 24.4mL of the prepared Percoll solution to a 50mL tube and layer the PBMC solution prepared in step 10 on top of the Percoll solution. Be careful to do this very slowly and carefully, both layers tend to mix easily. If done correctly the two phases can be distinguished due to their difference in colour.

13. Centrifuge at 550 x g without brake for 30 min at 23˚C.

14. For each gradient collect the white ring of monocytes which is located between the two phases with a plastic Pasteur pipette and transfer to a 50mL tube.

15. Fill each tube with PBS-EDTA up to the 45mL mark.

16. Centrifuge at 400 x g for 10 min without brake at 23˚C.

17. Aspirate the supernatant and resuspend the pellets in the needed amount of Complete Monocyte media or FBS to seed or freeze cells, respectively.

**EDTA Stock Preparation**

1. Make up 0.5M stock
2. Stir 186.1 g EDTA (372.24 g/mol) into 800 ml ddH₂O.
3. Add NaOH solution to adjust the pH to 8.0. The EDTA will slowly go into solution as the pH nears 8.0.
4. After EDTA has dissolved, top up the solution to 1L with ddH₂O.
5. Filter the solution with filter paper or through a 0.5μm filter.
6. Dispense into containers as needed and sterilize in an autoclave.

**PBS-EDTA (1mM) Preparation**

- Mix 1mL prepared EDTA (0.5M, 8.0 pH) with 500mL sterile PBS (0.1M, 1x).
Culture Conditions

Monocytes

- **Note:** Monocytes struggle to adhere to glass. Recommended alternatives are Crystal-grade polystyrene, Gamma sterilized, Non pyrogenic 35mm culture dishes or Nunc UpCell plates.

35mm Culture Dish

1. Suspend monocytes in Complete Monocyte media for counting and seeding.
2. Seed viable cells at 2x10⁶ – 3x10⁶ cells/ml (4x10⁶ – 6x10⁶ cells/well).
3. Add Complete Monocyte media to get final volume of 2mL.
4. Immediately treat with appropriate concentration of GM-CSF or M-CSF (discussed under “Pre-differentiation and polarisation of Monocytes into M1 and M2 Macrophages”).
5. Allow monocytes to adhere to culture plate for 24h.
6. Aspirate media and wash with warm 1x PBS.
7. Refresh media with only 1mL Complete Monocyte media and treat with appropriate cytokine.
8. Refresh media every 3rd day and treat with cytokine.
9. Optimal assessment time is 6 days after seeding, do not culture for more than 10 days.

Nunc UpCell Plates

1. **Work on hot ice pack or at least 6 tissue papers.**
2. Place plate on ice pack or tissues and seed monocytes at 2x10⁶ – 3x10⁶ cells/mL (4x10⁶ – 6x10⁶ wells).
3. Repeat step 3. + 4. stated above.
4. UpCell plates are hydrophobic (cell adherent) above 32°C and hydrophilic (cell repellent) below 32°C.
5. Place plate on warm (>32°C) surface when changing media
6. Repeat steps 5. – 9. stated above.

Complete Monocyte media

- Advanced RPMI-1640
- 10% Human serum form AB patient (Sigma-Aldrich)
- 100 U/ml Penicillin Streptomycin.
- 2 mM Glutamax.

Human serum preparation

1. Use Human serum from AB patient obtained from Sigma-Aldrich.
2. Heat inactivate this serum to inactivate compliment and remove fibrin by incubating at 56°C for 30min.
3. Filter serum if not already done by Sigma-Aldrich.
4. Make working aliquots and store at -20°C.
Preparing Human Serum from AB Donor

1. In the event of import restrictions preventing the buying of serum, serum can be harvested from healthy AB donor.
2. Keep in mind only 38.8% of peripheral blood will yield serum if collected with SST (Serum Separation Tubes).
3. Invert tube ±5 times.
4. Allow blood to clot for 1h or more if sufficient clotting has not occurred.
5. Centrifuge at 1200 x g for 10 mins at 23°C.
6. Remove top layer of serum with P1000 or Pasteur pipette.
7. Note: Be careful not to touch the separating gel with pipette tip.
8. Incubate serum at 56°C for 30min to inactivate complement and remove fibrin.
10. Store at 4°C or make working aliquots to store at -20°C.

HUVECs

1. Have one T25 culture flask coated with 1 μg/cm² fibronectin ready for use (explained under “Transmigration System”).
2. Thaw cryo vial, remove content and inject into T25.
3. Note: Do not centrifuge HUVECs before seeding into flask.
4. Fill T25 up to 3mL with warm Complete EBM media and place in incubator.
5. Refresh media and wash with warm 1x PBS after 24h.
6. Hereafter cells are washed with warm PBS and media replaced every 48h.
7. Culture cells until 90% confluent.
8. Split cells (explained under “Culture Detachment”).
9. Divide cells evenly into 3x T75 coated with 1 μg/cm² fibronectin.
10. Note: HUVECs rapidly proliferate after 5 days, keep in mind to minimize passages.
11. Fill up T75 to 8 mL in total with Complete EBM media.
12. Change media and wash after 24h.
13. Culture until 90% confluent and freeze down or use in experiments.

Complete EBM media

- Use EBM BulletKit from Lonza to make up HUVEC media.
- Do not mix all compounds into EBM (Endothelium Basal Media) when receiving the BulletKit as this may reduce shelf life and functioning of media.
- Aliquot all compounds into Eppendorfs.
- Store all compounds at -20°C, store EBM at 4°C.
- Complete EBM media
  - EBM
  - 2% FBS
  - 0.4% BBE (Bovine Brain Extract)
  - 0.1% hEGF (human Epidermal Growth Factor)
  - 0.1% GA (Gentamicin/Amphotericin)
  - 0.1% Ascorbic acid
  - 0.1% Hydrocortisone
- Media has to be warm before injecting onto HUVECs.
Note: Hydrocortisone solution is volatile. To prevent incorrect concentrations, it is recommended to aliquot out a known amount into 200µL Eppendorfs that corresponds to a known amount of media. In this way the loss of volume would not affect hydrocortisone concentration in Complete EBM media.

**Freezing Conditions**

**Monocytes**

**NOTE:** This is not recommended for primary monocytes

1. Counting viable monocytes with Countess.
   a. Resuspend cells in 1mL human serum.
   b. Make a 0.1% solution of Trypan Blue by diluting with PBS.
   c. Mix 10µL Trypan Blue and 10µL serum cell suspension.
   d. Inject 10µL of this mixture into each chamber of a Countess counting slide.
   e. Ensure Countess is calibrated for cell population.
   f. Insert slide into Countess to allow counting of each chamber.
   g. **Note:** The number of cells is given as cells/mL, i.e., the initial resuspension volume will affect this concentration.
   h. Work out the mean from the two chambers.
2. Work on ice.
3. Inject 200µL human serum into each cryo vial and allow to cool on ice.
4. Add needed amount of serum cell suspension into each cryo vial to yield 5-8x10^6 cells/mL.
5. Add needed amount of serum to a final volume of 900 µL.
6. Make 10% DMSO solution by adding 100µL DMSO to a final volume of 1mL.
7. Place tubes in Mr Frosty with isopropanol and store at -80°C for 24hr.
8. Remove from Mr. Frosty and store tubes in LN2.

**Thawing Monocytes**

1. Thaw cryo vial and inject content into appropriate flask or dish.
2. To remove DMSO from solution and count cells:
   a. Mix content of cryo vial with 10mL warm PBS-EDTA. This will prevent cells from clumping together.
   b. Centrifuge 400 x g for 5min at 23°C.
   c. Aspirate supernatant and resuspend pellet in 1mL Complete Monocyte media.
   d. Count viable monocytes. Primary monocytes lose 50% viability after freezing.

**HUVECs**

1. Suspend cells in EBM and count.
2. Freeze HUVECs in 80% EBM, 10% FBS and 10% DMSO.
3. Inject 200µL EBM into each vial followed by 100µL FBS.
4. Add needed amount of cell suspension to yield 5x10^5 cells/mL/vial.
5. Fill up vial to 900µL with EBM.
6. Add 100µL DMSO to a final volume of 1mL.
7. Place in Mr. Frosty with isopropanol and freeze at -80°C for 24hr.
8. Remove from Mr. Frosty and store in LN2.
Pre-differentiation and Polarisation of Monocytes into M1 and M2 Macrophages

1. M1 Classically activated:
   a. Culture with 50 ng/mL GM-CSF throughout.
2. M2 Alternatively activated:
   a. Culture with 50 ng/mL M-CSF throughout.
3. Inject GM-CSF or M-CSF directly into dish every time media is changed.
4. M1 Classically activated:
   a. Polarize with 50 ng/mL LPS and 20 ng/mL IFN-γ injected directly into dish 24h before assessment.
5. M2 Alternatively activated:
   a. Polarize with 20 ng/mL IL-10, IL-4 and TGF-β injected directly into dish 24h before assessment.
6. 6 days of culture with polarisation on the 5th day is optimal and recommended.

GM-CSF Stock Preparation

1. Centrifuge vial to ensure lyophilized powder is collected at the bottom of vial.
2. Reconstitute 20μg contents of vial with 200μL sterile ddH₂O to a concentration of 0.1 mg/mL.
3. Dilute this 200μL in 800μL 1x PBS to make a stock of 0.02 mg/mL.
4. Make working aliquots of 2 μg/mL by further diluting 100μL stock in 900μL 1x PBS.
5. Store aliquots at -20°C.
6. Avoid repeated freeze-thaw cycles.

M-CSF Stock Preparation

1. Centrifuge vial to ensure lyophilized powder is collected at the bottom of vial.
2. Reconstitute 10μg contents of vial with 100μL sterile ddH₂O to a concentration of 0.1 mg/mL.
3. Dilute this 100μL in 900μL 1x PBS to make a stock of 0.01 mg/mL.
4. Make working aliquots of 2 μg/mL by further diluting 200μL stock in 800 μL PBS.
5. Store aliquots at -20°C.
6. Avoid repeated freeze-thaw cycles.

LPS stock preparation

1. Reconstitute 5mg content of vial with 1mL sterile Hank’s Balanced Salt Solution (HBSS).
2. Make sure to completely dissolve powder, do not vortex solution.
3. Add 1.5mL sterile HBSS to make a stock of 2 mg/mL.
4. Note: Do not make up stock solutions or working aliquots under 1 mg/mL. LPS is known to stick to the sides of containers. Concentrations of >1 mg/mL present negligible sticking. Recommended to use silanized tubes to prevent endotoxin sticking.
5. Make up 2 μg/mL working aliquots directly before use by diluting 1μL stock in 999μL sterile HBSS.
6. If necessary, working aliquots can be stored at 4°C for 24h.

IFN-γ stock preparation

1. Centrifuge vial to ensure lyophilized powder is collected at the bottom of vial.
2. Reconstitute 100µg content of vial with 200µL sterile ddH₂O to a concentration of 0.5 mg/mL.
3. Dilute this 200µL in 9.8mL ddH₂O to make a stock of 10 µg/mL.
4. Make working aliquots of 1 µg/mL by diluting 100µL stock in 900µL ddH₂O.
5. Store aliquots at -20°C.
6. Avoid repeated freeze-thaw cycles.
7. **Note:** It is recommended to dilute the 0.5 mg/mL solution with RPMI containing 10% FBS or 5% human serum albumin. However, dilution with sterile ddH₂O served the purposes of this study.

### Culture Detachment

#### Macrophages

**35mm Culture Dish**

1. Optimally harvest macrophages after 6 days of culturing.
2. **Note:** Harvest cells with Accutase® cell detachment solution. Harsh passaging agents such as Trypsin breaks apart cell pseudopodia, leading to cell death.
3. Remove culture media and wash with 1x PBS at 23°C.
4. Inject 1 mL Accutase® onto dish and incubate at 23°C for 10-15min.
5. Swirl dish and add another 1mL Accutase®.
6. Incubate another 10-15min at 23°C.
7. Suck up Accutase® and spray back onto dish to facilitate detachment.
8. For optimal yield gently scrape surface with cell scraper.
9. Tilt dish and collect as many cells as possible.
10. Cells may be spun down at 400 x g for 5 min at 37°C and reseeded or assessed.
11. **Note:** Accutase® auto-inhibits at 37°C, eliminating the need to neutralise with media.

#### UpCell Plates

1. Optimally harvest macrophages after 6 days of culturing.
2. Place UpCell plate on **cold** ice pack.
3. Aspirate media and replace with **cold** 1x PBS or RPMI.
4. Optimal detachment of human macrophages:
   Leave UpCell plate on 10°C ice pack for 1h. During this time suck up PBS or RPMI and spray back onto culture surface to aid detachment.
5. For optimal yield gently scrape surface with cell scraper.
6. Tilt plate and collect as many cells as possible.
7. Cells may be spun down and reseeded or assessed.
HUVECs

1. T25:
   a. Aspirate media and wash with 3mL 1x PBS.
   b. Treat with 5mL warm Trypsin.
2. T75:
   a. Aspirate media and wash with 8mL 1x PBS.
   b. Treat with 7mL Trypsin.
3. Place flask in 37°C shaking incubator for 5 min.
4. Ensure cells have lifted and neutralize with 5mL (T25) or 7mL (T75) EBM.
5. Centrifuge cells at 1500 RPM for 3 min at 23°C.
6. Resuspend cells in Complete EBM media.

M1/M2 Phenotyping

Flow Cytometry

1. Analysis is done on BD FACSAria Cell Sorter.
2. Differentiate cell populations separately into M1 and M2 phenotypes for 6 days by culturing in 35mm dishes.
3. Prepare single stain and multiple stain solutions by mixing appropriate amount of antibody marker with 1 ml PBS (below).
4. Aspirate media and treat cells with 1 ml single stain or multiple stain PBS solution (below).
5. Incubate dishes at 37°C for 10 min to facilitate antibody binding.
6. Aspirate PBS and harvest cells with Accutase® cell detachment solution.
7. Centrifuge 400 x g for 5 min at 37°C and resuspend pellet in warm PBS.
8. Filter cells with filter paper and relocate to Flow Cytometry tube for immediate analysis.
9. Use unstained samples to determine background fluorescence.
10. Optimise fluorescent signal by adjusting voltage when analysing single stain samples.
11. Compensate for possible fluorophore spill-over using single stain samples.
12. Set up thresholds by recording 8x10⁶ events per sample.
13. Analyse samples by recording 3x10⁵ events per group in triplicate.

Fluorescent Antibody Markers and Setup

1. Prepare unstained sample by only harvesting cells.
2. Prepare single stain samples for every antibody by labelling with only one marker.
   o M1 single stain samples
      ▪ CD274 (PD-L1)
      ▪ CD86
      ▪ MHCII (HLA-DR)
   o M2 single stain samples
      ▪ CD163
      ▪ IL-10
3. Prepare multiple stain samples to be analysed by mixing all markers together.
   - CD274 (PD-L1) conjugated with PE-Cy7 (496nm/785nm).
     - 5µL per test.
     - Excitable with solid state Sapphire 488nm blue laser.
     - Detectable with 780/60nm band pass filter.
   - CD86 conjugated with APC (650nm/660nm).
     - 20µL per test.
     - Excitable with HeNe 633nm red laser.
     - Detectable with 660/20nm band pass filter.
   - MHCII (HLA-DR) conjugated with APC-Cy7 (650nm/785nm).
     - 5µL per test.
     - Excitable with HeNe 633nm red laser.
     - Detectable with 780/60nm band pass filter.

### Phagosome Maturation Arrest

- **Chloroquine**: Pretreat 1h before onset of phagocytosis with 10µM
- **Wortmannin**: Pretreat 30min before onset of phagocytosis with 100nM
- **Concanamycin A**: At onset of phagocytosis, directly after addition of AbsBeads, treat with 100nM

#### Chloroquine Stock Preparation

1. Make up directly before use.
2. Dissolve 0.05 g in 1mL sterile ddH$_2$O.
3. Vortex until solution is clear and colourless.
4. Dilute 10µL in 990µL sterile ddH$_2$O to get a working concentration of 0.96255mM.
5. Store stock at 4°C.
6. **Note**: Solution cannot be stored for longer than 7 days.

#### Wortmannin Stock Preparation

1. Reconstitute 1mg content of vial with 2mL sterile DMSO to a concentration of 1.167mM.
2. Remove 1mL from vial and store at 4°C, do not permit to freeze.
3. Dilute the remaining 1mL in 24mL sterile DMSO to make a stock concentration of 46.68µM.
4. Make working aliquots of 4.668µM by diluting 100µL stock in 900µL DMSO.
5. Store solutions at 4°C, do not permit to freeze.
Concanamycin A Stock Preparation

1. Reconstitute 25μg content of vial with 4mL sterile DMSO to a stock concentration of 7.216μM.
2. Make working aliquots directly from stock.
3. Store at -20°C.
4. Avoid repeated freeze-thaw cycles.

AbsBeads preparation

1. Prepare 100mL of 50mM PBS, pH 7.4, containing 0.9% NaCl.
2. Prepare 100mL of 50mM MES (2-(N-morpholino)ethanesulfonic acid) buffer, pH 6.0.
3. Dissolve 4mg of Alexa Fluor 647 secondary IgG at 2 mg/ml in MES buffer in a glass centrifuge tube.
4. Add 1.375mL of 2.5% aqueous suspension of carboxylate-modified microsphere. Incubate at room temperature for 30 min.
5. Add 16mg of EDAC (1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide). Mix by vortexing.
6. Adjust pH to 6.5 ± 0.2 with dilute NaOH. Incubate the reaction mixture on a rocker or orbital shaker overnight at 23˚C.
7. Add 0.0181g glycine to give a concentration of 100mM to quench the reaction. Incubate 1h at 23˚C.
8. Centrifuge 4000 x g for 20min to separate the protein-labeled beads from unreacted IgG.
9. Resuspend the pellet in 2mL of 50mM PBS. Centrifuge as described in step 8.
10. Repeat step 9 twice more (a total of 3 washes).
11. Resuspend the IgG conjugated beads in 10mL of 50mM PBS.
12. Add 1.3mg sodium azide to make a 2mM concentration.
13. Store AbsBeads at 4°C.
14. Note: Do not permit to freeze.
**MES Buffer Preparation**

- Dissolve 0.98g MES powder in 100mL sterile ddH$_2$O to make a 50mM solution. Store solution at 4°C for up to 6 months.

**Phagocytosis Assay**

1. Introduce 1.156x10$^6$ AbsBeads into macrophage culture by injecting 80µL AbsBeads/O+ solution into each 35mm dish or well of UpCell plate (below).
2. Addition of AbsBeads is characterised as the onset of phagocytosis.
3. Allow phagocytosis to commence for 2h.
4. **Note:** Phagocytosis is reduced to 1h during transmigration assay.

**O+ Serum preparation**

1. Collect peripheral blood in SST tube from healthy O+ donor.
2. Keep in mind 38.8% of peripheral blood will yield serum.
3. Invert tube ± 5 times.
4. Allow blood to clot for 1h or more if sufficient clotting has not occurred.
5. Centrifuge 1200 x g for 10mins at 23°C.
6. Remove top layer of serum with P1000 or Pasteur pipette.
7. **Note:** Be careful not to touch the separating gel with pipette tip.
8. Warm up serum to 56°C and incubate for 30min to inactivate compliment and remove fibrin.
9. Store at 4°C or make working aliquots to store at -20°C.

**AbsBeads incubation**

1. Mix 40µL of 2.89x10$^7$ AbsBeads/mL stock with 40µL O+ donor serum.
2. Incubate AbsBeads in O+ serum at 4˚C for 24h.

**Live Cell Imaging**

1. Analysis is done on Carl Zeiss LSM780 confocal microscope with Super-resolution platforms.
2. Treat cells with appropriate fluorophore markers for imaging (below).
3. Cells are imaged directly after onset of phagocytosis.
4. Ensure the incubator unit is on and CO$_2$ tank open before initiating imaging.
5. Place 35mm culture dish containing CellMask™, pHrodo® and AbsBeads/O+ solution on the appropriate microscope stage.
6. Inject ddH2O into incubation stage to ensure a humidified environment.
7. Carefully place lid onto stage to ensure incubation in a humidified, 37°C with 5% CO₂ environment.
8. Select needed lasers to excite various markers by setting up appropriate tracks.
9. Separately optimise individual laser intensities for each marker.
10. Compensate for possible fluorophore spill-over.
11. Set up time lapse imaging with smallest possible cycle time between images.
12. Image random field of view at 20x magnification for 2h.
13. **Note:** Microscope focus is lost during prolonged time lapse imaging and refocusing is required if automatic focus is not available.

**Fluorescent Markers**

- **AbsBeads:** This is the onset of phagocytosis. Treat at 1.156x10⁵ AbsBeads per 35mm dish.
- **pHrodo®:** Just before phagocytosis treat at 1 mg/mL.
- **CellMask™:** 10 min before phagocytosis (treatment groups) treat at 1x solution (below).

**Setup**

1. Carboxylate modified blue fluorescent beads have excitation/emission maxima of 306nm/407nm.
   a. Excitable with diode 405nm CW/PS (pulsed) for LSM7.
2. Alexa Fluor 647 red fluorescent secondary IgG have excitation/emission maxima of 650nm/668nm.
   a. Excitable with 633nm laser.
3. pHrodo® BioParticles® green pH indicator have excitation/emission maxima of 509nm/533nm.
   a. Excitable with Argon multiline laser 25mW at 488nm.
4. CellMask™ orange plasma membrane stain have excitation/emission maxima of 554nm/567nm.
   a. Excitable with 561nm laser.

**Preparing Fluorescent Markers**

**pHrodo®**

1. Thaw one vial of the pHrodo® BioParticles® fluorescent particles.
2. Pipette 200μL sterile PBS into the vial containing 2mg lyophilized pHrodo® and briefly vortex the solution to completely resuspend the particles at a 10 mg/mL stock solution.
3. Transfer the suspension into an Eppendorf and sonicate for 5 minutes, until all the fluorescent particles are homogeneously dispersed.
4. Store at -20°C.

**CellMask™**

**Treated groups**

1. Make up directly before use.
2. Thaw one vial containing 1000x stock solution.
3. Mix 1μL with 9μL warm 1x PBS to yield a 100x solution.
4. Inject the 10μL solution into 1mL media to make a final 1x working concentration.
5. **Note:** Swirl dish thoroughly in order to mix CellMask™.
6. Incubate at 37°C with 5% CO₂ before initiating phagocytosis.
Control groups

1. Repeat step 1 + 2 as stated above.
2. Mix 1µL stock solution with 999µL warm 1x PBS to yield a 1x solution.
3. Remove media from wells and wash with warm PBS.
4. Treat with 1x CellMask™/PBS working solution and incubate at 37°C for 10 mins.
5. Aspirate CellMask™/PBS solution and wash 3x with warm PBS.
6. Replace with complete monocyte media and assess under microscope.

Flow Cytometry Quantification

Digestion, pH and AbsBeads Ingestion

1. Analysis is done on BD FACSAria Cell Sorter.
2. Treat cells with pHrodo® and AbsBeads/O+ as appropriate (“Fluorescent Markers” above).
3. Note: Do not treat cells with CellMask™.
4. Allow phagocytosis to commence for 2h.
5. Aspirate media and wash with warm PBS.
6. Fixate cells with by injecting 0.5 mL warm 4% Paraformaldehyde and 0.5 mL warm RPMI into each well or dish (1:1 ratio).
7. Incubate at 37°C for 10 mins.
8. Aspirate Paraformaldehyde/RPMI solution and replace with 1mL PBS.
9. Gently scrape cells off with cell scraper and inject into 2mL Eppendorf for each culture dish.
10. Filter cells with filter paper and relocate to Flow Cytometry tubes.
11. Compensate for possible fluorophore spill-over.
12. Set up thresholds for control and treated groups by recording 16x10⁶ events per group.
13. Analyse samples by recording 3x10⁵ events per group in triplicate.

Setup

1. Carboxylate modified blue fluorescent beads have excitation/emission maxima of 306nm/407nm.
   a. Excitable with 405nm violet laser.
   b. Detectable with 450/40nm band pass filter.
2. Alexa Fluor 647 red fluorescent secondary IgG have excitation/emission maxima of 650nm/668nm.
   a. Excitable with HeNe 633nm red laser.
   b. Detectable with 660/20nm band pass filter.
3. pHrodo® BioParticles® green pH indicator have excitation/emission maxima of 509nm/533nm.
   a. Excitable with solid state Sapphire 488nm blue laser.
   b. Detectable with 530/30nm band pass filter.
Transmigration Assay

Preparation

7 Days Prior to Experiment
1. Start culturing HUVECs in fibronectin coated T75.
2. Coat transmigration inserts and wells with fibronectin (below).

6 Days Prior to Experiment
1. Isolate primary macrophages from peripheral blood or buffy coats.

3 Days Prior to Experiment
1. Seed HUVECs onto transmigration inserts at 1x 10^5 cells/insert.
2. Culture in complete EBM media with 0.7mL in bottom well and 0.2mL in insert for every well/insert complex used.

1 Day Prior to Experiment
1. Polarise macrophages to M1 with LPS and IFN-γ.
2. Activate LPS and IFN-γ HUVEC groups with, respectively, 50 ng/mL and 20 ng/mL 24h before experiment.

Experiment
1. Make up fresh Chloroquine stock and working solutions.
2. Make up Transmigration EBM media (only containing FBS, BBE and Ascorbic Acid).
   a. MCP-1 containing Transmigration EBM media
      i. 0.7mL EBM containing 2% FBS, 0.4% BBE, 0.1% Ascorbic acid and 100 ng/mL MCP-1 for each well used. This media is injected into the well underneath the insert.
   b. MCP-1 deficient Transmigration EBM media
      i. 0.2mL EBM containing 2% FBS, 0.4% BBE and 0.1% Ascorbic acid for each insert used. This media suspends the AbsBeads-containing macrophages and is injected onto the insets that are placed onto wells.
   c. GM-CSF and MCP-1 containing Transmigration EBM media
      i. 0.7mL EBM containing 2% FBS, 0.4% BBE, 0.1% Ascorbic acid, 100 ng/mL MCP-1 and 50 ng/mL GM-CSF for each GM-CSF well used. This media is injected into the well underneath the insert.
3. Treat macrophages with 10μM Chloroquine.
4. Start timer at 1h. After treatment with Chloroquine, phagosome maturation arrest is set in motion. Phagocytosis starts when timer reaches 0min.
5. Timer at 30min. Treat macrophages with 100nM Wortmannin.
6. Note: Do not use 46.7μM stock, the additional DMSO in the 4.67μM working solution facilitate entry of Wortmannin into cells.
7. Timer at 0min. Treat macrophages with 100nM Concanamycin A.
9. Swirl dish and place in incubator for 1h to allow phagocytosis of AbsBeads.
10. After 1h split macrophages with UpCell plates or Accutase® passaging solution.
11. Resuspend macrophages in MCP-1 deficient Transmigration EBM media.
12. Count macrophages with 0.4% Trypan Blue.
13. Remove complete EBM media from transmigration well/insert complexes and wash with PBS.
14. Inject 0.7mL MCP-1 **containing** Transmigration EBM media into appropriate wells used.
15. Inject 0.7mL MCP-1 **deficient** Transmigration EBM media into appropriate wells used.
16. Inject 0.7mL GM-CSF and MCP-1 containing Transmigration EBM media into appropriate wells used.
17. Place inserts into wells containing Transmigration EBM media.
18. Seed macrophages containing AbsBeads as well as those deficient of AbsBeads onto appropriate inserts at 3x10^5 cells/insert.
19. Fill up media in insert to 200μL with MCP-1 deficient Transmigration EBM media.
20. Incubate in 80% humidified, 37˚C with 5% CO₂ environment for 2:30h.
21. Fixate cells by matching the amount of media with 4% paraformaldehyde in each well or insert.
22. **Note:** Do not remove media before fixing, this prevents loss of non-adhered cells.
23. Place in 37˚C incubator with 5% CO₂ for 10min and aspirate fixative.
24. Inject 0.7mL 1x PBS into each well and 0.2mL 1x PBS into each insert.
25. Store at 4°C.

**Quantifying Migrated Cells**

1. Quantification is done by hand due to small number of migrating cells.
2. Remove inserts from wells.
3. Inject 25µL 0.4% Trypan Blue into each well containing 0.7mL PBS, this assists in counting.
4. Count cells with cell counter under 20x magnification.
5. Start counting at the top and move side to side in order to cover the entire well.

**MCP-1 Stock Preparation**

1. Centrifuge vial to ensure lyophilised powder is collected at the bottom of vial.
2. Reconstitute 20μg content of vial with 200μL sterile ddH₂O to a concentration of 0.1 mg/mL.
3. **Note:** Do not vortex.
4. Dilute this 200μL in 800μL 1x PBS to make a stock solution of 0.02 mg/mL.
5. **Note:** Dilution in 1x PBS containing 0.1% BSA is not advised. The BSA stabilizes the MCP-1, however also prevents sufficient receptor binding to induce macrophage transmigration.
6. Use MCP-1 at 100 ng/mL.

**Fibronectin coating**

1. Culture surfaces are coated with fibronectin in order to allow HUVEC adhesion.
2. Recommended coating density of 1 μg/cm².
3. 0.1% (1 mg/ml) fibronectin stock solution.
4. To coat 1 μg/cm² growth area:
a. Mix 1 μl fibronectin stock for every cm² of growth area with enough 1x PBS to cover the area.

5. Growth areas with accompanying volumes:
   a. T25 = 25 cm² (2.5 ml)
   b. T75 = 75 cm² (6 ml)

6. Incubate flasks at 37°C in 80% humidified incubator for 1h (applicable to all surfaces areas).

7. Aspirate fibronectin/PBS solution.

8. Remove caps from flasks and place in laminar flow hood under UV light to dry for 2 - 24h.

9. Store flasks in original resealable packaging to keep sterile.

Transmigration Inserts Coating with Fibronectin

1. Inserts as well as their accompanying wells are coated with fibronectin.

2. The minimum volume in a well of a 24 multiwell transmigration plate is 0.7mL and the approximate growth area is 1.9cm².

3. The minimum volume in an insert of a 24 multiwell transmigration plate is 0.2mL and the approximate growth area is 0.33cm² (rounded up to 0.5cm²).

4. Thus, the total growth area to be coated is 2.4 cm²/insert.

5. Mix 2.4µL fibronectin stock with 0.9mL 1x PBS for every well/insert complex coated.

6. Inject 0.7mL fibronectin/PBS solution into each well and place insert into well.

7. Inject 0.2mL fibronectin/PBS solution into insert.

8. Incubate and dry as stated above.

9. Note: Do not remove 24 multiwell plate lid when drying in laminar flow hood.

10. Place plates in original resealable packaging to keep sterile.
Appendix C: Supplementary Results

Flow Cytometric Distension of AbsBeads and Cells

Differentiation between Beads and Cells containing beads, using flow cytometry. In the scatter plot above, bead (blue, but pink in image) fluorescent intensity (y-axis) and pHrodo® (green, but blue here) fluorescent intensity (x-axis) is illustrated.